



(11) **EP 2 272 975 A1**

(12) **EUROPEAN PATENT APPLICATION**
published in accordance with Art. 153(4) EPC

(43) Date of publication:
12.01.2011 Bulletin 2011/02

(51) Int Cl.:
C12Q 1/68 ^(2006.01) **C12N 15/09** ^(2006.01)
G01N 33/53 ^(2006.01)

(21) Application number: **09725639.0**

(86) International application number:
PCT/JP2009/056785

(22) Date of filing: **25.03.2009**

(87) International publication number:
WO 2009/119891 (01.10.2009 Gazette 2009/40)

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
Designated Extension States:
AL BA RS

- **SATOH, Hideo**
Ibaraki-shi
Osaka 567-0826 (JP)
- **TARUI, Hirokazu**
Toyonaka-shi
Osaka 561-0802 (JP)

(30) Priority: **25.03.2008 JP 2008077967**

(74) Representative: **Duckworth, Timothy John**
J.A. Kemp & Co.
14 South Square
Gray's Inn
London WC1R 5JJ (GB)

(71) Applicant: **Sumitomo Chemical Company, Limited**
Tokyo 104-8260 (JP)

(72) Inventors:
• **TOMIGAHARA, Yoshitaka**
Toyonaka-shi
Osaka 560-0013 (JP)

(54) **METHOD FOR DETERMINATION OF DNA METHYLATION**

(57) The present invention relates to a method of measuring the content of methylated DNA in a DNA region of interest in a genomic DNA contained in a biological specimen, and so on.

EP 2 272 975 A1

Description

TECHNICAL FIELD

5 **[0001]** The present invention relates to a method of measuring the content of methylated DNA in a DNA region of interest in a genomic DNA contained in a biological specimen, and so on.

BACKGROUND ART

10 **[0002]** As a method for evaluating the methylation state of DNA in an objective DNA region in a genomic DNA contained in a biological specimen, for example, there is known a method of measuring the content of methylated DNA in an objective DNA region in a genomic DNA (see, for example, Nucleic Acids Res., 1994, Aug 11; 22(15): 2990-7, and Proc. Natl. Acad. Sci. U.S.A., 1997, Mar 18; 94(6): 2284-9 for reference). In such a measuring method, first, it is necessary to extract DNA containing the objective DNA region from a DNA sample derived from a genomic DNA, and the extracting operation is complicated.

15 **[0003]** As a method of measuring the content of methylated DNA in an objective region of extracted DNA, for example, (1) a method of amplifying an objective region by subjecting the DNA to a chain reaction for DNA synthesis by DNA polymerase after modification of the DNA with a sulfite or the like (Polymerase Chain Reaction; hereinafter also referred to as PCR), and (2) a method of amplifying an objective region by subjecting the DNA to PCR after digestion of the DNA using a methylation sensitive restriction enzyme are known. Both of these methods require time and labor for DNA modification for detection of methylation, subsequent purification of the product, preparation of a reaction system for PCR, and checking of DNA amplification.

DISCLOSURE OF THE INVENTION

25 **[0004]** It is an object of the present invention to provide a method of measuring the content of methylated DNA in an objective DNA region in a genomic DNA contained in a biological specimen in a simple and convenient manner.

[0005] That is, the present include the following inventions.

30 [Invention 1]

[0006] A method of measuring the content of methylated DNA in a objective DNA region in a genomic DNA contained in a biological specimen, comprising:

- 35 (1) First step of subjecting a DNA sample derived from the genomic DNA contained in the biological specimen to a digestion treatment with a methylation-sensitive restriction enzyme;
- (2) Second step of obtaining methylated single-stranded DNA from the DNA sample that has been subjected to the digestion treatment and obtained in First step, and binding the single-stranded DNA to an immobilized methylated DNA antibody, thereby selecting the single-stranded DNA; and
- 40 (3) Third step comprising, as a pre step of each of the following regular steps:

a step (First pre step) of separating the single-stranded DNA selected in Second step from the immobilized immobilized methylated DNA antibody to provide DNA in a single-stranded state (plus strand);

45 a step (Second pre step) of extensionally-forming a double-stranded DNA from a single-stranded DNA (plus strand) containing the objective DNA region by a single extension of an extension primer, using the genomic DNA (plus strand) provided in a single-stranded state in First pre step and the extension primer, wherein the extension primer (forward primer) comprises the nucleotide sequence (minus strand) complementary to a partial nucleotide sequence (plus strand) of the nucleotide sequence of the DNA in a single-stranded state (plus strand), the partial nucleotide sequence (plus strand) being located on further 3'-end side than the 3'-end of the nucleotide sequence (plus strand) of the objective DNA region; and

50 a step (Third pre step) of temporarily separating the double-stranded DNA extensionally formed in Second pre step into a single-stranded DNA (plus strand) containing the objective DNA region and a single-stranded DNA (minus strand) containing the nucleotide sequence complementary to the objective DNA region;

and as regular steps:

55 (a) Step A (regular step) of extensionally forming double-stranded DNA from the single-stranded DNA containing the objective DNA region, by a single extension of the extension primer, using as a template the generated single-stranded DNA (plus strand) containing the objective DNA region, and the forward primer

as the extension primer; and
(b) Step B (regular step) of extensionally forming double-stranded DNA from the single-stranded DNA containing the objective DNA region, by a single extension of an extension primer, using as a template the generated single-stranded DNA (minus strand) containing the nucleotide sequence complementary to the objective DNA region, and using as the extension primer an extension primer (reverse primer) comprising the nucleotide sequence (plus strand) complementary to a partial nucleotide sequence (minus strand) of the nucleotide sequence of the single-stranded DNA (minus strand) containing the nucleotide sequence complementary to the objective DNA region, the partial nucleotide sequence (minus strand) being located on further 3'-end side than the 3'-end of the nucleotide sequence (minus strand) complementary to the nucleotide sequence (plus strand) of the objective DNA region; and wherein

[0007] Third step further comprises:

amplifying the methylated DNA in the objective DNA region to a detectable level by repeating each regular step of Third step after temporarily separating the extensionally formed double-stranded DNA obtained in each of the regular steps into a single-stranded state; and quantifying the amount of the amplified DNA.

[Invention 2]

[0008] The method of Invention 1, wherein the immobilized methylated DNA antibody is a methylcytosine antibody.

[Invention 3]

[0009] The method of Invention 1 or 2, wherein the biological specimen is blood, a bodily fluid, serum, plasma, a cell lysate, or a tissue lysate from a mammal.

[Invention 4]

[0010] The method of any one of Inventions 1 to 3, wherein the DNA sample derived from the genomic DNA contained in the biological specimen is a DNA sample digested in advance with a restriction enzyme recognition cleavage site for which is not present in the objective DNA region of the genomic DNA, or a DNA sample purified in advance.

[Invention 5]

[0011] The method of any one of Inventions 1 to 4, wherein First step comprises:

First (A) step of mixing a single-stranded DNA (plus strand) containing the objective DNA region and a masking oligonucleotide comprising a nucleotide sequence complementary to a nucleotide sequence of a recognition site for a methylation-sensitive restriction enzyme, thereby selecting single-stranded DNA in which the recognition site for the methylation-sensitive restriction enzyme is protected; and
First (B) step of digesting the single-stranded DNA selected in First (A) step with the methylation-sensitive restriction enzyme.

[Invention 6]

[0012] The method of any one of Inventions 1 to 5, wherein the methylation-sensitive restriction enzyme is a restriction enzyme the restriction site for which is included in the objective DNA region in the genomic DNA contained in the biological specimen, or the methylation-sensitive restriction enzyme is HhaI.

[Invention 7]

[0013] The method of any one of Inventions 1 to 6, wherein Second step is performed without digestion treatment with the methylation-sensitive restriction enzyme in First step.

[Invention 8]

[0014] The method of any one of Inventions 1 to 7, wherein Second step comprises:

Second (A) step of separating into methylated single-stranded DNA the methylated double-stranded DNA contained in the DNA sample that has been subjected to the digestion treatment and obtained in First step; and
 Second (B) step of binding the methylated single-stranded DNA obtained in Second (A) step to an immobilized methylated DNA antibody; and wherein

a counter oligonucleotide is added when separating the methylated double-stranded DNA into the methylated single-stranded DNA in Second (A) step.

BRIEF DESCRIPTION OF THE DRAWINGS

[0015]

Fig. 1 shows results of 2% agarose gel electrophoresis of amplification products obtained by amplifying methylated DNA in the region comprising the nucleotide sequence of SEQ ID NO: 23 by PCR from a prepared sample in Example 1.

From the leftmost lane in the drawing, results in a DNA marker "MK", a sample "M" of a solution of a partially methylated oligonucleotide GPR7-2079-2176/98 mer-M(7) in which the recognition sequence of HpaII is methylated, subjected to an "A" treatment, a sample "H" of a solution of a partially methylated oligonucleotide GPR7-2079-2176/98 mer-HM(5) in which part of the recognition sequence of HpaII is not methylated, subjected to an "A" treatment, a sample "U" of a solution of an unmethylated oligonucleotide GPR7-2079-2176/98 mer-UM, subjected to an "A" treatment, a sample "M" of a solution of a partially methylated oligonucleotide GPR7-2079-2176/98 mer-M(7) in which the recognition sequence of HpaII is methylated, subjected to a "B" treatment, a sample "H" of a solution of a partially methylated oligonucleotide GPR7-2079-2176/98 mer-HM(5) in which part of the recognition sequence of HpaII is not methylated, subjected to a "B" treatment, a sample "U" of a solution of an unmethylated oligonucleotide GPR7-2079-2176/98 mer-UM, subjected to a "B" treatment, a sample "M" of a solution of a partially methylated oligonucleotide GPR7-2079-2176/98 mer-M(7) in which the recognition sequence of HpaII is methylated, subjected to a "C" treatment, a sample "H" of a solution of a partially methylated oligonucleotide GPR7-2079-2176/98 mer-HM(5) in which part of the recognition sequence of HpaII is not methylated, subjected to a "C" treatment, and a sample "U" of a solution of an unmethylated oligonucleotide GPR7-2079-2176/98 mer-UM, subjected to a "C" treatment are shown.

Fig. 2 shows results of 1.5% agarose gel electrophoresis of amplification products obtained by amplifying methylated DNA in the target DNA region comprising the nucleotide sequence of SEQ ID NO: 28 by PCR from a prepared sample in Example 2. From the leftmost lane in the drawing, results in a DNA marker "MK", a solution "MD" of a methylated DNA fragment MX (negative control), a solution "D" of an unmethylated DNA fragment X (negative control), a solution "MC" of a methylated DNA fragment MX, a solution "C" of an unmethylated DNA fragment X, a solution "MB" of a methylated DNA fragment MX, a solution "B" of an unmethylated DNA fragment X, a solution "MA" of a methylated DNA fragment MX, and a solution "A" of an unmethylated DNA fragment X are shown.

Fig. 3 shows results of 1.5% agarose gel electrophoresis of amplification products obtained by amplifying methylated DNA in the target DNA region comprising the nucleotide sequence of SEQ ID NO: 45 by PCR from a prepared sample in Example 3. From the leftmost lane in the drawing, results in a DNA marker "MK", a solution "MD" of a methylated DNA fragment MY (negative control), a solution "D" of an unmethylated DNA fragment Y (negative control), a solution "MC" of a methylated DNA fragment MY, a solution "C" of an unmethylated DNA fragment X, a solution "MB" of a methylated DNA fragment MY, a solution "B" of an unmethylated DNA fragment Y, a solution "MA" of a methylated DNA fragment MA, and a solution "A" of an unmethylated DNA fragment Y are shown.

Fig. 4 shows results of 1.5% agarose gel electrophoresis of amplification products obtained by amplifying methylated DNA in the target DNA region comprising the nucleotide sequence of SEQ ID NO: 53 by PCR from a prepared sample in Example 4. From the leftmost lane in the drawing, results in a DNA marker "MK", a solution "MD" of a methylated DNA fragment MT (negative control), a solution "D" of an unmethylated DNA fragment T (negative control), a solution "MC" of a methylated DNA fragment MT, a solution "C" of an unmethylated DNA fragment T, a solution "MB" of a methylated DNA fragment MT, a solution "B" of an unmethylated DNA fragment T, a solution "MA" of a methylated DNA fragment MT, and a solution "A" of an unmethylated DNA fragment T are shown.

Fig. 5 shows results of 1.5% agarose gel electrophoresis of amplification products obtained by amplifying methylated DNA in the target DNA region comprising the nucleotide sequence of SEQ ID NO: 53 by PCR from a prepared sample in Example 5. From the leftmost lane in the drawing, results in a DNA marker "MK", a solution "MD" of a methylated yeast genomic DNA (negative control), a solution "D" of an unmethylated yeast genomic DNA (negative control), a solution "MC" of a methylated yeast genomic DNA, a solution "C" of an unmethylated yeast genomic DNA, a solution "MB" of a methylated yeast genomic DNA, a solution "B" of an unmethylated yeast genomic DNA, a solution "MA" of a methylated yeast genomic DNA, and a solution "A" of an unmethylated yeast genomic DNA

are shown.

MODE FOR CARRYING OUT THE INVENTION

5 **[0016]** As the "biological specimen" in the present invention, for example, a cell lysate, a tissue lysate (here the term "tissue" is used in a broad sense including blood, lymph node and so on) or biological samples including bodily sections such as plasma, serum and lymph, bodily secretions (urine, milk and so on) and the like and a genomic DNA obtained by extracting these biological samples, in mammals can be recited. As a biological specimen, for example, samples derived from microorganisms, viruses and the like can be recited, and in such a case, "a genomic DNA" in the present

10 measuring method also means genomic DNA of microorganisms, viruses and the like.
[0017] When the specimen derived from a mammal is blood, use of the present measuring method in a regular health check or a simple examination is expected.

[0018] For obtaining a genomic DNA from a specimen derived from a mammal, for example, DNA may be extracted using a commercially available DNA extraction kit.

15 **[0019]** When blood is used as a specimen, plasma or serum is prepared from blood in accordance with a commonly used method, and using the prepared plasma or serum as a specimen, free DNA (including DNA derived from cancer cells such as gastric cancer cells) contained in the specimen is analyzed. This enables analysis of DNA derived from cancer cells such as gastric cancer cells while avoiding DNA derived from hemocytes, and improves the sensitivity of detection of cancer cells such as gastric cancer cells and a tissue containing the same.

20 **[0020]** The DNA sample derived from genomic DNA may be a DNA sample digested in advance with a restriction enzyme recognition cleavage site for which is not present in the objective DNA region of the genomic DNA, or a DNA sample purified in advance by a prescribed method.

[0021] Usually, a gene (a genomic DNA) consists of four kinds of bases. In these bases, such a phenomenon is known that only cytosine is methylated, and such methylation modification of DNA is limited to cytosine in a nucleotide sequence represented by 5'-CG-3' (C represents cytosine, and G represents guanine. Hereinafter, the nucleotide sequence is also referred to as "CpG"). The site to be methylated in cytosine is its position 5. In DNA replication prior to cell division, only cytosine in "CpG" of a template chain is methylated immediately after replication, however, cytosine in "CpG" of a newly-generated strand is immediately methylated by the action of methyltransferase. Therefore, the methylation state of DNA will be passed to new two sets of DNA even after DNA replication. The term "methylated DNA" in the present invention

25 means DNA occurring by such methylation modification.
[0022] The term "CpG pair" in the present invention means double-stranded oligonucleotide in which a nucleotide sequence represented by CpG and a CpG that is complement with this are base-paired.

[0023] The term "objective DNA region" (hereinafter, also referred to as an "objective region") used in the present invention means a DNA region for which presence or absence of methylation of cytosine included in the region is to be examined, and has a recognition site of at least one kind of methylation sensitive restriction enzyme. A DNA region containing at least one cytosine in a nucleotide sequence represented by CpG which is present in a nucleotide sequence of a promoter region, an untranslated region, or a translated region (coding region) of a useful protein gene such as Lysyl oxidase, HRAS-like suppressor, bA305P22.2.1, Gamma filamin, HAND1, Homologue of RIKEN 2210016F16, FLJ32130, PPARG angiopoietin-related protein, Thrombomodulin, p53-responsive gene 2, Fibrillin2, Neurofilament3, disintegrin and metalloproteinase domain 23, G protein-coupled receptor 7, G-protein coupled somatostatin and angiotensin-like peptide receptor, Solute carrier family 6 neurotransmitter transporter noradrenalin member 2 and so on can be recited.

[0024] To be more specific, when the useful protein gene is a Lysyl oxidase gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Lysyl oxidase gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 1 (corresponding to a nucleotide sequence represented by base No. 16001 to 18661 in the nucleotide sequence described in Genbank Accession No. AF270645) can be recited. In the nucleotide sequence of SEQ ID NO: 1, ATG codon encoding methionine at amino terminal of Lysyl oxidase protein derived from human is represented in base No. 2031 to 2033, and a nucleotide sequence of the above exon 1 is represented in base No. 1957 to 2661. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 1, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO: 1 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 1539, 1560, 1574, 1600, 1623, 1635, 1644, 1654, 1661, 1682, 1686, 1696, 1717, 1767, 1774, 1783, 1785, 1787, 1795 and so on in the nucleotide sequence of SEQ ID NO: 1 can be recited.

55 **[0025]** To be more specific, when the useful protein gene is a HRAS-like suppressor gene, as a nucleotide sequence

that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a HRAS-like suppressor gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 2 (corresponding to a nucleotide sequence represented by base No. 172001 to 173953 in the nucleotide sequence described in Genbank Accession No. AC068162) can be recited. In the nucleotide sequence of SEQ ID NO: 2, the nucleotide sequence of exon 1 of a HRAS-like suppressor gene derived from human is represented in base No. 1743 to 1953. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 2, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO: 2 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 1316, 1341, 1357, 1359, 1362, 1374, 1390, 1399, 1405, 1409, 1414, 1416, 1422, 1428, 1434, 1449, 1451, 1454, 1463, 1469, 1477, 1479, 1483, 1488, 1492, 1494, 1496, 1498, 1504, 1510, 1513, 1518, 1520 and so on in the nucleotide sequence of SEQ ID NO: 2 can be recited.

[0026] To be more specific, when the useful protein gene is a bA305P22.2.1 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a bA305P22.2.1 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 3 (corresponding to a nucleotide sequence represented by base No. 13001 to 13889 in the nucleotide sequence described in Genbank Accession No. AL121673) can be recited. In the nucleotide sequence of SEQ ID NO: 3, ATG codon encoding methionine at amino terminal of bA305P22.2.1 protein derived from human is represented in base No. 849 to 851, and a nucleotide sequence of the above exon 1 is represented in base No. 663 to 889. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 3, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO: 3 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 329, 335, 337, 351, 363, 373, 405, 424, 427, 446, 465, 472, 486 and so on in the nucleotide sequence of SEQ ID NO: 3 can be recited.

[0027] To be more specific, when the useful protein gene is a Gamma filamin gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Gamma filamin gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 4 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 63528 to 64390 in the nucleotide sequence described in Genbank Accession No. AC074373) can be recited. In the nucleotide sequence of SEQ ID NO: 4, ATG codon encoding methionine at amino terminal of Gamma filamin protein derived from human is represented in base No. 572 to 574, and a nucleotide sequence of the above exon 1 is represented in base No. 463 to 863. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 4, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO: 4 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 329, 333, 337, 350, 353, 360, 363, 370, 379, 382, 384, 409, 414, 419, 426, 432, 434, 445, 449, 459, 472, 474, 486, 490, 503, 505 and so on in the nucleotide sequence of SEQ ID NO: 4 can be recited.

[0028] To be more specific, when the useful protein gene is a HAND1 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a HAND1 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 5 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 24303 to 26500 in the nucleotide sequence described in Genbank Accession No. AC026688) can be recited. In the nucleotide sequence of SEQ ID NO: 5, ATG codon encoding methionine at amino terminal of HAND1 protein derived from human is represented in base No. 1656 to 1658, and a nucleotide sequence of the above exon 1 is represented in base No. 1400 to 2198. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 5, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO: 5 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 1153, 1160, 1178, 1187, 1193, 1218, 1232, 1266, 1272, 1292, 1305, 1307, 1316, 1356, 1377, 1399, 1401, 1422, 1434 and so on in the nucleotide sequence of SEQ ID NO: 5 can be recited.

[0029] To be more specific, when the useful protein gene is a Homologue of RIKEN 2210016F16 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Homologue of RIKEN 2210016F16 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 6 (corresponding to a complementary nucleotide sequence to a nucleotide sequence represented by base No. 157056 to 159000 in the nucleotide sequence described in Genbank Accession No. AL354733) can be recited. In the nucleotide sequence of SEQ ID NO: 6, a nucleotide sequence of exon 1 of a Homologue of a RIKEN 2210016F16 gene derived from human is represented in base No. 1392 to 1945. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 6, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO: 6 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 1172, 1175, 1180, 1183, 1189, 1204, 1209, 1267, 1271, 1278, 1281, 1313, 1319, 1332, 1334, 1338, 1346, 1352, 1358, 1366, 1378, 1392, 1402, 1433, 1436, 1438 and so on in the nucleotide sequence of SEQ ID NO: 6 can be recited.

[0030] To be more specific, when the useful protein gene is a FLJ32130 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a FLJ32130 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 7 (corresponding to a complementary nucleotide sequence to a nucleotide sequence represented by base No. 1 to 2379 in the nucleotide sequence described in Genbank Accession No. AC002310) can be recited. In the nucleotide sequence of SEQ ID NO: 7, ATG codon encoding methionine at amino terminal of FLJ32130 protein derived from human is represented in base No. 2136 to 2138, and a nucleotide sequence assumed to be the above exon 1 is represented in base No. 2136 to 2379. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 7, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO: 7 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 1714, 1716, 1749, 1753, 1762, 1795, 1814, 1894, 1911, 1915, 1925, 1940, 1955, 1968 and so on in the nucleotide sequence of SEQ ID NO: 7 can be recited.

[0031] To be more specific, when the useful protein gene is a PPARG angiopoietin-related protein gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a PPARG angiopoietin-related protein gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 8 can be recited. In the nucleotide sequence of SEQ ID NO: 8, ATG codon encoding methionine at amino terminal of PPARG angiopoietin-related protein derived from human is represented in base No. 717 to 719, and a nucleotide sequence of the 5' side part of the above exon 1 is represented in base No. 1957 to 2661. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 8, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO: 8 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 35, 43, 51, 54, 75, 85, 107, 127, 129, 143, 184, 194, 223, 227, 236, 251, 258 and so on in the nucleotide sequence of SEQ ID NO: 8 can be recited.

[0032] To be more specific, when the useful protein gene is a Thrombomodulin gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Thrombomodulin gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 9 (corresponding to a nucleotide sequence represented by base No. 1 to 6096 in the nucleotide sequence described in Genbank Accession No. AF495471) can be recited. In the nucleotide sequence of SEQ ID NO: 9, ATG codon encoding methionine at amino terminal of Thrombomodulin protein derived from human is represented in base No. 2590 to 2592, and a nucleotide sequence of the above exon 1 is represented in base No. 2048 to 6096. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 9, in particular, cytosine in CpG which is present in a region where CpGs are densely present in the nucleotide sequence of SEQ ID NO: 9 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as gastric cancer cells. More concretely, as cytosine exhibiting high methylation frequency in gastric cancer cells, for example, cytosines represented by base Nos. 1539, 1551, 1571, 1579, 1581, 1585, 1595, 1598, 1601, 1621, 1632, 1638, 1645, 1648, 1665, 1667, 1680, 1698, 1710,

EP 2 272 975 A1

1724, 1726, 1756 and so on in the nucleotide sequence of SEQ ID NO: 9 can be recited.

[0033] To be more specific, when the useful protein gene is a p53-responsive gene 2 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a p53-responsive gene 2 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 10 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 113501 to 116000 in the nucleotide sequence described in Genbank Accession No. AC009471) can be recited. In the nucleotide sequence of SEQ ID NO: 10, a nucleotide sequence of exon 1 of a p53-responsive gene 2 gene derived from human is represented in base No. 1558 to 1808. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 10 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented by base Nos. 1282, 1284, 1301, 1308, 1315, 1319, 1349, 1351, 1357, 1361, 1365, 1378, 1383 and so on in the nucleotide sequence of SEQ ID NO: 10 can be recited.

[0034] To be more specific, when the useful protein gene is a Fibrillin2 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Fibrillin2 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 11 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 118801 to 121000 in the nucleotide sequence described in Genbank Accession No. AC113387) can be recited. In the nucleotide sequence of SEQ ID NO: 11, a nucleotide sequence of exon 1 of a Fibrillin2 gene derived from human is represented in base No. 1091 to 1345. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 11 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented by base Nos. 679, 687, 690, 699, 746, 773, 777, 783, 795, 799, 812, 823, 830, 834, 843 and so on in the nucleotide sequence of SEQ ID NO: 11 can be recited.

[0035] To be more specific, when the useful protein gene is a Neurofilament3 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Neurofilament3 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 12 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 28001 to 30000 in the nucleotide sequence described in Genbank Accession No. AF106564) can be recited. In the nucleotide sequence of SEQ ID NO: 12, a nucleotide sequence of exon 1 of a Neurofilament3 gene derived from human is represented in base No. 614 to 1694. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 12 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented by base Nos. 428, 432, 443, 451, 471, 475, 482, 491, 499, 503, 506, 514, 519, 532, 541, 544, 546, 563, 566, 572, 580 and so on in the nucleotide sequence of SEQ ID NO: 12 can be recited.

[0036] To be more specific, when the useful protein gene is a disintegrin and metalloproteinase domain 23 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a disintegrin and metalloproteinase domain 23 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 13 (corresponding to a nucleotide sequence represented by base No. 21001 to 23300 in the nucleotide sequence described in Genbank Accession No. AC009225) can be recited. In the nucleotide sequence of SEQ ID NO: 13, a nucleotide sequence of exon 1 of a disintegrin and metalloproteinase domain 23 gene derived from human is represented in base No. 1194 to 1630. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 13 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented by base Nos. 998, 1003, 1007, 1011, 1016, 1018, 1020, 1026, 1028, 1031, 1035, 1041, 1043, 1045, 1051, 1053, 1056, 1060, 1066, 1068, 1070, 1073, 1093, 1096, 1106, 1112, 1120, 1124, 1126 and so on in the nucleotide sequence of SEQ ID NO: 13 can be recited.

[0037] To be more specific, when the useful protein gene is a G protein-coupled receptor 7 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a G protein-coupled receptor 7 gene derived from human, and a promoter region located 5' upstream

of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 14 (corresponding to a nucleotide sequence represented by base No. 75001 to 78000 in the nucleotide sequence described in Genbank Accession No. AC009800) can be recited. In the nucleotide sequence of SEQ ID NO: 14, a nucleotide sequence of exon 1 of a G protein-coupled receptor 7 gene derived from human is represented in base No. 1666 to 2652. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 14 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented by base Nos. 1480, 1482, 1485, 1496, 1513, 1526, 1542, 1560, 1564, 1568, 1570, 1580, 1590, 1603, 1613, 1620 and so on in the nucleotide sequence of SEQ ID NO: 14 can be recited.

[0038] To be more specific, when the useful protein gene is a G-protein coupled somatostatin and angiotensin-like peptide receptor gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a G-protein coupled somatostatin and angiotensin-like peptide receptor gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 15 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 57001 to 60000 in the nucleotide sequence described in Genbank Accession No. AC008971) can be recited. In the nucleotide sequence of SEQ ID NO: 15, a nucleotide sequence of exon 1 of a G-protein coupled somatostatin and angiotensin-like peptide receptor gene derived from human is represented in base No. 776 to 2632. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 15 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented by base Nos. 470, 472, 490, 497, 504, 506, 509, 514, 522, 540, 543, 552, 566, 582, 597, 610, 612 and so on in the nucleotide sequence of SEQ ID NO: 15 can be recited.

[0039] To be more specific, when the useful protein gene is a Solute carrier family 6 neurotransmitter transporter noradrenalin member 2 gene, as a nucleotide sequence that includes at least one nucleotide sequence represented by CpG present in a nucleotide sequence of its promoter region, untranslated region or translated region (coding region), a nucleotide sequence of a genomic DNA containing exon 1 of a Solute carrier family 6 neurotransmitter transporter noradrenalin member 2 gene derived from human, and a promoter region located 5' upstream of the same can be recited, and more concretely, the nucleotide sequence of SEQ ID NO: 16 (corresponding to a complementary sequence to a nucleotide sequence represented by base No. 78801 to 81000 in the nucleotide sequence described in Genbank Accession No. AC026802) can be recited. In the nucleotide sequence of SEQ ID NO: 16, a nucleotide sequence of exon 1 of a Solute carrier family 6 neurotransmitter transporter noradrenalin member 2 gene derived from human is represented in base No. 1479 to 1804. Cytosine in the nucleotide sequence represented by CpG which is present in the nucleotide sequence of SEQ ID NO: 16 exhibits high methylation frequency (namely, a high methylation state (hypermethylation)) in, for example, cancer cells such as pancreas cancer cells. More concretely, as cytosine exhibiting high methylation frequency in pancreas cancer cells, for example, cytosines represented by base Nos. 1002, 1010, 1019, 1021, 1051, 1056, 1061, 1063, 1080, 1099, 1110, 1139, 1141, 1164, 1169, 1184 and so on in the nucleotide sequence of SEQ ID NO: 16 can be recited.

[0040] The term "methylated DNA antibody" means an antibody that binds to a methylated base in DNA as its antigen. Concretely, it may be a methylcytosine antibody, and an antibody having a property of recognizing and binding to cytosine methylated at position 5 in single-stranded DNA can be recited. Also a commercially available methylated DNA antibody may be applicable as far as it specifically recognizes and specifically binds to DNA in a methylated state according to the present invention.

[0041] A methylated DNA antibody can be prepared by a conventional immunological technique from a methylated base, methylated DNA or the like as an antigen. Concretely, a methylcytosine antibody can be obtained by selecting from antibodies prepared against an antigen such as 5-methylcytidine, 5-methylcytosine or DNA containing 5-methylcytosine according to specific binding to methylcytosine in DNA as an index.

[0042] As an antibody obtainable by immunizing an animal against an antigen, after immunizing with a purified antigen, an antibody of an IgG fraction (polyclonal antibody), and an antibody produced by a single clone (monoclonal antibody) can be used. In the present invention, since an antibody capable of specifically recognizing methylated DNA or methylcytosine is desired, it is preferable to use a monoclonal antibody.

[0043] As a method of preparing a monoclonal antibody, a procedure based on a cell fusion method can be recited. For example, in the cell fusion method, a hybridoma is prepared by allowing cell fusion between a pancreatic cell (B cell) derived from an immunized mouse and a myeloma cell, and an antibody produced by the hybridoma is selected, and thus a methylcytosine antibody (monoclonal antibody) is prepared. When a monoclonal antibody is prepared by a cell fusion method, it is not necessary to purify an antigen, and for example, a mixture of 5-methyl cytidine, 5-methylcytosine or DNA or the like containing 5-methylcytosine may be administered as an antigen to an animal used for immunization. As an administration method, 5-methyl cytidine, 5-methylcytosine or DNA or the like containing 5-methylcytosine

is directly administered to a mouse for production of an antibody. When an antibody is difficult to be produced, an antigen bound to a support may be used for immunization.

5 [0044] Also, by thoroughly mixing an adjuvant solution (prepared, for example, by mixing liquid paraffin and Aracel A, and mixing killed tubercle bacilli as an adjuvant) and an antigen, and immunizing via liposome incorporating the same, immunity of an antigen can be improved. Also a method involving adding equivalent amounts of a solution containing an antigen and an adjuvant solution, fully emulsifying them, and subcutaneously or intraperitoneally injecting the resultant mixture to a mouse, and a method of adding killed Bordetella pertussis as an adjuvant after mixing well with alum water are known. A mouse may be boosted intraperitoneally or intravenously after an appropriate term from initial immunization. When the amount of an antigen is small, a solution in which the antigen is suspended may be directly injected into a mouse spleen to effect immunization.

10 [0045] After exenterating a spleen and peeling an adipose tissue off after several days from the final immunization, a spleen cell suspension is prepared. The spleen cell is fused, for example, with an HGPRT-deficient myeloma cell to prepare a hybridoma. As a cell fusion agent, any means capable of efficiently fusing a spleen cell (B cell) and a myeloma cell is applicable, and for example, a method of using a hemagglutinating virus of Japan (HVJ), polyethyleneglycol (PEG) and the like are recited. Cell fusion may be conducted by a method using a high voltage pulse.

15 [0046] After the cell fusion operation, cells are cultured in an HAT medium, a clone of a hybridoma in which a spleen cell and a myeloma cell are fused is selected, and the cell is allowed to grow until screening becomes possible. In a method of detecting an antibody from a hybridoma that produces an intended antibody, or a method of measuring a titer of an antibody, an antigen-antibody reaction system may be used. Concretely, as a method of measuring an antibody against a soluble antigen, a radioisotope immune assay (RIA), an enzyme-linked immunosorbent assay (ELISA) and the like can be recited.

20 [0047] Single-stranded DNA is able to bind with an anti methylation antibody as far as at least one position of a CpG existing therein is methylated. The term "methylated single-stranded DNA" in the present invention means single-stranded DNA in which at least one position of a CpG existing in single-stranded DNA is methylated, rather than meaning exclusively single-stranded DNA in which every CpG existing in single-stranded DNA is methylated.

25 [0048] The expression "an amount of amplified DNA obtained by (amplifying methylated DNA in a target DNA region to a detectable level)" means an amount itself after amplification of methylated DNA in a target region comprised by genomic DNA contained in a biological specimen, namely, an amount determined in Third step of the present invention as described below. For example, when the biological specimen is 1 mL of serum, it means an amount of DNA amplified based on the methylated DNA contained in 1 mL of serum.

30 [0049] In First step, a DNA sample derived from genomic DNA contained in a biological specimen is subjected to a digestion treatment with a methylation-sensitive restriction enzyme.

35 [0050] The "methylation-sensitive restriction enzyme" in the present invention, for example, a restriction enzyme or the like that does not digest a recognition sequence containing methylated cytosine, but digests only a recognition sequence containing unmethylated cytosine. In other words, in the case of DNA wherein cytosine contained in a recognition sequence inherently recognizable by the methylation sensitive restriction enzyme is methylated, the DNA will not be cleaved even when the methylation sensitive restriction enzyme is caused to act on the DNA. On the other hand, in the case of DNA wherein cytosine contained in a recognition sequence inherently recognizable by the methylation sensitive restriction enzyme is not methylated, the DNA will be cleaved when the methylation sensitive restriction enzyme is caused to act on the DNA. Concrete examples of such methylation sensitive restriction enzymes include HpaII, BstUI, NarI, SacII, and HhaI which are restriction enzymes recognition cleavage site for which is present in the objective DNA region of the genomic DNA contained in a biological specimen. The aforementioned methylation sensitive restriction enzymes have already been revealed by Gruenbaum et al. (Nucleic Acid Research, 9, 2509-2515).

40 [0051] As a method of examining whether or not digestion by the methylation sensitive restriction enzyme occurs, concretely, for example, a method of conducting PCR using a pair of primers capable of amplifying DNA containing cytosine which is a target of analysis in a recognition sequence while using the DNA as a template, and examining whether or not the DNA is amplified (amplified product) can be recited. When the cytosine which is a target of analysis is methylated, an amplified product is obtained. On the other hand, when the cytosine which is a target of analysis is not methylated, an amplified product is not obtained. In this manner, by comparing the amounts of amplified DNA, it is possible to measure the methylated rate of the cytosine which is a target of analysis. In brief, when genomic DNA contained in the biological specimen is methylated, it is possible to distinguish whether or not cytosine in CpG pair existing in the recognition site of the methylation sensitive restriction enzyme in genomic DNA contained in the biological specimen is methylated by utilizing the characteristic that the methylation sensitive restriction enzyme fails to cleave methylated DNA. In other words, when cytosine in at least one CpG pair existing in the recognition site of the methylation sensitive restriction enzyme in genomic DNA contained in the biological specimen is not methylated, the DNA having such a recognition site will be cleaved by the methylation sensitive restriction enzyme when it is subjected to a digestion treatment with the methylation sensitive restriction enzyme. Further, when cytosine in every CpG pair existing in the recognition site of the methylation sensitive restriction enzyme in genomic DNA contained in the biological specimen is

methylated, the DNA having such a recognition site will not be cleaved by the methylation sensitive restriction enzyme. Therefore, by conducting PCR using a pair of primers capable of amplifying the objective DNA region as will be described later after executing the digestion treatment, an amplified product by PCR will not be obtained when cytosine in at least one CpG pair existing in the recognition site of the methylation sensitive restriction enzyme in genomic DNA contained in the biological specimen is not methylated, and on the other hand, an amplified product by PCR will be obtained when cytosine in every CpG pair existing in the recognition site of the methylation sensitive restriction enzyme in genomic DNA contained in the biological specimen is methylated.

[0052] Concretely, First step may be executed, for example, in the following manner when genomic DNA contained in the biological specimen is genomic DNA from mammals. Genomic DNA from mammals is added with 3 μ L of an optimum 10 x buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 3 μ L of 1 mg/mL BSA aqueous solution, each 1.5 μ L of a methylation sensitive restriction enzyme such as HpaII or HhaI (10 U/ μ L), and the resultant mixture is added with sterilized ultrapure water to make the liquid amount 30 μ L, and incubated at 37°C for one to three hours.

[0053] Preferred embodiments of the treatment with a methylation-sensitive restriction enzyme in First step include addition of a masking oligonucleotide. In particular, the treatment may comprise First (A) step of mixing a single-stranded DNA (plus strand) containing the objective DNA region and a masking oligonucleotide comprising a nucleotide sequence complementary to a nucleotide sequence of a recognition site for a methylation-sensitive restriction enzyme, thereby selecting single-stranded DNA in which the recognition site for the methylation-sensitive restriction enzyme is protected; and First (B) step of digesting the single-stranded DNA selected in First (A) step with the methylation-sensitive restriction enzyme. In particular, for example, a masking oligonucleotide may be added to a solution for the treatment with a methylation-sensitive restriction enzyme.

[0054] By undergoing First (A) and First (B) steps, any DNA sample derived from a genomic DNA contained in a biological specimen may be digested with a methylation-sensitive restriction enzyme with double-stranded DNA exclusively as a substrate, even if the DNA sample is single-stranded DNA. First (A) and First (B) steps may be performed either simultaneously or sequentially.

[0055] The term "masking oligonucleotide" means oligonucleotide having a nucleotide sequence complementary to the nucleotide sequence of the recognition site of the methylation sensitive restriction enzyme, and is oligonucleotide that forms double strand by complementary base-pairing at least one site (even every site is possible) of several recognition sites of the methylation sensitive restriction enzyme contained in the objective DNA region in the single-stranded DNA (that is, the site is made into double-stranded state), thereby enabling the methylation sensitive restriction enzyme that uses only double-stranded DNA as a substrate to digest the site, and improving digestion efficiency at the site for the methylation sensitive restriction enzyme capable of digesting single-stranded DNA (methylation sensitive restriction enzyme capable of digesting single-stranded DNA also digests double-stranded DNA, and digestion efficiency thereof is higher with respect to double-stranded DNA than with respect to single-stranded DNA), and means oligonucleotide not inhibiting formation of double strand between single-stranded DNA containing the objective DNA region and single-stranded immobilized oligonucleotide. Further, when a sample is a single-stranded DNA, the masking oligonucleotide should be oligonucleotide that is unavailable in a reaction for extending an extension primer by using a later-described reverse primer (plus strand) as the extension primer and the masking oligonucleotide (minus strand) as a template. As a nucleotide length, 8 to 200 bases long is preferred.

[0056] The masking oligonucleotide to be mixed with a DNA sample derived from genomic DNA may be one kind or plural kinds. When plural kinds are used, many of recognition sites of the methylation sensitive restriction enzyme in the single-stranded DNA containing the objective DNA region become double-strand state, and "DNA remaining undigested" as will be described later by the methylation sensitive restriction enzyme can be minimized. For example, it is particularly useful to use the masking oligonucleotide designed in accordance with a site intended not to be digested when it is methylated and intended to be digested when it is not methylated among several recognition sequences of the methylation sensitive restriction enzyme contained in the objective DNA region (for example, the site that is methylated at 100% in a diseased patient specimen, but is not methylated at 100% in a healthy specimen).

[0057] As a concern in a digestion treatment in First step, a fear that a recognition sequence containing non-methylated cytosine cannot be completely digested (so called "DNA remaining undigested") can be recited. When such a fear is problematic, since the "DNA remaining undigested" can be minimized if recognition sites of the methylation sensitive restriction enzyme abundantly exist, it is considered that as the objective DNA region, the one having one or more recognition sites of the methylation sensitive restriction enzyme is preferred and the more the better.

[0058] One preferable embodiment is that "a DNA sample derived from a genomic DNA contained in a biological specimen" is a DNA sample digested in advance with a restriction enzyme recognition cleavage site for which is not present in the objective DNA region possessed by the genomic DNA. Here, when a digested substance of a genomic DNA contained in a biological specimen is selected with the use of present immobilized oligonucleotide, shorter template DNA is more likely to be selected, and when the objective region is amplified by PCR, shorter template DNA is more preferred. Therefore, a digestion treatment may be executed while using a restriction enzyme whose recognition cleavage

site excludes the objective DNA region directly on the DNA sample derived from a genomic DNA contained in a biological specimen. As a method of digesting with a restriction enzyme recognition cleavage site for which is not present in the objective DNA region, a commonly used restriction enzyme treatment method may be used. These embodiments are preferred because the methylation amount can be determined accurately by digesting the biological specimen itself in advance with a restriction enzyme as described above. Such a method is useful for avoiding the "DNA remaining undigested" as described above.

[0059] As a method of digesting a sample derived from a genomic DNA contained in a biological specimen with the methylation sensitive restriction enzyme, when the biological specimen is a genomic DNA itself, the method similar to that described above is preferred, and when the biological specimen is a tissue lysate, a cell lysate or the like, a digestion treatment may be executed using a large excess of methylation sensitive restriction enzyme, for example, a methylation sensitive restriction enzyme in an amount of 500 times (10 U) or more with respect to 25 ng of the DNA amount, according to a similar method as described above.

[0060] Basically, genomic DNA exists as double-stranded DNA. Therefore, in the present operation, not only a methylation sensitive restriction enzyme (for example, HhaI) capable of digesting single-stranded DNA, but also a methylation sensitive restriction enzyme capable of digesting double-stranded DNA (for example, HpaII, BstUI, NarI, SacII, HhaI and the like) may be used.

[0061] As another embodiment of First step, executing Second step without executing a digestion treatment with a methylation sensitive restriction enzyme capable of digesting single-stranded DNA can be recited. When there is no nucleotide sequence that is cleaved by a methylation sensitive restriction enzyme capable of digesting single-stranded DNA in the objective DNA region, Second step may be executed without executing First step.

[0062] In Second step of the present measuring method, methylated single-stranded DNA is obtained from the DNA sample that has been subjected to the digestion treatment and obtained in First step, and the single-stranded DNA is bound to an immobilized methylated DNA antibody, thereby selecting the single-stranded DNA. Second step may comprise Second (A) step of separating into methylated single-stranded DNA the methylated double-stranded DNA contained in the DNA sample that has been subjected to the digestion treatment and obtained in First step; and Second (B) step of binding the methylated single-stranded DNA obtained in Second (A) step to an immobilized methylated DNA antibody.

[0063] In Second (A) step of the present measuring method, in "separating into methylated single-stranded DNA the methylated double-stranded DNA contained in the DNA sample that has been subjected to the digestion treatment and obtained in First step", a commonly used operation for making double-stranded DNA into single-stranded DNA may be conducted. Concretely, a DNA sample derived from genomic DNA contained in a biological specimen may be dissolved in an appropriate amount of ultrapure water, heated at 95°C for 10 minutes, and rapidly cooled on ice.

[0064] In Second (B) step, the methylated single-stranded DNA obtained in Second (A) step is bound to an immobilized methylated DNA antibody, thereby selecting the single-stranded DNA. The immobilized methylated DNA antibody is used for selecting methylated single-stranded DNA from a DNA sample derived from genomic DNA contained in a biological specimen. The immobilized methylated DNA antibody may be one immobilizable to a support, and the expression "one immobilizable to a support" means that a immobilized methylated DNA antibody can be immobilized to a support directly or indirectly. For achieving such immobilization, a immobilized methylated DNA antibody may be immobilized to a support according to a commonly used genetic engineering operation method or a commercially available kit, apparatus or the like (binding to a solid phase). Concretely, a method of immobilizing a biotinylated immobilized methylated DNA antibody obtained by biotinylating an immobilized methylated DNA antibody to a support coated with streptavidin (for example, a PCR tube coated with streptavidin, magnetic beads coated with streptavidin and so on) can be recited.

[0065] Also there is a method of letting a molecule having an active functional group such as an amino group, a thiol group, or an aldehyde group covalently bind to an immobilized methylated DNA antibody, and letting the resultant bound body covalently bind to a support made of glass, a polysaccharide derivative, silica gel, the synthetic resin or thermostable plastic whose surface is activated with a silane coupling agent or the like. Covalent bonding may be achieved, for example, using a spacer formed by serially connecting five triglycerides, a cross linker or the like.

[0066] An immobilized methylated DNA antibody may be directly immobilized to a support, or an antibody against an immobilized methylated DNA antibody (secondary antibody) may be immobilized to a support, and a methylated antibody may be bound to the secondary antibody to achieve immobilization to a support.

[0067] It suffices that the present immobilized immobilized methylated DNA antibody is immobilized to a support when single-stranded DNA (plus strand) containing the objective DNA region is selected, and (1) immobilization may be achieved by binding between the present immobilized immobilized methylated DNA antibody and a support before binding between the single-stranded DNA (plus strand) and the present immobilized immobilized methylated DNA antibody, or (2) immobilization may be achieved by binding between the present immobilized immobilized methylated DNA antibody and a support after binding between the single-stranded DNA (plus strand) and the present immobilized immobilized methylated DNA antibody.

[0068] In Second (B) step, when "the single-stranded DNA is selected by binding between methylated single-stranded

DNA and an immobilized methylated DNA antibody," it may be concretely executed in the following manner, for example, using a "biotin-labeled biotinylated methylated cytosine antibody" as an immobilized methylated DNA antibody.

5 (a) An avidin-coated PCR tube is added with an appropriate amount (for example, 0.1 $\mu\text{g}/50 \mu\text{L}$) of a biotinylated methylated cytosine antibody, left still at room temperature for about an hour, to promote immobilization between the biotinylated methylated cytosine antibody and streptavidin. Then the remaining solution is removed and washing is performed. A washing buffer [for example, a 0.05% Tween 20-containing phosphate buffer (1 mM KH_2PO_4 , 3 mM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 154 mM NaCl, pH 7.4)] is added in a proportion of 100 $\mu\text{L}/\text{tube}$, and the solution is removed. This washing operation is repeated several times, to leave the biotinylated methylated cytosine antibody immobilized to a support inside the PCR tube.

10 (b) Double-stranded DNA derived from genomic DNA contained in a biological specimen is mixed with a buffer (for example, 33 mM Tris-Acetate pH 7.9, 66 mM KOAc, 10 mM MgOAc_2 , 0.5 mM Dithiothreitol) and heated at 95°C for several minutes. Then the reaction is rapidly cooled to about 0 to 4°C, and kept for several minutes at this temperature to cause formation of single-stranded DNA. Then the reaction is returned to room temperature.

15 (c) The formed single-stranded DNA is added to an avidin-coated PCR tube to which a biotinylated methylated cytosine antibody is immobilized, and then left still at room temperature for about an hour, to promote binding between the biotinylated methylated cytosine antibody and methylated single-stranded DNA among the single-stranded DNA (formation of a bound body)(in this stage, at least single-stranded DNA containing an unmethylated DNA region does not form a bound body). Thereafter, the remaining solution is removed and washing is performed. A washing buffer [for example, a 0.05% Tween 20-containing phosphate buffer (1 mM KH_2PO_4 , 3 mM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 154 mM NaCl, pH 7.4)] is added in a proportion of 100 $\mu\text{L}/\text{tube}$, and the solution is removed. This washing operation is repeated several times, to leave the bound body inside the PCR tube (selection of a bound body).

25 **[0069]** The buffer used in (b) is not limited to the above buffer and may be any buffer that is suited for separating double-stranded DNA derived from genomic DNA from a biological sample into single-stranded DNA.

30 **[0070]** The washing operation in (a) and (c) is important for removing an unimmobilized methylated DNA antibody suspended in the solution, unmethylated single-stranded DNA that does not bind with a immobilized methylated DNA antibody and hence is suspended in the solution, and DNA suspended in a solution digested by a restriction enzyme as will be described later, from the reaction solution. The washing buffer is not limited to the foregoing washing buffer, and any buffer suited for removing the free immobilized methylated DNA antibody, single-stranded DNA and so on suspended in the solution and the like is applicable, and a DELFIA buffer (available from Perkin Elmer, Tris-HCl pH 7.8 with Tween 80), a TE buffer and the like may be used.

35 **[0071]** In Second (A) step, as a preferred embodiment in separating methylated single-stranded DNA, addition of a counter oligonucleotide and the like can be recited. A counter oligonucleotide means a short oligonucleotide comprising a part of the same nucleotide sequence as that of the objective DNA region. It may be designed to have a length of usually 10 to 100 bases, and more preferably 20 to 50 bases. Here, a counter oligonucleotide is not designed on the nucleotide sequence where a forward primer or a reverse primer complementarily binds with the target DNA region. A counter oligonucleotide is added in excess relative to genomic DNA, and is added so as to prevent a complementary strand of a target DNA region (minus strand) and a single strand of a target DNA region (plus strand) from re-binding by complementation when binding with an immobilized methylated DNA antibody is caused after making a target DNA region into a single strand (plus strand). This is because in measuring a methylation frequency of DNA or an index value having correlation therewith while a methylated DNA antibody is bound to the target DNA region, the target region is more likely to bind with the methylated DNA antibody when it is a single strand. Preferably, a counter oligonucleotide is added in an amount of at least 10 times, usually 100 times or more relative to the target DNA region.

40 **[0072]** "Adding a counter oligonucleotide in separating methylated single-stranded DNA" may be concretely achieved by mixing a DNA sample derived from genomic DNA contained in a biological specimen with a counter oligonucleotide to form a double strand between the complementary strand of the target DNA region and the counter oligonucleotide so as to select methylated single-stranded DNA from a DNA sample derived from genomic DNA contained in a biological specimen. For example, the DNA sample and the counter oligonucleotide are added to 5 μL of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc_2 , 5 mM Dithiothreitol), 5 μL of a 100 mM MgCl_2 solution, and 5 μL of a 1 mg/mL of BSA solution, and the resultant mixture is added with sterile ultrapure water to a liquid volume of 50 μL , and mixed, heated at 95°C for 10 minutes, rapidly cooled to 70°C, kept at this temperature for 10 minutes, then cooled to 50°C, kept at this temperature for 10 minutes, and then kept at 37°C for 10 minutes and returned to room temperature.

55 **[0073]** Third step comprises, as a pre step of each of the following regular steps:

a step (First pre step) of separating the single-stranded DNA selected in Second step from the immobilized immobilized methylated DNA antibody to provide DNA in a single-stranded state (plus strand);

a step (Second pre step) of extensionally-forming a double-stranded DNA from a single-stranded DNA (plus strand) containing the objective DNA region by a single extension of an extension primer, using the genomic DNA (plus strand) provided in a single-stranded state in First pre step and the extension primer, wherein the extension primer (forward primer) comprises the nucleotide sequence (minus strand) complementary to a partial nucleotide sequence (plus strand) of the nucleotide sequence of the DNA in a single-stranded state (plus strand), the partial nucleotide sequence (plus strand) being located on further 3'-end side than the 3'-end of the nucleotide sequence (plus strand) of the objective DNA region; and

a step (Third pre step) of temporarily separating the double-stranded DNA extensionally formed in Second pre step into a single-stranded DNA (plus strand) containing the objective DNA region and a single-stranded DNA (minus strand) containing the nucleotide sequence complementary to the objective DNA region; and as regular steps:

(a) Step A (regular step) of extensionally forming double-stranded DNA from the single-stranded DNA containing the objective DNA region, by a single extension of the extension primer, using as a template the generated single-stranded DNA (plus strand) containing the objective DNA region, and the forward primer as the extension primer; and

(b) Step B (regular step) of extensionally forming double-stranded DNA from the single-stranded DNA containing the objective DNA region, by a single extension of an extension primer, using as a template the generated single-stranded DNA (minus strand) containing the nucleotide sequence complementary to the objective DNA region, and using as the extension primer an extension primer (reverse primer) comprising the nucleotide sequence (plus strand) complementary to a partial nucleotide sequence (minus strand) of the nucleotide sequence of the single-stranded DNA (minus strand) containing the nucleotide sequence complementary to the objective DNA region, the partial nucleotide sequence (minus strand) being located on further 3'-end side than the 3'-end of the nucleotide sequence (minus strand) complementary to the nucleotide sequence (plus strand) of the objective DNA region; and wherein Third step further comprises amplifying the methylated DNA in the objective DNA region to a detectable level by repeating each regular step of Third step after temporarily separating the extensionally formed double-stranded DNA obtained in each of the regular steps into a single-stranded state; and quantifying the amount of the amplified DNA.

[0074] In Third step, first, as First pre step among the respective pre steps of the following regular steps, single-stranded DNA selected in Second step is temporarily separated from the immobilized methylated DNA antibody into DNA in a single-stranded state. Concretely, for example, by adding an annealing buffer to single-stranded DNA selected in Second step, a mixture is obtained. Then the resultant mixture is heated at 95°C for several minutes, to obtain DNA in a single-stranded state (plus strand). Thereafter, in Second pre step, concretely, for example, DNA in a single-stranded state (plus strand) obtained in First pre step and a forward primer are mixed in a solution that is prepared by adding 17.85 µL of sterile ultrapure water, 3 µL of an optimum buffer (for example, 100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl₂), 3 µL of 2 mM dNTP, and 6 µL of 5 N betaine, and adding the resultant mixture with 0.15 µL of AmpliTaq (a kind of DNA polymerase: 5 U/µL) to a liquid volume of 30 µL, and incubated at 37°C for about two hours, to extensionally form double-stranded DNA from the single-stranded DNA (plus strand) containing an objective DNA region. In Third pre C step, concretely, for example, the double-stranded DNA extensionally formed in Second pre step is added with an annealing buffer to obtain a mixture, and the DNA is temporarily separated into single-stranded DNA containing the target DNA region by heating the mixture at 95°C for several minutes.

[0075] Thereafter, the following regular steps are conducted.

(i) The reaction is rapidly cooled to a temperature lower than T_m of the forward primer by about 0 to 20°C, and kept at this temperature for several minutes for annealing the forward primer to the generated single-stranded DNA (plus strand) containing the target DNA region.

(ii) Thereafter, the reaction is returned to room temperature.

(iii) Double-stranded DNA is extensionally formed from single-stranded DNA comprising the nucleotide sequence complementary to the objective DNA region by one extension of an extension primer by using the DNA in a single-stranded state annealed in the above (i) as a template, and the forward primer as an extension primer (namely, Step A). Concretely, it may be executed, for example, according to the later-described explanation, or the operation method in an extension reaction in Second pre step of the present invention as described above.

(iv) Single-stranded DNA is made into extensionally formed double-stranded DNA by one extension of an extension primer by using the generated single-stranded DNA (minus strand) comprising the nucleotide sequence complementary to the target DNA region as a template, and an extension primer (reverse primer) comprising a nucleotide sequence (plus strand) which is complementary to a partial nucleotide sequence (minus strand) of the nucleotide sequence comprised by the single-stranded DNA (minus strand) containing the target DNA region, the partial nu-

cleotide sequence (minus strand) located on further 3'-end side than 3'-end of the nucleotide sequence (minus strand) complementary to the nucleotide sequence (plus strand) of the target DNA region as the extension primer (namely, Step B). Concretely, it may be executed, for example, according to the operation method in an extension reaction in Second pre step similarly to Step A of the above (iii).

(v) By repeating the regular steps of Third step after temporarily separating the extensionally formed double-stranded DNA obtained in each of the regular steps into a single-stranded state (for example, Step A and Step B), the methylated DNA in the objective DNA region is amplified to a detectable level and a content of the amplified DNA is quantified.

[0076] In Third step, concretely the reaction starting from First pre step and up to regular steps may be executed as a single PCR reaction. Also, from First pre step step to Third pre step, each reaction may be independently executed, and only regular steps may be executed as a PCR reaction.

[0077] As a method of amplifying an objective DNA region (namely, an objective region) contained in the selected single-stranded DNA, for example, PCR may be used. Using a primer preliminarily labeled with fluorescence or the like and utilizing the label as an index in amplifying the target region make it possible to evaluate presence or absence of an amplification product without executing a burdensome operation such as electrophoresis. As a PCR reaction solution, for example, a reaction solution obtained by mixing DNA obtained in Second step of the present measuring method with 0.15 μ L of a 50 μ M primer solution, 2.5 μ L of 2 mM dNTP, 2.5 μ L of a 10 x buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 20 mM MgCl₂, 0.01% Gelatin), and 0.2 μ L of AmpliTaq Gold (one kind of thermostable DNA polymerase: 5 U/ μ L), and adding sterilized ultrapure water to make the liquid volume 25 μ L can be recited.

[0078] Since an objective DNA region (namely, an objective region) often has a GC rich nucleotide sequence, the reaction may be occasionally executed with addition of an appropriate amount of betaine, DMSO or the like. In one exemplary reaction condition, the reaction solution as described above is kept at 95°C for 10 minutes, and then a cycle including incubation of 30 seconds at 95°C, 30 seconds at 55 to 65°C, and 30 seconds at 72°C is repeated 30 to 40 times. After conducting such PCR, the obtained amplification product is detected. For example, when a preliminarily labeled primer is used, an amplification amount by a PCR reaction can be evaluated by measuring an amount of a fluorescent label after executing washing and purification operations similar to those as described above. When PCR is conducted using a normal primer that is not labeled, a probe or the like that is labeled with a gold colloid particle, fluorescence or the like is caused to anneal, and detection may be achieved by measuring an amount of the probe bound to the target region. Also, for determining an amount of an amplification product more accurately, for example, a real time PCR method may be used. Real time PCR is a method in which PCR is monitored in real time, and the obtained monitor result is analyzed kinetically, and is known as a high-accuracy quantitative PCR method capable of detecting a very small difference of as small as twice in a gene amount. As such a real time PCR method, for example, a method using a probe such as a template-dependent nucleic acid polymerase probe, a method using an intercalator such as SYBR-Green and the like can be recited. As an apparatus and a kit for the real time PCR method, those commercially available may be used. As described above, detection may be executed by any method conventionally well-known without any particular limitation. These methods make it possible to conduct the operations up to detection without requiring change of the reaction container.

[0079] The present invention may be used in the following situations.

[0080] It is known that DNA methylation abnormality occurs in various diseases (for example, cancer), and it is believed that the degree of various diseases can be measured by detecting this DNA methylation abnormality.

[0081] For example, when there is a DNA region where methylation occurs at 100% in genomic DNA contained in a diseased biological specimen, and the present invention is executed for the DNA region, the amount of methylated DNA will increase. For example, when there is a DNA region where methylation does not occur at 100% in genomic DNA contained in a diseased biological specimen, and the present measuring method is executed for the DNA region, the amount of methylated DNA will be approximately 0. For example, when there is a DNA region which is in hypomethylation in genomic DNA contained in a specimen derived from a healthy subject, and in hypermethylation in genomic DNA contained in a specimen derived from a disease subject, and the present measuring method is executed for the DNA region, the amount of methylated DNA would be approximately 0 for the healthy subject, and a significantly higher value than that of the healthy subject will be exhibited by the disease patient, so that the "degree of disease" can be determined based on this difference in value. The "degree of disease" used herein has the same meaning commonly used in this field of art, and concretely means, for example, malignancy when the biological specimen is a cell, and means, for example, abundance of disease cells in the tissue when the biological specimen is a tissue. Further, when the biological specimen is plasma or serum, it means the probability that the individual has the disease. Therefore, the present measuring method makes it possible to diagnose various diseases by examining methylation abnormality.

[0082] Restriction enzymes, primers or probes that can be used in various methods for measuring a methylated DNA amount in a target region in the present measuring method are useful as reagents of a detection kit. The present invention also provides a detection kit containing these restriction enzymes, primers or probes as reagents, and a detection chip

EP 2 272 975 A1

in which these primers, probes and so on are immobilized on a support, and a scope of the present measuring method or the present methylation rate measuring method of course embraces use in the form of a detection kit or a detection chip as described above utilizing the substantial principle of the method.

5 Examples

[0083] In the following, the present invention will be explained in detail by way of examples, however, the present invention will not be limited to these examples.

10 Example 1

[0084] A commercially available methylated cytosine antibody (available from Aviva Systems Biology) was labeled with biotin using a commercially available biotinylating kit (Biotin Labeling Kit-NH₂, available from DOJINDO Laboratories) according to the method described in the catalogue. The obtained biotin-labeled methylated cytosine antibody was refrigerated as a solution [about 0.1 μg/100 μL solution of an antibody in a 0.1% BSA-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO · 7H₂O, 154 mM NaCl, pH 7.4)].

[0085] To each PCR tube coated with streptavidin (a total of 9 tubes), 50 μL of the synthetically obtained biotin-labeled methylcytosine antibody solution was added and immobilized to the PCR tube by leaving it still for about an hour at room temperature. Then, after removing the solution by pipetting, 100 μL of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO · 7H₂O, 154 mM NaCl, pH 7.4)] was added, and then the buffer was removed by pipetting. This operation was repeated another two times (these correspond to preparation of an immobilized methylated DNA antibody used in the present measuring method).

[0086] A partially methylated oligonucleotide GPR7-2079-2176/98 mer-M(7) in which a recognition site of HpaII comprising the nucleotide sequence of SEQ ID NO: 17 is methylated; a partially methylated oligonucleotide GPR7-2079-2176/98 mer-HM(5) in which part of a recognition site of HpaII having the nucleotide sequence of SEQ ID NO: 18 is not methylated; and an unmethylated oligonucleotide GPR7-2079-2176/98 mer-UM having the nucleotide sequence of SEQ ID NO: 19 were synthesized, and a 0.001 pmol/10 μL solution in a TE buffer was prepared for each oligonucleotide.

<Partially methylated oligonucleotide in which recognition sequence of HpaII is methylated>

[0087] N denotes methylated cytosine.

GPR7-2079-2176/98mer-M(7) :

5' -

GTTGGCCACTGCGGAGTCGNGCNGGGTGGCNGGCCGCACCTACAGNGCCGNGNGNGCGGTGA

GCCTGGCCGTGTGGGGGATCGTCACACTCGTCGTGC-3' (SEQ ID NO: 17)

<Partially methylated oligonucleotide in which recognition sequence of HpaII is not methylated>

[0088] N denotes methylated cytosine.

GPR7-2079-2176/98mer-HM(5) :

5' -

GTTGGCCACTGCGGAGTCGCGCCGGGTGGCNGGCCGCACCTACAGNGCCGNGNGNGCGGTGA

GCCTGGCCGTGTGGGGGATCGTCACACTCGTCGTGC-3' (SEQ ID NO: 18)

EP 2 272 975 A1

<Unmethylated oligonucleotide>

[0089]

5 GPR7-2079-2176/98mer-UM:
5' -
10 GTTGGCCACTGCGGAGTCGCGCCGGGTGGCCGGCCGCACCTACAGCGCCGCGCGCGGGTGA
GCCTGGCCGTGTGGGGGATCGTCACACTCGTCGTGC-3' (SEQ ID NO: 19)

15 **[0090]** Each of the obtained solutions (each solution was prepared in triplicate) was subjected to the following A treatment, B treatment or C treatment (each prepared singly).

[0091] A treatment group (no treatment group): The sample prepared above was added with 5 μ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), and 5 μ L of BSA (Bovine serum albumin 1 mg/mL), and the resultant mixture was added with sterile ultrapure water to a liquid volume of 50 μ L.

20 **[0092]** B treatment group (HpaII treatment group): The sample prepared above was added with 5 μ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 5 μ L of BSA (Bovine serum albumin 1 mg/mL), and 10 U of HpaII, and the resultant mixture was added with sterile ultrapure water to a liquid volume of 50 μ L.

25 **[0093]** C treatment group (addition of masking oligonucleotide + HpaII treatment group): The sample prepared above was added with 5 μ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 5 μ L of BSA (Bovine serum albumin 1 mg/mL), 10 U of HpaII, and 5 pmol of the oligonucleotide MA comprising the nucleotide sequence of SEQ ID NO: 20 as masking oligonucleotide, and the resultant mixture was added with sterile ultrapure water to a liquid volume of 50 μ L.

<Masking oligonucleotide>

30 **[0094]** MA: 5'-GCCACCCGGCGCGA-3' (SEQ ID NO: 20)

[0095] Each reaction mixture was incubated overnight at 37°C (these correspond to First step of the present invention).

35 **[0096]** The PCR tube coated with streptavidin to which a biotin-labeled methylcytosine antibody was immobilized was added with 50 μ L of a reaction solution of an oligonucleotide prepared as described above, and left still for an hour at room temperature. Then the solution was removed by pipetting, and 100 μ L of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄ · 7H₂O, 154 mM NaCl, pH 7.4)] was added, and then the buffer was removed by pipetting. This operation was repeated another two times (these correspond to Second step of the present invention).

40 **[0097]** Next, the above PCR tube was subjected to PCR using each solutions of a primer comprising the nucleotide sequences of SEQ ID NO: 21 and a primer comprising the nucleotide sequences of SEQ ID NO: 22 (PF1 and PR1), and the following reaction condition, to amplify methylated DNA in a target DNA region (GPR7-2079-2176, SEQ ID NO: 23, methylated cytosine is also denoted by C).

<Primers>

45 **[0098]**

PF1: 5'-GTTGGCCACTGCGGAGTCG-3' (SEQ ID NO: 21)

PR1: 5'-GCACGACGAGTGTGACGATC-3' (SEQ ID NO: 22)

50 <Target DNA region>

[0099]

55

GPR7-2079-2176: 5' -

GTTGGCCACTGCGGAGTCGCGCCGGGTGGCCGGCCGCACCTACAGCGCCGCGCGCGGGTGA

GCCTGGCCGTGTGGGGGATCGTCACACTCGTCGTGC-3' (SEQ ID NO: 23)

[0100] A reaction solution of PCR was prepared by mixing each 5 μ L of a solution of primer comprising the nucleotide sequence of SEQ ID NO: 21 and a solution of primer comprising the nucleotide sequence of SEQ ID NO: 22 prepared to 3 μ M, each 5 μ L of 2 mM dNTPs, 5 μ L of a buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl₂, 0.01% Gelatin), 0.25 μ L of 5 U/ μ L thermostable DNA polymerase (AmpliTaq Gold), and 10 μ L of a 5 N betaine aqueous solution to DNA which is a template, and adding sterile ultrapure water to a liquid volume of 50 μ L. The reaction solution was kept at 95°C for 10 minutes, and then subjected to PCR conducting 25 cycles of incubation each including 30 seconds at 95°C, 30 seconds at 59°C, and 45 seconds at 72°C.

[0101] After conducting PCR, the amplification of DNA was checked by 2% agarose gel electrophoresis (these correspond to Third step of the present invention). The result is shown in Fig. 1.

[0102] In the case of A treatment group (no treatment group), in the partially methylated oligonucleotide GPR7-2079-2176/98 mer-M(7) in which the recognition sequence of HpaII is methylated, and the partially methylated oligonucleotide GPR7-2079-2176/98 mer-HM(5) in which part of the recognition sequence of HpaII is not methylated, amplification of DNA was observed, and an amplification product thereof (target DNA region: GPR7-2079-2176) was obtained. In the unmethylated oligonucleotide GPR7-2079-2176/98 mer-UM, amplification of DNA was not observed, and an amplification product thereof was not obtained. Also in the case of B treatment group (HpaII treatment group), the result was similar to that in A treatment group. In the case of C treatment group (addition of masking oligonucleotide + HpaII treatment group), in the partially methylated oligonucleotide GPR7-2079-2176/98 mer-M(7) in which the recognition sequence of HpaII is methylated, amplification of DNA was observed, and an amplification product thereof (target DNA region: GPR7-2079-2176) was obtained. Contrarily, in the cases of the partially methylated oligonucleotide GPR7-2079-2176/98 mer-HM(5) in which part of the recognition sequence of HpaII is not methylated, and in the unmethylated oligonucleotide GPR7-2079-2176/98 mer-UM, amplification of DNA was not observed, and an amplification product thereof was not obtained.

[0103] From the above, it was demonstrated that single-stranded DNA containing a methylated target DNA region can be selected by an immobilized methylated cytosine antibody, and a target DNA region in which methylation sensitive restriction enzyme recognition site is unmethylated and protected by a masking oligonucleotide can be digested by a treatment with a methylation sensitive restriction enzyme after addition and mixing of a masking oligonucleotide, and only methylated DNA can be amplified to a detectable level and an amount of amplified DNA can be quantified while unmethylated DNA in the target DNA region is not amplified.

Example 2

[0104] A commercially available methylated cytosine antibody (available from Aviva Systems Biology) was labeled with biotin using a commercially available biotinylating kit (Biotin Labeling Kit-NH₂, available from DOJINDO Laboratories) according to the method described in the catalogue. The obtained biotin-labeled methylated cytosine antibody was refrigerated as a solution [about 0.25 μ g/ μ L solution of an antibody in a 0.1% BSA-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄ · 7H₂O, 154 mM NaCl, pH 7.4)].

[0105] To each PCR tube coated with streptavidin (a total of 8 tubes), 50 μ L of the synthetically obtained biotin-labeled methylcytosine antibody solution was added and immobilized to the PCR tube by leaving it still for about an hour at room temperature. Then, after removing the solution by pipetting, 100 μ L of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄ · 7H₂O, 154 mM NaCl, pH 7.4)] was added, and then the buffer was removed by pipetting. This operation was repeated another two times (these correspond to preparation of an immobilized methylated DNA antibody used in the present measuring method).

[0106] For genomic DNA derived from human blood purchased from Clontech, a DNA fragment (X, SEQ ID NO: 26, a region corresponding to the base numbers 25687390 to 25687775 shown in Genbank Accession No. NT_029419 and so on) to be used as a test sample was amplified by conducting PCR using an oligonucleotide primer of SEQ ID NO: 24 and an oligonucleotide primer of SEQ ID NO: 25 (PF2 and PR2) and the following reaction condition.

<Oligonucleotide primers designed for PCR>

[0107]

EP 2 272 975 A1

PF2: 5'-CTCAGCACCCAGGCGGCC-3' (SEQ ID NO: 24)

PR2: 5'-CTGGCCAAACTGGAGATCGC-3' (SEQ ID NO: 25)

<DNA fragment>

5

[0108]

X: 5' -

10

CTCAGCACCCAGGCGGCCGCGATCATGAGGCGCGAGCGGCGCGGGCTGTTGCAGAGTCTT

GAGCGGGTGGCACACCGCGATGTAGCGGTGGCTGTCATGACTACCAGCATGTAGGCCGACG

15

CAAACATGCCGAACACCTGCAGGTGCTTCACCACGCGGCACAGCCAGTCGGGGCCGCGGAAG

CGGTAGGTGATGTCCCAGCACATTTGCGGCAGCACCTGGAAGAATGCCACGGCCAGGTCGGC

20

CAGGCTGAGGTGTCGGATGAAGAGGTGCATGCGGGACGTCTTGCGCGGCGTCCGGTGCAGAG

CCAGCAGTACGCTGCTGTTGCCAGCACGGCCACCGCGAAAGTCACCGCCAGCACGGCGATC

TCCAGTTTGGCCAG-3' (SEQ ID NO: 26)

25

[0109] As a reaction solution of PCR, 5 ng of genomic DNA which is a template, mixed with each 3 μ L of oligonucleotide primer solutions prepared to 5 μ M, each 5 μ L of 2 mM dNTPs, 5 μ L of a 10 \times buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl₂, 0.01% Gelatin), and 0.25 μ L of 5 U/ μ L thermostable DNA polymerase (AmpliTaq Gold, available from ABI), and added with sterile ultrapure water to a liquid volume of 50 μ L was used. The reaction solution was kept at 95°C for 10 minutes, and then subjected to PCR conducting 40 cycles of incubation each including 30 seconds at 95°C, 30 seconds at 61°C, and 45 seconds at 72°C.

30

[0110] After conducting PCR, amplification was checked by 1.5% agarose gel electrophoresis, and a DNA fragment X was purified with Wizard SV Gel/PCR Kit (PROMEGA).

35

[0111] For a part of the obtained DNA fragment solution, a reaction solution was prepared by mixing 1 μ L of SssI methylase (available from NEB), 10 μ L of a 10 \times NEBuffer 2 (available from NEB), and 1 μ L of S-adenosyl methionine (3.2 mM, available from NEB), and adding sterile ultrapure water to a liquid volume of 100 μ L. The reaction solution was incubated at 37°C for 15 to 30 minutes, and further added with 1 μ L of S-adenosyl methionine (3.2 mM, available from NEB) and incubated at 37°C for 15 to 30 minutes. This was then purified with Wizard SV Gel/PCR Kit (PROMEGA). These operations were repeated another 5 times, to obtain a methylated DNA fragment (MX, SEQ ID NO: 27).

40

<DNA fragment> (N denotes 5-methylcytosine.)

[0112]

45

50

55

EP 2 272 975 A1

MX: 5' -

5 CTCAGCACCCAGGNGGCNGNGATCATGAGGNGNGAGNGGNGNGGGCTGTTGCAGAGTCTT
GAGNNGGTGGCACACNGNGATGTAGNNGTNGGCTGTCATGACTACCAGCATGTAGGCNGANG
10 CAAACATGCNGAACACCTGCAGGTGCTTCACCANGNGGCACAGCCAGTNGGGGCNGNGGAAG
NGGTAGGTGATGTCCCAGCACATTTGNGGCAGCACCTGGAAGAATGCCANGGCCAGGTNGGC
CAGGCTGAGGTGTNGGATGAAGAGGTGCATGNNGGGANGTCTTGNGNGGNGTCNGGTGCAGAG
15 CCAGCAGTANGCTGCTGTTGCCAGCANGGCCACNGNGAAAGTCACNGCCAGCANGGNGATC
TCCAGTTTGGCCAG-3' (SEQ ID NO: 27)

20 **[0113]** For each obtained DNA fragment X, the following solutions were prepared.

25 Solution A: 100 pg/5 μ L solution in TE
Solution B: 10 pg/5 μ L solution in TE
Solution C: 1 pg/5 μ L solution in TE
Solution D: TE solution (negative control solution)

30 **[0114]** For each obtained DNA fragment MX, the following solutions were prepared.

35 Solution MA: 100 pg/5 μ L solution in TE
Solution MB: 10 pg/5 μ L solution in TE
Solution MC: 1 pg/5 μ L solution in TE
Solution MD: TE solution (negative control solution)

40 **[0115]** For each of the solutions of the DNA fragment X and the solutions of the methylated DNA fragment MX, the following treatment was executed.

45 **[0116]** Five (5) μ L of the DNA fragment solution prepared above was added with 2 μ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 2 μ L of BSA (Bovine serum albumin 1 mg/ml), 12 U of a methylation sensitive restriction enzyme HpaII, and the resultant mixture was further added with sterile ultrapure water to a liquid volume of 20 μ L. Each of the mixture was incubated 37°C for 3 hours (these correspond to First step of the present measuring method).

50 **[0117]** Counter oligonucleotides C1 to C12 comprising the nucleotide sequences of SEQ ID NO: 29 to SEQ ID NO: 40 capable of complementarily base-pairing with a minus strand of the target DNA region X' comprising the nucleotide sequence of SEQ ID NO: 28 were synthesized, and each 0.01 μ M solutions in TE buffer were prepared.

55 <Target DNA region>

[0118]

X' : 5' -

5 CTCAGCACCCAGGCGGCCGCGATCATGAGGCGCGAGCGGCGCGGGCTGTTGCAGAGTCTT
 GAGCGGGTGGCACACCCGCGATGTAGCGGTTCGGCTGTCATGACTACCAGCATGTAGGCCGACG
 CAAACATGCCGAACACCTGCAGGTGCTTCACCACGCGGCACAGCCAGTCGGGGCCGCGGAAG
 10 CGGTAGGTGATGTCCCAGCACATTTGCGGCAGCACCTGGAAGAATGCCACGGCCAGGTTCGGC
 CAGGCTGAGGTGTCGGATGAAGAGGTGCATGCGGGACGTCTTGCGCGGGCGTCCGGTGCAGAG
 CCAGCAGTACGCTGCTGTTGCCAGCACGGCCACCGCGAAAGTCACCGCCAGCACGGCGATC
 15 TCCAGTTTGGCCAG-3' (SEQ ID NO: 28)

<Counter oligonucleotides>

[0119]

25 C1:5' - GCCACCGCGAAAGTCACCGCCAGCACGGCG -3' (SEQ ID NO: 29)
 C2:5' - GCCAGCAGTACGCTGCTGTTGCCAGCACG -3' (SEQ ID NO: 30)
 C3:5' - CGGGACGTCTTGCGCGGCGTCCGGTGCAGA -3' (SEQ ID NO: 31)
 C4:5' - AGGCTGAGGTGTCGGATGAAGAGGTGCATG -3' (SEQ ID NO: 32)
 C5:5' - ACCTGGAAGAATGCCACGGCCAGGTTCGGCC -3' (SEQ ID NO: 33)
 C6:5' - TAGGTGATGTCCCAGCACATTTGCGGCAGC -3' (SEQ ID NO: 34)
 C7:5' - CGGCACAGCCAGTCGGGGCCGCGGAAGCGG -3' (SEQ ID NO: 35)
 30 C8:5' - ATGCCGAACACCTGCAGGTGCTTCACCACG -3' (SEQ ID NO: 36)
 C9:5' - ATGACTACCAGCATGTAGGCCGACGCAAAC -3' (SEQ ID NO: 37)
 C10:5' - TGGCACACCGCGATGTAGCGGTTCGGCTGTC -3' (SEQ ID NO: 38)
 C11:5' - CGCGCGGGCTGTTGCAGAGTCTTGAGCGGG -3' (SEQ ID NO: 39)
 C12:5' - CAGGCGGCCGCGATCATGAGGCGCGAGCGG -3' (SEQ ID NO: 40)

35 **[0120]** To the above reaction solution, 10 μ L of a counter oligonucleotide solution prepared as described above, 5 μ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 5 μ L of a 100 mM MgCl₂ solution, and 5 μ L of a 1 mg/mL BSA solution were added, and the resultant mixture was added with sterile ultrapure water to a liquid volume of 50 μ L, and mixed. Thereafter, this PCR tube was heated at 95°C for 10 minutes, rapidly cooled to 70°C, and kept at this temperature for 10 minutes. Then the tube was cooled to 50°C and kept at this temperature for 10 minutes, and further kept at 37°C for 10 minutes, and returned to room temperature (these correspond to Second step of the present measuring method).

40 **[0121]** The PCR tube coated with streptavidin to which a biotin-labeled methylcytosine antibody was immobilized was added with 50 μ L of a reaction solution of a DNA fragment prepared as described above, and left still for 30 minutes at room temperature. Then the solution was removed by pipetting, and 100 μ L of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄ · 7H₂O, 154 mM NaCl, pH 7.4)] was added, and then the buffer was removed by pipetting. This operation was repeated another two times (these correspond to Third step of the present measuring method).

50 **[0122]** Then by subjecting the above PCR tube to PCR using respective solutions of oligonucleotide primers PF2 and PR2 comprising the nucleotide sequences of SEQ ID NO: 24 and SEQ ID NO: 25, and the following reaction condition, methylated DNA in a target DNA region X' comprising the nucleotide sequence of SEQ ID NO: 28 was amplified.

<Oligonucleotide primers designed for PCR>

[0123]

55 PF2: 5'-CTCAGCACCCAGGCGGCC-3' (SEQ ID NO: 24)
 PR2: 5'-CTGGCCAAACTGGAGATCGC-3' (SEQ ID NO: 25)

<Target DNA region>

[0124]

5 X' : 5' -
 CTCAGCACCCAGGCGGCCGCGATCATGAGGCGCGAGCGGCCGCGGGCTGTTGCAGAGTCTT
 10 GAGCGGGTGGCACACCGCGATGTAGCGGTTCGGCTGTCATGACTACCAGCATGTAGGCCGACG
 CAAACATGCCGAACACCTGCAGGTGCTTCACCACGCGGCACAGCCAGTCGGGGCCGCGGAAG
 15 CGGTAGGTGATGTCCCAGCACATTTGCGGCAGCACCTGGAAGAATGCCACGGCCAGGTTCGGC
 CAGGCTGAGGTGTCGGATGAAGAGGTGCATGCGGGACGTCTTGCGCGGCGTCCGGTGCAGAG
 20 CCAGCAGTACGCTGCTGTTGCCAGCACGGCCACCGCGAAAGTCACCGCCAGCACGGCGATC
 TCCAGTTTGGCCAG-3' (SEQ ID NO: 28)

[0125] As a reaction solution of PCR, DNA which is a template, mixed with each 3 μ L of oligonucleotide primer solutions prepared to 5 μ M, each 5 μ L of 2 mM dNTPs, 5 μ L of a buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl₂, 0.01% Gelatin), and 0.25 μ L of 5 U/ μ L thermostable DNA polymerase (AmpliAq Gold, available from ABI), and added with sterile ultrapure water to a liquid volume of 50 μ L was used. The reaction solution was kept at 95°C for 10 minutes, and then subjected to PCR conducting 25 cycles of incubation each including 20 seconds at 95°C, 30 seconds at 61°C, and 30 seconds at 72°C.

[0126] After conducting PCR, amplification was checked by 1.5% agarose gel electrophoresis (these correspond to Fourth step of the present measuring method).

[0127] The result is shown in Fig. 2. In Solutions MA, MB and MC of the methylated DNA fragment MX, amplification was observed, and an amplification product thereof was obtained. In the negative control solution MD, amplification of DNA was not observed, and an amplification product was not obtained. In solutions A, B, C and D of the unmethylated DNA fragment X, amplification was not observed, and an amplification product thereof was not obtained.

[0128] From the above, it was demonstrated that DNA containing a methylated target DNA region can be selected by an immobilized methylcytosine antibody, and amplified DNA can be detected with higher sensitivity by amplifying methylated DNA to a detectable level.

Example 3

[0129] A commercially available methylated cytosine antibody (available from Aviva Systems Biology) was labeled with biotin using a commercially available biotinylation kit (Biotin Labeling Kit-NH₂, available from DOJINDO Laboratories) according to the method described in the catalogue. The obtained biotin-labeled methylated cytosine antibody was refrigerated as a solution [about 0.25 μ g/ μ L solution of an antibody in a 0.1% BSA-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄ · 7H₂O, 154 mM NaCl, pH 7.4)].

[0130] To each PCR tube coated with streptavidin (a total of 8 tubes), 50 μ L of 0.1 μ g/50 μ L solution of the synthetically obtained biotin-labeled methylcytosine antibody was added and immobilized to the PCR tube by leaving it still for about an hour at room temperature. Then, after removing the solution by pipetting, 100 μ L of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄ · 7H₂O, 154 mM NaCl, pH 7.4)] was added, and then the buffer was removed by pipetting. This operation was repeated another two times (these correspond to preparation of an immobilized methylated DNA antibody used in the present measuring method).

[0131] For genomic DNA derived from human blood purchased from Clontech, a DNA fragment (Y, SEQ ID NO: 43, a region corresponding to the base numbers 76606 to 76726 shown in Genbank Accession No. ac009800 and so on) to be used as a test sample was amplified by conducting PCR using oligonucleotide primers (PF3 and PR3) of SEQ ID NO: 42 and SEQ ID NO: 43 and the following reaction condition.

EP 2 272 975 A1

<Oligonucleotide primers designed for PCR>

[0132]

5 PF3: 5'-TGAGCTCCGTAGGGCGTCC-3' (SEQ ID NO: 41)
PR3: 5'-GCGCCGGGTCCGGGCC-3' (SEQ ID NO: 42)

<DNA fragment>

10 [0133]

Y: 5' -

15 GCGCCGGGTCCGGGCCCGATGCGTTGGCGGGCCAGGGCTCCGAGAACGAGGCGTTGTCCATC
TCAACGAGGGCAGAGGAGCCGGCGACCTGGCGTCCCCAAGGACGCCCTACGGAGCTCA-3'
(SEQ ID NO: 43)

20
[0134] As a reaction solution of PCR, 5 ng of genomic DNA which is a template, mixed with each 3 μ L of oligonucleotide primer solutions prepared to 5 μ M, each 5 μ L of 2 mM dNTPs, 5 μ L of a 10 \times buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl₂, 0.01% Gelatin), and 0.25 μ L of 5 U/ μ L thermostable DNA polymerase (AmpliTaq Gold, available from ABI), and added with sterile ultrapure water to a liquid volume of 50 μ L was used. The reaction solution was kept at 95°C for 10 minutes, and then subjected to PCR conducting 50 cycles of incubation each including 30 seconds at 95°C, 30 seconds at 60°C, and 45 seconds at 72°C.

[0135] After conducting PCR, amplification of DNA was checked by 1.5% agarose gel electrophoresis, and a DNA fragment Y was purified with Wizard SV Gel/PCR Kit (PROMEGA).

30 [0136] For a part of the obtained DNA fragment solution, a reaction solution was prepared by mixing 1 μ L of SssI methylase (available from NEB), 10 μ L of a 10 \times NEBuffer 2 (available from NEB), and 1 μ L of S-adenosyl methionine (3.2 mM, available from NEB), and adding sterile ultrapure water to a liquid volume of 100 μ L. The reaction solution was incubated at 37°C for 15 to 30 minutes, and further added with 1 μ L of S-adenosyl methionine (3.2 mM, available from NEB) and incubated at 37°C for 15 to 30 minutes. This was then purified with Wizard SV Gel/PCR Kit (PROMEGA).
35 These operations were repeated another 5 times, to obtain a methylated DNA fragment (MY, SEQ ID NO: 44).

<DNA fragment> (N denotes 5-methylcytosine.)

40 [0137]

MY: 5' -

45 GNGCNGGGTCNGGGCCNGATGNGTTGGNGGGCCAGGGCTCNGAGAANGAGGNGTTGTCCATC
TCAANGAGGGCAGAGGAGCNGGNGACCTGGNGTCCCCAAGGANGCCCTANGGAGCTCA-3'

50 (SEQ ID NO: 44)

[0138] For each obtained DNA fragment Y, the following solutions were prepared.

55 Solution A: 100 pg/5 μ L solution in TE
Solution B: 10 pg/5 μ L solution in TE
Solution C: 1 pg/5 μ L solution in TE

EP 2 272 975 A1

Solution D: TE solution (negative control solution)

[0139] For each obtained DNA fragment MY, the following solutions were prepared.

5 Solution MA: 100 pg/5 μ L solution in TE
Solution MB: 10 pg/5 μ L solution in TE
Solution MC: 1 pg/5 μ L solution in TE
Solution MD: TE solution (negative control solution)

10 **[0140]** For each of the solutions of the DNA fragment Y and the solutions of the methylated DNA fragment MY, the following treatment was executed.

[0141] Five (5) μ L of the DNA fragment solution prepared above was added with 2 μ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 2 μ L of BSA (Bovine serum albumin 1 mg/ml), 12 U of a methylation sensitive restriction enzyme HpaII, and the resultant mixture was further added with sterile ultrapure water to a liquid volume of 20 μ L. Each of the mixture was incubated 37°C for 3 hours (these correspond to First step of the present measuring method).

15 **[0142]** Counter oligonucleotides C13, C14, and C15 comprising the each nucleotide sequences of SEQ ID NO: 46, SEQ ID NO: 47, and SEQ ID NO: 48 capable of complementarily base-pairing with a minus strand of the target DNA region Y' comprising the nucleotide sequence of SEQ ID NO: 45 were synthesized, and each 0.01 μ M solutions in a TE
20 buffer were prepared.

<Target DNA region>

[0143]

25

Y' : 5' -

30 GCGCCGGGTCCGGGCCCGATGCGTTGGCGGGCCAGGGCTCCGAGAACGAGGCGTTGTCCATC

TCAACGAGGGCAGAGGAGCCGGCGACCTGGCGTCCCCCAAGGACGCCCTACGGAGCTCA-3'

(SEQ ID NO: 45)

35

<Counter oligonucleotides>

[0144]

40 C13: 5'-GCGTCCCCCAAGGACGCCCTACGGAGCTCA-3' (SEQ ID NO: 46)
C14: 5'-CTCAACGAGGGCAGAGGAGCCGGCGACCTG-3' (SEQ ID NO: 47)
C15: 5'-CGCCGGGTCCGGGCCCGATGCGTTGGCGGG-3' (SEQ ID NO: 48)

45 **[0145]** To the above reaction solution, 10 μ L of a counter oligonucleotide solution prepared as described above, 5 μ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 5 μ L of a 100 mM MgCl₂ solution, and 5 μ L of a 1 mg/mL BSA solution were added, and the resultant mixture was added with sterile ultrapure water to a liquid volume of 50 μ L, and mixed. Thereafter, this PCR tube was heated at 95°C for 10 minutes, rapidly cooled to 70°C, and kept at this temperature for 10 minutes. Then the tube was cooled to 50°C and kept at this temperature for 10 minutes, and further kept at 37°C for 10 minutes, and returned to room temperature (these correspond
50 to Second step of the present measuring method).

[0146] The PCR tube coated with streptavidin to which a biotin-labeled methylcytosine antibody was immobilized was added with 50 μ L of a reaction solution of a DNA fragment prepared as described above, and left still for 30 minutes at room temperature. Then the solution was removed by pipetting, and 100 μ L of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄ · 7H₂O, 154 mM NaCl, pH 7.4)] was added, and then the
55 buffer was removed by pipetting. This operation was repeated another two times (these correspond to Third step of the present measuring method).

[0147] Then by subjecting the above PCR tube to PCR using respective solutions of oligonucleotide primers PF3 and PR3 comprising the nucleotide sequences of SEQ ID NO: 41 and SEQ ID NO: 42, and the following reaction condition,

EP 2 272 975 A1

methylated DNA in a target DNA region Y' comprising the nucleotide sequence of SEQ ID NO: 45 was amplified.

<Oligonucleotide primers designed for PCR>

5 **[0148]**

PF3: 5'-TGAGCTCCGTAGGGCGTCC-3' (SEQ ID NO: 41)

PR3: 5'-GCGCCGGGTCCGGGCCC-3' (SEQ ID NO: 42)

10 <Target DNA region>

[0149]

15 Y' : 5' -

GCGCCGGGTCCGGGCCCCGATGCGTTGGCGGGCCAGGGCTCCGAGAACGAGGCGTTGTCCATC

TCAACGAGGGCAGAGGAGCCGGCGACCTGGCGTCCCCCAAGGACGCCCTACGGAGCTCA-3'

20

(SEQ ID NO: 45)

25 **[0150]** As a reaction solution of PCR, DNA which is a template, mixed with each 3 μ L of oligonucleotide primer solutions prepared to 5 μ M, each 5 μ L of 2 mM dNTPs, 5 μ L of a 10 \times buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl₂, 0.01% Gelatin), and 0.25 μ L of 5 U/ μ L thermostable DNA polymerase (AmpliTaq Gold, available from ABI), and added with sterile ultrapure water to a liquid volume of 50 μ L was used. The reaction solution was kept at 95°C for 10 minutes, and then subjected to PCR conducting 25 cycles of incubation each including 20 seconds at 95°C, 30 seconds at 60°C, and 30 seconds at 72°C.

30

[0151] After conducting PCR, amplification of DNA was checked by 1.5% agarose gel electrophoresis (these correspond to Third step of the present measuring method).

[0152] The result is shown in Fig. 3. In Solutions MA, MB and MC of the methylated DNA fragment MY, amplification was observed. In the negative control solution MD, amplification of DNA was not observed. In solutions A, B, C and D of the unmethylated DNA fragment Y, amplification of DNA was not observed.

35

[0153] From the above, it was demonstrated that DNA containing a methylated target DNA region can be selected by an immobilized methylcytosine antibody, and amplified DNA can be detected with higher sensitivity by amplifying methylated DNA to a detectable level.

40 Example 4

[0154] A commercially available methylated cytosine antibody (available from Aviva Systems Biology) was labeled with biotin using a commercially available biotinylating kit (Biotin Labeling Kit-NH₂, available from DOJINDO Laboratories) according to the method described in the catalogue. The obtained biotin-labeled methylated cytosine antibody was refrigerated as a solution [about 0.25 μ g/ μ L solution of an antibody in a 0.1% BSA-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄ · 7H₂O, 154 mM NaCl, pH 7.4)].

45

[0155] To each PCR tube coated with streptavidin (a total of 8 tubes), 50 μ L of 0.1 μ g/50 μ L solution of the synthetically obtained biotin-labeled methylcytosine antibody was added and immobilized to the PCR tube by leaving it still for about an hour at room temperature. Then, after removing the solution by pipetting, 100 μ L of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄ · 7H₂O, 154 mM NaCl, pH 7.4)] was added, and then the buffer was removed by pipetting. This operation was repeated another two times (these correspond to preparation of an immobilized methylated DNA antibody used in the present measuring method).

50

[0156] Yeast strain X2180-1A of baker's yeast was cultured in a YPD medium (1% Yeast extract, 2% Peptone, 2% Glucose, pH 5.6 to 6.0) to a turbidity of OD₆₀₀ 0.6 to 1.0, and centrifuged at 10,000 g for 10 minutes, to prepare 1 \times 10⁷ of yeast cells. From the prepared yeast cells, a yeast genome was acquired using a generally used preparation method of a yeast genome as described in Methods in Yeast Genetics (Cold Spring Harbor Laboratory).

55

[0157] The prepared yeast cells were suspended in Buffer A (1 M sorbitol, 0.1 M EDTA, pH 7.4), added with 0.1% 2-mercaptoethanol (final concentration 14 mM) and 100 U zymolase (10 mg/ml), and incubated under stirring at 30°C for

EP 2 272 975 A1

an hour until the solution became clear. After collecting a protoplast by centrifugation at 550 g for 10 minutes, it was suspended in Buffer B (50 mM Tris-HCl, pH 7.4, 20 mM EDTA), added with sodium dodecyl sulfate in 1% (w/v), and then incubated at 65°C for 30 minutes. Sequentially, 5 M CH₃COOK was added and mingled in a volume ratio of 2/5, and the mixture was cooled on ice for 30 minutes, and then centrifuged at 15,000 g for 30 minutes to collect the supernatant. The collected supernatant was added with 3 M CH₃COONa in a volume ratio of 1/10 and an equal amount of isopropanol and mingled well, and the precipitate obtained by centrifugation at 15,000 g at 4°C for 30 minutes was rinsed with 70% ethanol and collected. After drying, the precipitate was dissolved in 1 mL of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA), and added with RNase A (available from Sigma) in a concentration of 40 µg/ml, incubated at 37°C for an hour, and then the mixture was added with proteinase K (available from Sigma) and sodium dodecyl sulfate in a concentrations of 500 µg/mL and 1% (w/v), respectively, and shaken at 55°C for about 16 hours. After end of the shaking, the mixture was extracted with phenol [saturated with 1 M Tris-HCl (pH 8.0)] · chloroform. An aqueous layer was collected, added with NaCl in a concentration of 0.5 N, and allowed to precipitate from ethanol, and the generated precipitate was collected. The collected precipitate was rinsed with 70% ethanol, to obtain genomic DNA.

[0158] From the obtained genomic DNA, a DNA fragment to be used as a test sample (T, SEQ ID NO: 51, a region corresponding to the base numbers 384569 to 384685 of yeast chromosome VII shown in Genbank Accession No. NC_001139 and so on) was amplified by conducting PCR using oligonucleotide primers (PF4 and PR4) designed for PCR of SEQ ID NO: 49 and SEQ ID NO: 50 and the following reaction condition.

<Oligonucleotide primers designed for PCR>

[0159]

PF4: 5'-GGACCTGTGTTTGACGGGTAT-3' (SEQ ID NO: 49)

PR4: 5'-AGTACAGATCTGGCGTTCTCG-3' (SEQ ID NO: 50)

<DNA fragment>

[0160]

T: 5' -

GGACCTGTGTTTGACGGGTATAACACTAAGTTGCGCAATTTGCTGTATTGCGAAATCCGCC

GGACGATATCACTCTTGAGCGCATGTGCCGTTTCCGAGAACGCCAGATCTGTACT-3'

(SEQ ID NO: 51)

[0161] As a reaction solution of PCR, 10 ng of genomic DNA which is a template, mixed with each 3 µL of oligonucleotide primer solutions prepared to 5 µM, each 5 µL of 2 mM dNTPs, 5 µL of a 10 × buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl₂, 0.01% Gelatin), and 0.25 µL of 5 U/µL thermostable DNA polymerase (AmpliTaq Gold, available from ABI), and added with sterile ultrapure water to a liquid volume of 50 µL was used. The reaction solution was kept at 95°C for 10 minutes, and then subjected to PCR conducting 40 cycles of incubation each including 20 seconds at 95°C, 30 seconds at 58°C, and 30 seconds at 72°C.

[0162] After conducting PCR, amplification was checked by 1.5% agarose gel electrophoresis, and a DNA fragment T was purified with Wizard SV Gel/PCR Kit (PROMEGA).

[0163] For a part of the obtained DNA fragment solution, a reaction solution was prepared by mixing 1 µL of SssI methylase (available from NEB), 10 µL of a 10 × NEBuffer 2 (available from NEB), and 1 µL of S-adenosyl methionine (3.2 mM, available from NEB), and adding sterile ultrapure water to a liquid volume of 100 µL. The reaction solution was incubated at 37°C for 15 to 30 minutes, and further added with 1 µL of S-adenosyl methionine (3.2 mM, available from NEB) and incubated at 37°C for 15 to 30 minutes. This was then purified with Wizard SV Gel/PCR Kit (PROMEGA). These operations were repeated another 3 times, to obtain a methylated DNA fragment (MT, SEQ ID NO: 52).

<DNA fragment> (N denotes 5-methylcytosine.)

[0164]

EP 2 272 975 A1

MT: 5' -

GGACCTGTGTTTGANGGGTATAACACTAAGTTGNGCAATTTGCTGTATTGNGAAATCNGCCN

GGANGATATCACTCTTGAGNGCATGTGCNGTTTCNGAGAANGCCAGATCTGTACT-3'

(SEQ ID NO: 52)

[0165] For each obtained DNA fragment T, the following solutions were prepared.

Solution A: 100 pg/5 μ L solution in TE

Solution B: 10 pg/5 μ L solution in TE

Solution C: 1 pg/5 μ L solution in TE

Solution D: TE solution (negative control solution)

[0166] For each obtained DNA fragment MZ, the following solutions were prepared.

Solution MA: 100 pg/5 μ L solution in TE

Solution MB: 10 pg/5 μ L solution in TE

Solution MC: 1 pg/5 μ L solution in TE

Solution MD: TE solution (negative control solution)

[0167] For each of the solutions of the DNA fragment T and the solutions of the methylated DNA fragment MT, the following treatment was executed.

[0168] Five (5) μ L of the DNA fragment solution prepared above was added with 2 μ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 2 μ L of BSA (Bovine serum albumin 1 mg/ml), 12 U of a methylation sensitive restriction enzyme HpaII, and the resultant mixture was further added with sterile ultrapure water to a liquid volume of 20 μ L. Each of the mixture was incubated 37°C for 3 hours (these correspond to First step of the present measuring method).

[0169] Counter oligonucleotides C16 to C19 each comprising the nucleotide sequences of SEQ ID NO: 54 to SEQ ID NO: 57 capable of complementarily base-pairing with a minus strand of the target DNA region T' comprising the nucleotide sequence of SEQ ID NO: 53 were synthesized, and each 0.01 μ M solutions in a TE buffer were prepared.

<Target DNA region>

[0170]

T' : 5' -

GGACCTGTGTTTGACGGGTATAACACTAAGTTGCGCAATTTGCTGTATTGCGAAATCCGCCC

GGACGATATCACTCTTGAGCGCATGTGCCGTTTCCGAGAACGCCAGATCTGTACT-3'

(SEQ ID NO: 53)

<Counter oligonucleotides>

[0171]

C16: 5'-GGACCTGTGTTTGACGGGTAT-3' (SEQ ID NO: 54)

C17: 5'-AACACTAAGTTGCGCAATTTGCTGT-3' (SEQ ID NO: 55)

C18: 5'-ATTGCGAAATCCGCCCCGACGATAT-3' (SEQ ID NO: 56)

C19: 5'-CACTCTTGAGCGCATGTGCCGTTTC-3' (SEQ ID NO: 57)

EP 2 272 975 A1

[0172] To the above reaction solution, 10 μL of a counter oligonucleotide solution prepared as described above, 5 μL of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 5 μL of a 100 mM MgCl₂ solution, and 5 μL of a 1 mg/mL BSA solution were added, and the resultant mixture was added with sterile ultrapure water to a liquid volume of 50 μL , and mixed. Thereafter, this PCR tube was heated at 95°C for 10 minutes, rapidly cooled to 70°C, and kept at this temperature for 10 minutes. Then the tube was cooled to 50°C and kept at this temperature for 10 minutes, and further kept at 37°C for 10 minutes, and returned to room temperature (these correspond to Second step of the present measuring method).

[0173] The PCR tube coated with streptavidin to which a biotin-labeled methylcytosine antibody was immobilized was added with 50 μL of a reaction solution of a DNA fragment prepared as described above, and left still for 30 minutes at room temperature. Then the solution was removed by pipetting, and 100 μL of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO · 7H₂O, 154 mM NaCl, pH 7.4)] was added, and then the buffer was removed by pipetting. This operation was repeated another two times (these correspond to Third step of the present measuring method).

[0174] Then the above PCR tube was subjected to PCR using respective solutions of oligonucleotide primers PF4 and PR4 comprising the nucleotide sequences of SEQ ID NO: 49 and SEQ ID NO: 50, and the following reaction condition, methylated DNA in a target DNA region T' comprising the nucleotide sequence of SEQ ID NO: 53 was amplified.

<Oligonucleotide primers designed for PCR>

[0175]

PF4: 5'-GGACCTGTGTTTGACGGGTAT-3' (SEQ ID NO: 49)

PR4: 5'-AGTACAGATCTGGCGTTCTCG-3' (SEQ ID NO: 50)

<Target DNA region> (Also 5-methylcytosine is denoted by C.)

[0176]

T' : 5' -

GGACCTGTGTTTGACGGGTATAACACTAAGTTGCGCAATTTGCTGTATTGCGAAATCCGCC

GGACGATATCACTCTTGAGCGCATGTGCCGTTTCCGAGAACGCCAGATCTGTACT-3'

(SEQ ID NO: 53)

[0177] As a reaction solution of PCR, DNA which is a template, mixed with each 3 μL of oligonucleotide primer solutions prepared to 5 μM , each 5 μL of 2 mM dNTPs, 5 μL of a buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl₂, 0.01% Gelatin), and 0.25 μL of 5 U/ μL thermostable DNA polymerase (AmpliTaQ Gold, available from ABI), and added with sterile ultrapure water to a liquid volume of 50 μL was used. The reaction solution was kept at 95°C for 10 minutes, and then subjected to PCR conducting 28 cycles of incubation each including 20 seconds at 95°C, 30 seconds at 58°C, and 30 seconds at 72°C.

[0178] After conducting PCR, amplification of DNA was checked by 1.5% agarose gel electrophoresis (these correspond to Fourth step of the present measuring method).

[0179] The result is shown in Fig. 4. In Solutions MA, MB and MC of the methylated DNA fragment MT, amplification of DNA was observed, and an amplification product thereof was obtained. In the negative control solution MD, amplification of DNA was not observed, and an amplification product was not obtained. In solutions A, B, C and D of the unmethylated DNA fragment T, amplification of DNA was not observed, and an amplification product thereof was not obtained.

[0180] From the above, it was demonstrated that DNA containing a methylated target DNA region can be selected by an immobilized methylcytosine antibody, and amplified DNA can be detected with higher sensitivity by amplifying methylated DNA to a detectable level.

Example 5

[0181] A commercially available methylated cytosine antibody (available from Aviva Systems Biology) was labeled with biotin using a commercially available biotinylating kit (Biotin Labeling Kit-NH₂, available from DOJINDO Laboratories)

EP 2 272 975 A1

according to the method described in the catalogue. The obtained biotin-labeled methylated cytosine antibody was refrigerated as a solution [about 0.25 $\mu\text{g}/\mu\text{L}$ solution of an antibody in a 0.1% BSA-containing phosphate buffer (1 mM KH_2PO_4 , 3 mM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 154 mM NaCl, pH 7.4)].

5 **[0182]** To each PCR tube coated with streptavidin (a total of 8 tubes), 50 μL of 0.1 $\mu\text{g}/50 \mu\text{L}$ solution of the synthetically obtained biotin-labeled methylcytosine antibody was added and immobilized to the PCR tube by leaving it still for about an hour at room temperature. Then, after removing the solution by pipetting, 100 μL of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH_2PO_4 , 3 mM $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 154 mM NaCl, pH 7.4)] was added, and then the buffer was removed by pipetting. This operation was repeated another two times (these correspond to preparation of an immobilized methylated DNA antibody used in the present measuring method).

10 **[0183]** Yeast strain X2180-1A of baker's yeast was cultured in a YPD medium (1% Yeast extract, 2% Peptone, 2% Glucose, pH 5.6 to 6.0) to a turbidity of OD_{600} 0.6 to 1.0, and centrifuged at 10,000 g for 10 minutes, to prepare 1×10^7 of yeast cells. From the prepared yeast cells, a yeast genome was acquired using a generally used preparation method of a yeast genome as described in Methods in Yeast Genetics (Cold Spring Harbor Laboratory).

15 **[0184]** The prepared yeast cells were suspended in Buffer A (1 M sorbitol, 0.1 M EDTA, pH 7.4), added with 0.1% 2-mercaptoethanol (final concentration 14 mM) and 100 U zymolase (10 mg/ml), and incubated under stirring at 30°C for an hour until the solution became clear. After collecting a protoplast by centrifugation at 550 g for 10 minutes, it was suspended in Buffer B (50 mM Tris-HCl, pH 7.4, 20 mM EDTA), added with sodium dodecyl sulfate in 1% (w/v), and then incubated at 65°C for 30 minutes. Sequentially, 5 M CH_3COOK was added and mingled in a volume ratio of 2/5, and the mixture was cooled on ice for 30 minutes, and then centrifuged at 15,000 g for 30 minutes to collect the supernatant. The collected supernatant was added with 3 M CH_3COONa in a volume ratio of 1/10 and an equal amount of isopropanol and mingled well, and the precipitate obtained by centrifugation at 15,000 g at 4°C for 30 minutes was rinsed with 70% ethanol and collected. After drying, the precipitate was dissolved in 1 mL of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA), and added with RNase A (available from Sigma) in a concentration of 40 $\mu\text{g}/\text{ml}$, incubated at 37°C for an hour, and then the mixture was added with proteinase K (available from Sigma) and sodium dodecyl sulfate in a concentrations of 500 $\mu\text{g}/\text{mL}$ and 1% (w/v), respectively, and shaken at 55°C for about 16 hours. After end of the shaking, the mixture was extracted with phenol [saturated with 1 M Tris-HCl (pH 8.0)] \cdot chloroform. An aqueous layer was collected, added with NaCl in a concentration of 0.5 N, and allowed to precipitate from ethanol, and the generated precipitate was collected. The collected precipitate was rinsed with 70% ethanol, to obtain genomic DNA.

25 **[0185]** Part of the obtained genomic DNA was mixed with 1 μL of SssI methylase (available from NEB), 10 μL of a $10 \times$ NEBuffer 2 (available from NEB), and 1 μL of S-adenosyl methionine (3.2 mM, available from NEB), and added with sterile ultrapure water to a liquid volume of 100 μL . The reaction solution was incubated at 37°C for 15 to 30 minutes, added with 1 μL of S-adenosyl methionine (3.2 mM, available NEB) and incubated at 37°C for 15 to 30 minutes. This was then purified by Wizard SV Gel/PCR Kit (PROMEGA). This operation was repeated three times, and methylated genomic DNA was obtained.

30 **[0186]** For the obtained yeast genomic DNA, the following solutions were prepared.

- 35 Solution A: 10 ng/5 μL solution in TE
Solution B: 1 ng/5 μL solution in TE
Solution C: 0.1 ng/5 μL solution in TE
40 Solution D: TE solution (negative control solution)

[0187] For the obtained methylated yeast genomic DNA, the following solutions were prepared.

- 45 Solution MA: 10 ng/5 μL solution in TE
Solution MB: 1 ng/5 μL solution in TE
Solution MC: 0.1 ng/5 μL solution in TE
Solution MD: TE solution (negative control solution)

50 **[0188]** For each of the above yeast genomic DNA solutions and methylated yeast genomic DNA solutions, the following treatment was executed.

[0189] A PCR tube was added with 5 μL of the genomic DNA solution prepared as described above, 5 U of a restriction enzyme XspI, and 1 μL of a $10 \times$ buffer (200 mM Tris-HCl pH 8.5, 100 mM MgCl_2 , 10 mM Dithiothreitol, 1000 mM KCl) suited for XspI, and added with sterile ultrapure water to a liquid volume of 10 μL . The reaction solution was incubated at 37°C for an hour.

55 **[0190]** The above solution was added with 2 μL of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc_2 , 5 mM Dithiothreitol), 2 μL of BSA (Bovine serum albumin 1 mg/ml), 12 U of a methylation sensitive restriction enzyme HpaII, and the resultant mixture was further added with sterile ultrapure water to a liquid volume of 20 μL . Each of the mixture was incubated 37°C for 3 hours (these correspond to First step of the present measuring method).

EP 2 272 975 A1

[0191] Counter oligonucleotides C16 to C23 each comprising the nucleotide sequences of SEQ ID NO: 54 to SEQ ID NO: 57 and SEQ ID NO: 59 to SEQ ID NO: 62, capable of complementarily base-pairing with a minus strand of the target DNA region T'(a region corresponding to the base numbers 384523 to 384766 of yeast chromosome VII shown in Genbank Accession No. NC_001139 and so on) comprising the nucleotide sequence of SEQ ID NO: 58 were synthesized, and each 0.01 μ M solutions in a TE buffer were prepared.

<Target DNA region>

[0192]

T' : 5' -

TAGGAAATACATTCCGAGGGCGCCCGCACAAAGGCTATTATTAGAGGGACCTGTGTTTGACG
GGTATAAACAATAAGTTGCGCAATTTGCTGTATTGCGAAATCCGCCCGGACGATATCACTCTT
GAGCGCATGTGCCGTTTCCGAGAACGCCAGATCTGTACTGCGATCGCACACGAGGAGACACA
GCGTCACGTGTTTTGCCATTTTGTACGACAAATGAACCGCCTGGCCACGCCTCTAATC-3'

(SEQ ID NO: 58)

<Counter oligonucleotides>

[0193]

C16: 5'-GGACCTGTGTTTGACGGGTAT-3' (SEQ ID NO: 54)
C17: 5'-AACACTAAGTTGCGCAATTTGCTGT-3' (SEQ ID NO: 55)
C18: 5'-ATTGCGAAATCCGCCCGGACGATAT-3' (SEQ ID NO: 56)
C19: 5'-CACTCTTGAGCGCATGTGCCGTTTC-3' (SEQ ID NO: 57)
C20: 5'-AATACATTCCGAGGGCGCCCGCACAAAGGCC-3' (SEQ ID NO: 59)
C21: 5'-GCGATCGCACACGAGGAGACA-3' (SEQ ID NO: 60)
C22: 5'-AGCGTCACGTGTTTTGCCATTTTGTACGAC-3' (SEQ ID NO: 61)
C23: 5'-AAATGAACCGCCTGGCCACGCCTCTAATC-3' (SEQ ID NO: 62)

[0194] To the above reaction solution, 10 μ L of a counter oligonucleotide solution prepared as described above, 5 μ L of a buffer (330 mM Tris-Acetate pH 7.9, 660 mM KOAc, 100 mM MgOAc₂, 5 mM Dithiothreitol), 5 μ L of a 100 mM MgCl₂ solution, and 5 μ L of a 1 mg/mL BSA solution were added, and the resultant mixture was added with sterile ultrapure water to a liquid volume of 50 μ L, and mixed. Thereafter, this PCR tube was heated at 95°C for 10 minutes, rapidly cooled to 70°C, and kept at this temperature for 10 minutes. Then the tube was cooled to 50°C and kept at this temperature for 10 minutes, and further kept at 37°C for 10 minutes, and returned to room temperature (these correspond to Second step of the present measuring method).

[0195] The PCR tube coated with streptavidin to which a biotin-labeled methylcytosine antibody was immobilized was added with 50 μ L of a reaction solution of a DNA fragment prepared as described above, and left still for 30 minutes at room temperature. Then the solution was removed by pipetting, and 100 μ L of a washing buffer [0.05% Tween 20-containing phosphate buffer (1 mM KH₂PO₄, 3 mM Na₂HPO₄ · 7H₂O, 154 mM NaCl, pH 7.4)] was added, and then the buffer was removed by pipetting. This operation was repeated another two times (these correspond to Third step of the present measuring method).

[0196] Then by subjecting the above PCR tube to PCR using respective solutions of oligonucleotide primers PF4 and PR4 comprising the nucleotide sequences of SEQ ID NO: 49 and SEQ ID NO: 50, and the following reaction condition, methylated DNA in a target DNA region T' comprising the nucleotide sequence of SEQ ID NO: 53 was amplified.

EP 2 272 975 A1

<Oligonucleotide primers designed for PCR>

[0197]

5 PF3: 5'-GGACCTGTGTTTGACGGGTAT-3' (SEQ ID NO: 49)
PR3: 5'-AGTACAGATCTGGCGTTCTCG-3' (SEQ ID NO: 50)

<Target DNA region>

10 [0198]

T': 5' -

15 GGACCTGTGTTTGACGGGTATAACACTAAGTTGCGCAATTTGCTGTATTGCGAAATCCGCCC
GGACGATATCACTCTTGAGCGCATGTGCCGTTTCCGAGAACGCCAGATCTGTACT-3'
(SEQ ID NO: 53)

20

[0199] As a reaction solution of PCR, DNA which is a template, mixed with each 3 μ L of oligonucleotide primer solutions prepared to 5 μ M, each 5 μ L of 2 mM dNTPs, 5 μ L of a buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl₂, 0.01% Gelatin), and 0.25 μ L of 5 U/ μ L thermostable DNA polymerase (AmpliTaq Gold, available from ABI), and added with sterile ultrapure water to a liquid volume of 50 μ L was used. The reaction solution was kept at 95°C for 10 minutes, and then subjected to PCR conducting 31 cycles of incubation each including 20 seconds at 95°C, 30 seconds at 58°C, and 30 seconds at 72°C.

[0200] After conducting PCR, amplification was checked by 1.5% agarose gel electrophoresis (these correspond to Fourth step of the present measuring method).

30 [0201] The result is shown in Fig. 5. In Solutions MA, MB and MC of methylated yeast genomic DNA, amplification of DNA was observed. In the negative control solution MD, amplification of DNA was not observed. In solutions A, B, C and D of unmethylated yeast genomic DNA, amplification of DNA was not observed.

[0202] From the above, it was demonstrated that DNA containing a methylated target DNA region can be selected by an immobilized methylcytosine antibody, and methylated DNA is amplified to a detectable level and the amplified DNA can be detected with higher sensitivity.

35

INDUSTRIAL APPLICABILITY

[0203] Based on the present invention, it becomes possible to provide a method of measuring the content of methylated DNA in an objective DNA region in a genomic DNA contained in a biological specimen in a simple and convenient manner, and so on.

40

Free Text in Sequence Listing

45 [0204]

SEQ ID NO:17

Designed oligonucleotide consisting of objective DNA domain (GPR7-2079-2176)

SEQ ID NO:18

50 Designed oligonucleotide consisting of objective DNA domain (GPR7-2079-2176)

SEQ ID NO:19

Designed oligonucleotide consisting of objective DNA domain (GPR7-2079-2176)

SEQ ID NO:20

Designed oligonucleotide for experiment

55 SEQ ID NO:21

Designed oligonucleotide primer for PCR

SEQ ID NO:22

Designed oligonucleotide primer for PCR

EP 2 272 975 A1

SEQ ID NO:23
Designed oligonucleotide consisting of objective DNA domain (GPR7-2079-2176)

5 SEQ ID NO:24
Designed oligonucleotide primer for PCR

SEQ ID NO:25
Designed oligonucleotide primer for PCR

10 SEQ ID NO:26
Amplified oligonucleotide consisting of objective DNA domain (Genbank Accession No.NT_029419
25687390-25687775 Homo sapiens)

SEQ ID NO:27
Amplified oligonucleotide consisting of objective DNA domain (Genbank Accession No.NT_029419
25687390-25687775 Homo sapiens)

15 SEQ ID NO:28
Amplified oligonucleotide consisting of objective DNA domain (Genbank Accession No.NT_029419
25687390-25687775 Homo sapiens)

SEQ ID NO:29
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

20 SEQ ID NO:30
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

SEQ ID NO:31
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

25 SEQ ID NO:32
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

SEQ ID NO:33
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

30 SEQ ID NO:34
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

SEQ ID NO:35
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

35 SEQ ID NO:36
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

SEQ ID NO:37
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

40 SEQ ID NO:38
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

SEQ ID NO:39
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

45 SEQ ID NO:40
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

SEQ ID NO:41
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

50 SEQ ID NO:42
Designed oligonucleotide primer for PCR

SEQ ID NO:43
Designed oligonucleotide primer for PCR

45 SEQ ID NO:44
Amplified oligonucleotide consisting of objective DNA domain (Genbank Accession No.AC009800 76606-76726
Homo sapiens)

SEQ ID NO:45
Designed oligonucleotide consisting of objective DNA domain (Genbank Accession No.AC009800 76606-76726
Homo sapiens) n=m5c

50 SEQ ID NO:46
Designed oligonucleotide consisting of objective DNA domain (Genbank Accession No.AC009800 76606-76726
Homo sapiens)

55 SEQ ID NO:47
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

SEQ ID NO:48
Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

EP 2 272 975 A1

SEQ ID NO:49

Designed oligonucleotide primer for PCR

SEQ ID NO:50

Designed oligonucleotide primer for PCR

5 SEQ ID NO:51

Amplified oligonucleotide consisting of objective DNA domain (Genbank Accession No.NC001139 384569-384685 Saccharomyces cerevisiae chromosome VII)

SEQ ID NO:52

10 Designed oligonucleotide consisting of objective DNA domain (Genbank Accession No.NC001139 384569-384685 Saccharomyces cerevisiae chromosome VII) n=m5c

SEQ ID NO:53

Designed oligonucleotide consisting of objective DNA domain (Genbank Accession No.NC001139 384569-384685 Saccharomyces cerevisiae chromosome VII)

SEQ ID NO:54

15 Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

SEQ ID NO:55

Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

SEQ ID NO:56

20 Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

SEQ ID NO:57

Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

SEQ ID NO:58

Designed oligonucleotide primer for PCR

SEQ ID NO:59

25 Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

SEQ ID NO:60

Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

SEQ ID NO:61

30 Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

SEQ ID NO:62

Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

35

40

45

50

55

EP 2 272 975 A1

SEQUENCE LISTING

<110> Sumitomo Chemical Co., Ltd.

5 <120> Method for measuring DNA methylation

<130> N112271

<140> 09725639.0

<141> 2009-03-25

10 <150> JP2008-077967

<151> 2008-03-25

<160> 62

15 <210> 1

<211> 2661

<212> DNA

<213> Homo sapiens

<400> 1

20	acagacatgt	gccaccatgc	ccagctaatt	tttgtttgt	ttgtttgtt	gtttgtattt	60
	ttagtagaga	tggggtttt	ccatgttggc	caggctggc	tcgaactcct	gacctcgaat	120
	gataatgatc	cgccgcttgg	cctccaaagt	gctaggatta	cagggtgtgag	ccactgcgcc	180
	aggcctgggc	actttcttta	gtagtttgag	gagcaacatt	tttgacagt	tccttctgct	240
	caagattcaa	gatcccagat	aaaattaaac	catctagaga	gatggcttga	ttggccttga	300
	ctggatctca	tgaccacttc	ttgaagtggg	taagtctcat	aaatgctcag	tccttccact	360
	atgcaactga	gtggggtggg	tgggaagccc	ctcaaaggaa	aatccggttg	ttcttactag	420
25	aaagaaaagg	aaaatggatg	tgaggcagtc	aaaatcagca	gaggtccacc	acaccaccaa	480
	aatgtggtga	ttaaataatg	agagacagag	actaacagag	gtatgtgaat	attgaagtat	540
	gtctggacaa	tagccaatg	atgagaccaa	taaaatggtt	accaaactct	ggttttgagt	600
	agtagtgtta	aatcagacca	tttagtaacc	atTTTTTgtt	gcaaagtttc	tagcactgcc	660
	caaaccctga	gtggtatatg	aataactcgt	ccattatgta	tctctttcca	gtcagcataa	720
	tttatccccc	acctatatct	ttttctgacc	actcctactt	ccttctcttt	accaaactct	780
30	aaactctaag	gctgtttctt	cagcaacttc	tttgtttaga	ttggaagata	aattaaacag	840
	catgcatgtg	tttactgact	ttcagtat	aacagagggt	atttaatttt	tttttaaact	900
	caaagtcaaa	cttctttata	agatgaagga	gaaaaatgtc	ttataaaatg	catatgtgaa	960
	gatgccttct	gagtgttttc	tcatgcagac	ttgttctagt	ctttaatgaa	tcttccttgt	1020
	agacactgtg	gagatgaaag	atggttctoc	acttctactc	aaagtacaaa	tcaggccggc	1080
	atTTTgaaaa	agagacaggt	ttattcatag	ctgcagcgtt	agctggcttt	gttcctgtta	1140
35	caatTTTcact	tttggttatt	aaaatatcca	ctgtaggaaa	taaatttgta	accattttct	1200
	catattacct	acacacagaa	aaacaaaaat	tgatatacctg	gggttttatt	gctgagggcg	1260
	cttcccataa	aagcgagaga	gtgtgcgttg	ggaaatgtgt	ctggttact	ctttatgga	1320
	taaactTTtag	tcacaatcct	ccccgcgcc	cctctcacc	ccagcaccct	cccaacctcc	1380
	cgacttcccg	cctctcaagg	gctggtgacc	taatagcatt	tttctctgtg	catatTTTgg	1440
	cgtcgcccc	tggcctggct	gccttcgcct	gtctgagttt	tttgaattc	ctgcatgttc	1500
40	gccccagatt	aagccagtgt	gtctcaggat	gtgtgttccg	ttttgttctt	tccccttaac	1560
	gctccctgtg	caacgtgtct	ggggggagga	gggcagggac	gggagagagg	gaggggcaga	1620
	ggcgaggagc	tgtccgcctt	gcacgtttcc	aatcgcatta	cgtgaacaaa	tagctgaggg	1680
	gcggccgggc	cagaacggct	tgtgtaactt	tgcaaacgtg	ccagaaagtt	taaatctctc	1740
	ctccttctct	cactccagac	actgccccgt	ctccgggact	gccgcgcggc	tccccgttgc	1800
	cttccaggac	tgagaaaggg	gaaagggag	ggtgccacgt	ccgagcagcc	gccttgactg	1860
45	gggaagggtc	tgaatcccac	ccttggcatt	gcttgggtga	gactgagata	cccgtgctcc	1920
	gctcgcctcc	ttggttgaag	atTTTctcct	ccctcacgtg	atTTTgagccc	cgTTTTtatt	1980
	ttctgtgagc	cacgtcctcc	tcgagcgggg	tcaatctggc	aaaaggagt	atgctcttcg	2040
	cctggaccgt	gctcctgctc	gggcctttgc	agctctgcgc	gctagtgcac	tgcgccccct	2100
	ccgccgcggc	ccaacagcag	ccccgcgcg	agccgcgggc	ggctccgggc	gcctggcgcc	2160
	agcagatcca	atgggagaac	aacgggcagg	tgttcagctt	gctgagcctg	ggctcacagt	2220
	accagcctca	ggcgcgcggc	gaccggggcg	cgccgtccc	tggtgcagcc	aacgcctccg	2280
50	cccagcagcc	ccgactccg	atcctgctga	tccgcgacaa	ccgcaccgcc	gcggcgcgaa	2340
	cgcgacggc	cggctcatct	ggagtcaccg	ctggccgcc	caggccccacc	gccccgctact	2400
	ggttccaagc	tggctactcg	acatctagag	cccgcgaacc	tggcgcctcg	cgcgcgagaga	2460
	accagacagc	gccgggagaa	gttctctcgc	tcagttaacct	gcggccgcc	agccgcgtgg	2520
	acggcatggt	ggcgacgcac	ccttacaacc	cctacaagta	ctctgacgac	aaccttatt	2580
	acaactacta	cgatacttat	gaaaggccca	gacctggggg	caggtaccgg	cccggatacg	2640
55	gcactggcta	cttccagtac	g				2661

EP 2 272 975 A1

<210> 2
 <211> 1953
 <212> DNA
 <213> Homo sapiens

5

<400> 2

tataaattcc	acgcaggcat	tgaattgaat	ttgttcttaa	ccaaatgcgt	tttatctata	60
cctggcagga	atctagaagt	gaaattacaa	gatttatttc	atnttaattc	tattatgaag	120
catttaataca	caaataccct	gaaaatgaaa	agataattta	tcattttacc	ttgactgagc	180
aactctcctc	acttcacatt	catgaatcca	taacgcagag	aggagactgg	atgattaagt	240
gtttgattag	agaaaacaga	ttaacctagc	aaacataata	aatttggctc	ataagcagga	300
tggtcttata	aatgctcaca	atacctctcc	tgtataaaat	catgaaccac	ttcctacagt	360
gatgactcca	tcgaaatagt	tgagaaacat	aaagcaaatg	catgtttatg	gctttctctt	420
tgagacatta	aaagggattt	gaaaggcata	tctgattcag	cttataactc	tgatatata	480
ttaaggaaca	tgtaagaaaa	tattaatgca	taaaaaaagc	tacaacttct	caagtgttct	540
agtttcaact	ttgtcaataa	ttacgttttc	aatgtccttc	tgtggactgt	ttcctaaagt	600
gccaatccag	acccaaagtt	tcagatcact	cagattcacc	cttaaccttc	ataacacaac	660
ccaatagctt	tacgaaaaaa	gttgcatatt	taggtagttg	ttatcccatt	atgacaaaaat	720
acataaaatt	agcgagatat	tttttagcct	tcaaataagt	gggaaaaaat	ccttttagct	780
gagattccat	ttacatcaga	ataaaaaatct	aagttagtac	taggttgaag	caacgtcctg	840
tgacagcctc	cataaagttc	acttagtctt	caagggttcc	ttacttagct	aggttagtat	900
tcctggcctc	tttttttagc	agtgagaaaa	aggatactct	ccctgcccc	gctttatttt	960
taaactcaca	gccatatcct	ggaggctctt	gctggctatt	tggcgcgtgg	ggcgaggagg	1020
gggcccgggg	agggggcg	ggcgggtctt	ggaggctctg	gctggctatc	tggcgtgtgt	1080
gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	aggtctctgc	tggctatctg	gcgtgtgtgt	1140
gtgtgtgtgt	tggtgtgtgt	aagcagttag	ggtgttttag	ggccagtctt	tcctccgcca	1200
ctttgctgac	tcaaagacc	agaggctttc	ttgggtgca	ggtaccatga	ttccttgggc	1260
cctaagggaa	ttttgttag	gctagaagag	tgggtgtact	catgatgggt	gtaccggaac	1320
attcctgggc	tcaacaaaac	cgattatctt	tataaccgcg	gcgcttagca	cagcgcctgg	1380
tgccctaaac	ggtggctg	ggaacgtccg	agacgcgggt	gcgagccgg	ggcggaata	1440
actggttgcg	cggcgtttg	accgtaggcg	ctggagcgcg	tgcgttgcgt	gcgcgcgcgg	1500
aggcggctgc	gtcggggcgc	gagaaggtgc	agttccccgc	cgggcggggc	ggcgggcggg	1560
cgaagctggg	ctcggggcca	agcgaggtct	agccggagcg	actgtgcccc	gcctcctggg	1620
cggagcgggc	ggctccccat	ggtcagagcc	tcgtgccggc	tcggcagcgc	ccggacgccg	1680
agccagcgcg	gtcggcccc	cggcgtcgcg	gcgtctcaga	gcccggagg	ggccgcccgg	1740
accgtttcag	cgtggcggcg	ctggtgctgg	cgttggccct	ggaggacggc	cccagtgat	1800
ggctggcgc	tgctcccgcg	gtgtctcccg	ggtacagatg	gagtcgtccc	gcggccgccg	1860
gcggaaggt	cggcagctgc	gaggccaaga	gagaccccag	gacacacaca	gctgcctccc	1920
ggtgcgagaa	gaagacccc	gcttgagagt	gag			1953

<210> 3
 <211> 889
 <212> DNA
 <213> Homo sapiens

35

<400> 3

cggccccatg	gctccgtgtc	gtgtccaagg	gatgggctgg	cacctcttgg	accaggctta	60
ccaccagggc	ccttctctga	agccccagtc	tgaccggcct	gctgtggga	atccccctct	120
gccccacac	taacctctgc	tgggctgag	ccagggcgcg	tcggacagtc	agggcgacc	180
agccagggcg	accgttggcc	ccgctcctat	ggggcagcag	ggaccgacgt	cagcaggtg	240
gggcccggcac	ccgagtggta	tgccccgcc	tgccccgctt	gccccctctg	gtggcctct	300
gggggagaca	agtcctgaga	gaaccagacg	gaagcgcgct	gggactgaca	cgtggacttg	360
ggcgggtgctg	cccgggtggg	tcagcctggg	ctgggaggca	gccccgggac	acagctgtgc	420
ccacgcgcgtc	tgagcacc	aagcccgatg	cagccacccc	cagacgaggc	ccgcagggac	480
atggccgggg	acaccagtg	gtccaggtgt	ggcgggggtg	aggggagggg	gggtgggagc	540
ggtggagatg	gggcccgtgg	gagggagctg	agatactgcc	acgtgggacg	atgctaggtg	600
gggagggctg	agctgggccc	gctcctctgg	ctgtggggcc	ccctgtgttc	cttgtgggag	660
gtggaagaa	gtgagtgccc	tgtccttctt	ccctgccatg	agattccagg	accggacctg	720
gcaagtgccc	tatcccagcc	agtgttcctg	ggctcttcc	aggcagggct	atgttcccc	780
ggccaggggc	attgtcctgg	acagtcagga	ggcatacccc	tcgccaggtg	gaaccacct	840
gtgtatgcat	gacctgaca	agcaggcgc	aggacagtc	ggaggccag		889

<210> 4
 <211> 863
 <212> DNA
 <213> Homo sapiens

55

<400> 4

EP 2 272 975 A1

	gttgttgggt	gtgaatggag	aactgtgggc	cctccccgac	accttccagc	gggacggcaa	60
	cgggggccca	gggggtggc	gccatcaacc	ccgtcccacc	gccaggacg	cgcgggggag	120
	ggccggcggg	ggcggggcgt	cctgtaaggc	gcggccccc	cccggggcgg	ggggcgccatt	180
5	cctgggaggc	cgcgctctg	acgtggacc	gggggcccgc	ggcacggcgg	ggggcgggcg	240
	gtccgggggc	ttcttaaacc	ccccgcccc	gcccagccc	cacttcccga	gcaccgctcc	300
	gaccctggag	ggagagagag	ccagagagcg	gcccagcgc	taggaggccc	gcccagcctc	360
	gcccagcccc	gccagcccc	gcgcgagaga	agttggagag	gagagcagc	cagcgagcgc	420
	agtcccgtg	tcgccccca	acagcgcgg	acagccccg	atagcccaa	ccgcgccct	480
	agccccggc	gcacccccag	ccccgcgccc	catgatgaa	aacagcggc	actcagacgc	540
	cggcctcggc	ctgggcgatg	agacagacga	gatgccgtcc	acggagaagg	acctggcgga	600
10	ggagcgcggc	tggaagaaga	tccagcagaa	cacattcac	cgctgggtgca	atgagcacct	660
	caagtgcgtg	ggcaagcggc	tgaccgacct	gcagcgcgac	ctcagcgacg	ggctccggct	720
	catcgcgctg	ctcggaggtg	tcagccagaa	gcgatgtac	cgcaagttcc	atccgcgccc	780
	caacttccgc	caaatgaaag	tggaacagc	gtccgtggcc	ctcagattcc	tcgagcgcga	840
	gcacatcaag	ctcgtgtcca	tag				863
15	<210> 5						
	<211> 2198						
	<212> DNA						
	<213> Homo sapiens						
20	<400> 5						
	aagagaggca	cactccctct	accacaccga	gggagggggc	ggtgagctga	gaaaggttga	60
	gagaatgagg	gacccaggtg	ggtggacatc	ggccaagaaa	ggaaccacag	cgggaggtta	120
	gaccgagagt	ccccagcttg	aagcgtcacc	actccgggat	tcccagattc	caacgcgagc	180
	ctggggaaaag	cccacagtgg	agagagtcgg	gctggcagg	aatggcccta	ccccgggggt	240
	gaaatctcgg	agggtcgtgc	agccgagtcg	cgctctcgcg	ctgatgcgtg	agagatgccg	300
	gacgtcgcgt	ttgcctgtgc	gagcctcggc	gatgctgtgc	agtcttggtc	ccctctgcgt	360
25	gtgtctaacg	ccgaatgctg	gtgtctcgag	gtgtgagctt	cggggcgggt	gtctttaaag	420
	aaccaaaagt	tcttaaggag	tgatgatctg	gtagagcgg	ccgacgtag	ccgcgctccc	480
	aggtctcggg	gcgagtcctg	cggacagacc	agaggagacc	tgctggccag	atgccccggg	540
	cccaaggcgg	acgccagact	gtctctgccc	cagccgggct	ggccttcgga	atggatcagg	600
	caccggggag	gcccggagtg	atctcagacc	ctcaagccgg	gaacaaacc	gtcgatgccc	660
	gtggccctgg	agtccgcctc	ctccttccc	ccccaccct	accctgcct	ccgaaaggct	720
	tcttcgctgg	tcagtagctg	cgtgcccgtc	tgctgaggg	tggttcagaa	ttggcgggct	780
30	ggtaacgacc	ccgtgcacaa	gcggctccca	gtctctccag	aaagggccga	tgactaaggg	840
	gtgggggtgg	ggcgggagg	ctggaagggt	ttagggaaga	acgttagcgg	cctatcctgt	900
	cttcagcagc	gcctctcat	cttctagctc	tgacgccgag	cagagcagtt	ggagctcggg	960
	actgggaact	gctggaattc	ctatttagac	ttctagacag	tctagaaaca	agaacctttc	1020
	tttccctggg	cctcagtttc	cttgtctgta	aaatcaaaa	gcgggctcta	ggtgtagggc	1080
	ttcttttcgc	ttgggtgattc	tggtattcctt	tccttggatc	cgtggggagg	gggtggcagc	1140
35	aacagtccag	ggcgttggcc	gtcctgtgcc	tcaagtacgt	agtccccgtg	cccgccccct	1200
	caacaccccc	agcagcccc	ccccctaagc	ccgcagagca	gggagctgag	tgggaggggg	1260
	agaggcgggg	ccggttccca	gtccctgctg	gcggactaga	gtggcggggg	ctgagcgtaa	1320
	aacctgggat	agccactccc	ccttttcctt	atccccgcc	ccctgccatt	ggtccccggg	1380
	agaggttgac	atcaaagccg	cggtcttata	taagccagat	ccgcagggga	gtccgcagaa	1440
	gggttaaaca	ggtctttggg	cttcggcgac	ctcgcccgcg	gcagaaaccg	gtaagaagac	1500
40	agtgggctgc	gcgtctcatt	ttcagccttg	cccggactct	ccccaaagccg	gcgcccagta	1560
	gtggctccag	agcccacagg	tgcccccg	cagtctctgg	ggcgcatgga	gcggcgctta	1620
	gagggctggc	ggcgcaggcc	agtagccgct	ccaacatgaa	cctcgtgggc	agctacgcac	1680
	accatcacca	ccatcaccac	ccgcaccctg	cgcaccccat	gctccacgaa	cccttctctt	1740
	tcggtccggc	ctcgcgctgt	catcaggaaa	ggcctactt	ccagagctgg	ctgctgagcc	1800
	cggctgacgc	tgccccggac	ttccctgccc	gcgggcccgc	gcccgcggcc	gctgcagccg	1860
45	ccaccgccta	tggtcctgac	ggcagccctg	ggcagagccc	cgggcggctg	gagggccttg	1920
	gcggcgtct	tgccggcg	aaaggctcag	gacccaagaa	ggagcgggaga	cgactgaga	1980
	gcattaacag	cgatttcg	gagttgcgg	agtgcattccc	caacgtgccg	gccgacacca	2040
	agcttcccaa	gatcaagact	ctgcgcctag	ccaccagcta	catcgcctac	ctgatggagc	2100
	tgctggccaa	ggatgcacag	tctggcgatc	ccgagggcctt	caaggctgaa	ctcaagaagg	2160
	cggatggcgg	ccgtgagagc	aagcggaaaa	gggagctg			2198
50	<210> 6						
	<211> 1945						
	<212> DNA						
	<213> Homo sapiens						
55	<400> 6						
	ctggatgaca	gagtgagact	ccgtctcaaa	aaaaaagctc	catttgggag	gccgaggagg	60
	gtggattacc	tgaggtcagg	agtttgagac	cagcctggcc	cacatagga	aaccccatct	120

EP 2 272 975 A1

	ctactaaaa	tacaaaaatt	agtcaggtgt	ggtggctgac	acctataatc	ccagctactt	180
	gggaagctga	ggcagggaga	atcacttgaa	ccggggaggt	ggaggttgca	gtgagctgag	240
	atcatgccac	tgactccag	cctgggcgac	agggtgagat	tctgtctcaa	acaacaaat	300
5	ttaaaagctc	cgaatcctcc	aaaaatacca	agatcttcct	gtcggtaact	agagatgggt	360
	actgatgatt	atctttaata	ggtgatcttc	aaagatgtga	acgttatcca	tggagattta	420
	agtctccaaa	agggaaaaaa	atgcatacct	ttatactaaa	acttcatcac	cagtcaaatt	480
	catgaccacg	ctaaattggc	ttctacacct	ctctccta	ataaggtact	tgtgtaagtt	540
	tgagttgtg	agacacttat	ttcctcattt	ttaatgtctt	ctcagtaggg	ccactgatat	600
	agtcactatt	tgactgacca	gaatggttgg	cactgggtgat	tggctcataa	agtgccctcg	660
	atctaggggg	ctcaattatc	aaaggtttaa	atcctagccc	aaaccattgc	tgtgatgggg	720
10	gttaatcaat	gaaccactca	gcttcaactg	caaaagcggg	atcacaatag	ccgctttcgt	780
	catgaccacg	cctaggtgag	atcttagtact	taagtacact	gccaggcaca	caaggttaat	840
	ttaacaattt	aacacatttg	tttctctatc	catttctcca	aaccttccaa	ctaactctaa	900
	cgcttcgtcg	gccaaatggg	ccaggaattc	acttaaacia	aaacaaaaaa	caaaacaaac	960
	aaaaaaaaac	tccttggggc	ttggggaagg	aggcaccgcc	gcccatgtcg	cagtctgggg	1020
	gtggctcagt	cctcagcacc	cagatctacg	gccataatgc	tcttcgaggg	caaggagccc	1080
15	ggatgcgggg	cgttgccgaa	ggcgtcttgc	tcaggctgcg	ggaaaggaga	ggggtgggag	1140
	cggggtgggg	gcatcgcgac	ccagggcaag	gcggcgagtc	gccgtcttcg	agtccacact	1200
	gtccgaagcg	gggtgagaaa	aggcaaaaca	tggcaaagcc	atgcacctcc	caggggtggc	1260
	aactcacggc	cgtgaaacgc	cggaccctta	gcagtttcca	gacctttgga	accggaagcg	1320
	gagcctgaga	gcgcgcccca	gagggcgtga	acgggaccgc	tttcccggaa	gtgcttgcgg	1380
	cctctgcccc	gcgagctgcc	ccgggtcttc	tctggtttcc	taatcagggc	aacgcccgcg	1440
20	gagagaacct	ttaccttggc	tgactaagt	tctcgggtgc	actccctggc	aggggcggac	1500
	cttggttagg	ccctgtgatc	gcgcggttcg	tagtagcgca	aggcgcagag	tggaccttga	1560
	cccgcctagg	gcgggaagag	tttggcccgc	cggttcccaa	agggcagaat	ggacgggctc	1620
	ctaaatccca	ggaaatcctc	taaattcatt	gcagaaaaaa	gtcgggatgt	gtttattgac	1680
	agcggagggc	tacggagggt	ggcagagctg	ctgctggcca	aggcggcggg	gccagagctg	1740
	cgcggtgagg	ggtggaaagc	ccttcatgag	ctgaacccca	gggcggccga	cgaggcccg	1800
25	gtcaactggg	tgttcgtgac	agacacgctc	aacttctcct	tttggtcgga	gcaggacgag	1860
	cacaagtgtg	tggtgaggta	caaggggaaa	acatacagtg	ggtactggtc	cctgtgcgcc	1920
	gccgtcaaca	gagccctcga	cgaag				1945

<210> 7
 <211> 2379
 <212> DNA
 <213> Homo sapiens

	<400> 7						
	aagcttgtgg	tttacttggg	cctctgcctc	atctttcttc	ttttgcgctt	cagcctgcgc	60
	attcgcttcc	tccactaggc	tctcatggtg	cagaggtttc	caagaagatg	gtgtgaaggc	120
	cgagatcatt	tggttatatt	ataaaataga	atgcaaattc	acacaagttt	ttgtttttta	180
35	tttattttatt	tttttagaga	tgaggctctg	ctatggtggt	tagtctggtc	tcgaactcct	240
	ggcctcgtga	tcctcccacc	ttgacctccc	aaagtgctgg	gattacaggc	ctgaggcctg	300
	agccactaca	cccaactgaa	ttcacatttt	ttttttctt	ttctgagacg	gagtctcact	360
	ctgtcaccca	gtatggagtg	cagtgccgcg	actgcgctc	actgcaagct	ccgtctctcg	420
	ggttcaagtg	attctcatgc	ctcagcccc	caagtagctg	gaattacagg	ggtgcactac	480
	cacacctggc	taatttttct	gttttagtag	agatgggggt	tcacatggtt	gcctgggtctc	540
40	aaactcctga	ctttaagtga	tccacacacc	tcagcctccc	aaagtgtggt	gattacaggt	600
	gtgagcctcc	acaccgggc	gaattcacat	gaattttaa	gtgatgtctt	caaagtgtgt	660
	tcactgtggg	gatgggcagc	tttttgttat	acatctagaa	cgttctctct	ctgtttctat	720
	gaatactcgg	ttggaaaggg	ctgaaaaacg	gtcttaagag	attatctgat	tcgtttccca	780
	gttttattac	tcacatatca	gctgtaattt	gagcacgttt	tctgattgag	acaagactca	840
	gatggtatta	aacattacta	caacacatcc	gggcacgggtg	gctcacgcct	gtaatcccag	900
45	cactttggga	ggcggagggc	ggcggatcac	gaggtcagga	gatcgagacc	atcctggcta	960
	acacggtgaa	gccctgtctc	tactaaaaat	acaaaaaatt	aggcgggcat	ggtggcgggg	1020
	gcctgtagtc	ccagctactc	gggaggctga	ggcaggagaa	tggcgtgaac	ccgggagggc	1080
	gagcttgacg	tgagccgaga	tcgcgccact	gcactccagc	ctgggcgaca	gagcaagact	1140
	ccatctcaaa	aaaaaaaaaa	aaaaaaaaaa	actacaacac	tataaattca	tatctattat	1200
	aatagtaact	tgtgcagggc	cctaccctaa	gtccttaacc	gaacccggaa	gcgagaagat	1260
	gacttttggg	tggttttaga	gatgggcgcc	tggtctgttc	gccagcctgg	agtgtggggg	1320
50	cgcgatctcg	actcacagca	gcctccacct	cccaggttca	ggcgatcttc	ctgcctcagc	1380
	ccctcgagga	gctgggacca	ccggcgcgct	ccatcgcgcc	cggctaggag	ctgactttga	1440
	atccgggctc	tgccgctggc	cttctgcatc	tctataaggg	aagacatctg	tgacctcggg	1500
	gcaaagggtca	aattagatcc	tgggtaggat	cctgttcccg	ctgcccctcg	gctgggcaact	1560
	gccaggagta	ctcagagctc	aaagctggga	tctgcagctc	cttaccctact	cagtgcacgc	1620
	cgctaagggc	tttgcgcttc	acctttactc	acctcgaagc	cctggacatc	cgcatctgcc	1680
55	ctaagacttc	tcacctcagt	agcagaagga	agtcgcgctc	gctggccaca	gcctctctcc	1740
	taggagaccg	tccgggaaaa	gcgagtcagg	gtagaccctg	aggcccctca	gctccggcta	1800

EP 2 272 975 A1

	ttttcagatc	tgtcgcctct	tcaccctcag	cctttcaaac	aggccactcc	aaaaaaaaagc	1860
	ccaatcacag	ccttccttct	tctcctggcc	ttccggcact	gtccaatcaa	cgtacgccat	1920
	ctatcgggta	gtggtgttgc	ggggccaccc	ttcccgctgg	tttccctcgt	ggtgtgtaaa	1980
5	ggcagagagg	aaaggcaggg	ggtgttgacg	ccaggaaggt	tccatcttgg	ttaagggcag	2040
	gagtccttta	cggacttgtc	tgaggaaaga	caggaaagcg	ccagcatctc	caccttcccc	2100
	ggaagcctcc	ctttgccagg	cagaaagggc	ttcccatggg	gccgcccctg	cgcccgccgc	2160
	cggcccacgt	accgggggag	gccgggcccc	ggaggacgag	ggaaaacagg	ccggggcgccg	2220
	tgagcttcgc	ggacgtggcc	gtgtacttct	ctcccgagga	gtgggaatgc	ctcgggccag	2280
	cgcagagggc	cctgtaccgg	gacgtgatgc	gggagacctt	cggccacctg	ggcgcgctgg	2340
10	gtgaggccgg	gccctccggc	cgggaccccc	agtccgtcg			2379
	<210>	8					
	<211>	933					
	<212>	DNA					
	<213>	Homo sapiens					
15	<400>	8					
	gagacgtact	ctggctctgt	cgcccaggct	ggagcgcaat	ggcgccatct	cggcgactg	60
	caacctccac	ctcccggggt	caagcgattc	tactgcctca	gcctcccagag	tagctgggac	120
	tacaggcgcg	caactaccaag	cccggctaata	ttcttttgta	tttttagtag	agactggggt	180
	tcacgatggt	ggccgggctg	gtctggaagt	cttgacctca	agcgtgcgcc	ctctccgccca	240
	ctgggtaagg	cggggggcgg	aatagggggc	ttgcaatttc	acactagagg	cggggcgccgt	300
20	gggggaaaga	agagtcacgt	ctcccacggg	tcgtagagga	aggcctgcct	gagcctggag	360
	cgggggcggg	agagccacag	tttggcatcc	ccagggcatc	ccccagcccg	cagactacca	420
	ggcctccaga	ggacaggagg	ccaccccggc	ccacaggccc	tgccccagc	actccccgca	480
	ccccgcctcc	aagactcctc	cgcccactcc	gcacccaact	tataaaaacc	gtcctcgggc	540
	gcggcgggga	gaagccgagc	tgagcggatc	ctcacacgac	tgtgatccga	ttctttccag	600
	cggcttctgc	aaccaagcgg	gtcttaccct	cggtcctccg	cgtctccagt	cctcgcacct	660
25	ggaaccccaa	cgtccccgag	agtccccgaa	tccccgctcc	caggctacct	aagaggatga	720
	gcggtgctcc	gacggccggg	gcagccctga	gtctctgcgc	cgccaccgcc	gtgctactga	780
	gcgctcaggg	cggacccgtg	cagtccaagt	cgccgcgctt	tgctctctgg	gacgagatga	840
	atgtcctggc	gcacggactc	ctgcggtcgc	gccaggggct	gcgcgaacac	gcggagcgca	900
	cccgcagcca	gctgagcgcg	ctggagcggc	gcc			933
30	<210>	9					
	<211>	6096					
	<212>	DNA					
	<213>	Homo sapiens					
35	<400>	9					
	atctgcacct	cctcatatag	ggttgatcca	agtttcacag	acatcactga	gttcttagtg	60
	gactcagcta	ttggggctgt	tctcacactt	tttttttctt	tgcaagaatc	agcaatgggt	120
	gcaagtggac	ctgtgtagga	cgtccagtga	aacattgtgt	tggtgaatca	gctagaatcc	180
	atccaagaac	tcagccagcc	tggtgtgggg	tgagatctga	tccttgaatg	tcctcagctg	240
	gcttttaggg	ctggcagggt	cagaagggcc	ctctcatcac	ccccccaggg	cctcattcct	300
	tgtttaacac	tttgctatca	cagtcttgaa	tccttgtaat	tgaacaatgg	acccccacatt	360
	ttcactttgc	actggtttct	gattctgtaa	cgatcctgt	ccccctctct	tgtctcattc	420
40	actctgggaa	ttgtccccac	attctgagac	ctttcagcag	tgccccaaacg	aggttctctg	480
	ccttatctga	agctccacc	tcacccccat	ggcggcaccg	caggcagccc	tgcttttgcg	540
	tcccgcctag	cagggtgtg	caccggagtc	acgaccccct	gattcagcct	aggcagccac	600
	agcttgactg	ctcccgcggg	acaagcccta	ctgtgctatc	tgccgctctt	cccttctctt	660
	tcccaggggg	tccgcgtcag	gggaggcgca	gctgtgtgca	ttccgggagc	ttcagacccc	720
	cgtgtccagc	agctccttgc	tttctctggg	gctggggcgg	ccttcccagc	gaagagctca	780
45	actcagcggg	acgtttggag	gctctctgcc	ccaaggcgct	ggggagtgtg	cgccgggaca	840
	gtcgtgcttg	cctttttcac	tttcagagtg	tccaagcccc	accggtttgg	tcactgcagg	900
	tcagtccagt	ccagcccggc	ccaccccacc	ggtgcgtgtc	tgctgcacgt	ggcagacgcc	960
	atactctctg	ttcttgttta	aagcccagga	tctactgggc	cctggaggca	agaggtgaac	1020
	gcagcggaat	ccacgctgag	ctgcccggga	acggagcttc	caaccccaga	aggaggactc	1080
	tgtgctccta	caccttaacc	cttttttagcc	cgaacttctt	ccaacttctt	tgcttttgtt	1140
	tagagctcga	cagcgcggcc	ccctggcgct	cgttgtgagg	acagtagagg	agagaggcaa	1200
50	gggtgttttt	aaacagtttg	cctctcacca	ttatgggggc	gacccgaggg	ggagaccac	1260
	tcttccgcat	tcccggtaag	tgaaccaccg	gaagaggtcg	aaagtacggg	attccccatg	1320
	cctctccagc	cccccccccc	accctgccca	tccacaggac	ggtggctctt	cagtgcctt	1380
	tgccgagcaa	gtggcgtttc	tatgcacgtg	ggtatcaatt	cggactctgg	acgaaatgga	1440
	aacctcctta	gccgacccgg	gtgggatcag	ctgggatcct	gcgcgctccc	ctgggggggt	1500
	gccagccact	ctgttggggg	gcaagaagca	ccatccttcc	gaagctgggc	cgaactggc	1560
55	caggctgact	cgctcccacg	cgcccggccc	taccggcgcc	cgcagcaatt	cacctgccac	1620
	cgcctctgag	ccgggtccgg	acttcggcgc	cctgacagtg	tccccgcgac	ttccccacc	1680

EP 2 272 975 A1

	gatgagatgg	ggtctggcgt	tggccagtgc	gtgtccaggg	actcgcgggt	ccctggccag	1740
	ccatggggca	gagggcgctg	gtgttaggcc	agtcttcccc	accctgcccc	gtcaccaccag	1800
	ccacaccac	tgtcctgtga	ggccaagcgc	gctccgctgg	tttctgagc	caggcaccct	1860
5	ggccgcgac	aggatccagc	tgtctctcct	tgcgatcctg	tcttcgggga	agtccacgtc	1920
	ctaggcaggt	cctcccaaag	tgcccttgg	gccgatcacc	cctcccagcg	tcttgcaggt	1980
	cctgtgcacc	acctccccca	ctccccattc	aaagccctct	tctctgaagt	ctccggttcc	2040
	cagagctctt	gcaatccagg	ctttccttgg	aagtggctgt	aacatgtatg	aaaagaaaga	2100
	aaggaggacc	aagagatgaa	agagggctgc	accgctgggg	gcccagatgg	tgggcgggga	2160
	cagtcgtctt	gttacagggg	tgtgtgcctt	ccctggcgcc	tgcccctgtc	ggccccgccc	2220
	gagaacctcc	ctgcgccagg	gcagggttta	ctcatcccgg	cgaggtgatc	ccatgcgcga	2280
10	ggcggggcg	aagggcgggc	agagaacca	gcaatccgag	tatgcgcat	cagcccttcc	2340
	caccaggcac	ttccttctt	ttcccgaacg	tccagggagg	gagggccggg	cacttataaa	2400
	ctcgagccct	ggccgatccg	catgtcacag	gctgcctcgc	aggggctgcg	cgcagcgcca	2460
	agaagtgtct	gggtggggac	ggacaggaga	ggctgtgcgc	atcggcgctc	tgtgcccctc	2520
	tgtctccgca	cgccctgtc	gcagtgcgcg	cgctttcccc	ggcgctgca	cgcggcgcg	2580
	ctgggtaaca	tgttgggggt	cctggctcct	ggcgcgctgg	ccctggccgg	cctgggggtc	2640
15	cccgcacccg	cagagcccca	gccgggtggc	agccagtgcg	tcgagcacga	ctgcttcgcg	2700
	ctctacccgg	gccccgagc	cttcctcaat	gccagtcaag	tctgagcgg	actgcccggc	2760
	cacctaatga	cagtgcgctc	ctcgggtggc	gccgatgtca	tttcttggct	actgaacggc	2820
	gacggcgggg	ttggccgccc	gcgctcttgg	atcggcctgc	agctgccacc	cggtgcccgc	2880
	gacctcaagc	gcctcggggc	cctgcgcggc	ttccagtggt	ttacgggaga	caacaacacc	2940
	agctatagca	ggtgggacag	gctcgacctc	aatggggctc	ccctctgccc	cccgttgtgc	3000
20	gtcgtgtct	ccgctgctga	ggccactgtg	cccagcgagc	cgatctggga	ggagcagcag	3060
	tgcgaagtga	aggccgatgg	cttcctctgc	gagttccact	tcccagccac	ctgcaggcca	3120
	ctggctgtgg	agcccggcgc	cgccgctgcc	gccgtctcga	tcacctacgg	caccccgttc	3180
	gcgcccgcg	gagcggactt	ccaggcgctg	ccgggtggga	gctccgccc	ggtggctccc	3240
	ctcggcttac	agctaagtgt	caccgcgccc	ccgggagcgg	tccaggggca	ctgcccagg	3300
	gagggcgccg	gcgcttggga	ctgcagcgtg	gagaacggcg	gctgcgagca	cgctgcaat	3360
25	gcgatccctg	gggtcccccg	ctgccagtgc	ccagccggcg	ccgcctgca	ggcagacggg	3420
	cgctcctgca	ccgcatccgc	gacgcagtcc	tgcaacgacc	tctgagagca	cttctgcgtt	3480
	cccaaccccg	accagccggg	ctcctactcg	tgcattgtcg	agaccggcta	ccggctggcg	3540
	gccgaccaac	accggtgcca	ggactgggat	gactgcatac	tggagcccag	tccgtgtccg	3600
	cagcgtctgt	tcaacacaca	gggtggcttc	gagtgccact	gctaccctaa	ctacgacctg	3660
	gtggacggcg	agtgtgtgga	gccctgtggac	ccgtgcttca	gagccaactg	cgagtaccag	3720
	tgccagcccc	tgaaccaaac	tagctacctc	tgcgtctgcg	ccgagggctt	cgcccccatt	3780
30	ccccacgagc	cgcacaggtg	ccagatgttt	tgaaccaga	ctgcctgtcc	agccgactgc	3840
	gaccccaaca	cccaggctag	ctgtgagtgc	cctgaaggct	acatcctgga	cgacggtttc	3900
	atctgcacgg	acatcgacga	gtgcgaaaac	ggcggcttct	gctccggggg	gtgccacaac	3960
	ctccccggta	ccttcgagtg	catctgcggg	cccgactcgg	cccttgcccg	ccacattggc	4020
	accgactgtg	actccggcaa	ggtggacggg	ggcgacagcg	gctctgggca	gcccccgccc	4080
	agcccgacgc	ccggtccac	cttgactcct	ccggccctgg	ggctcgtgca	ttcggcttg	4140
35	ctcataggca	tctccatcgc	gagcctgtgc	ctgggtgggg	cgcttttggc	gctcctctgc	4200
	cacctgcgca	agaagcaggg	cgccgccagg	gccaagatgg	agtacaagtg	cgccggccct	4260
	tccaaggagg	tagtgcgca	gcacgtgcgg	accgagcgga	cgccgagag	actctgagcg	4320
	gcctccgctc	aggagcctgg	ctccgtccag	gagcctgtgc	ctcctcacc	ccagctttgc	4380
	taccaagca	ccttagctgg	cattacagct	ggagaagacc	ctccccgcac	cccccaagct	4440
	gttttcttct	attccatggc	taactggcga	gggggtgatt	agagggagga	gaatgagcct	4500
40	cgccctcttc	cgtgacgtca	ctggaccact	gggcaatgat	ggcaattttg	taacgaagac	4560
	acagactgcg	atthgtccca	ggtcctcact	accgggcgca	ggaggggtgag	cgttattggg	4620
	cgcgagcctt	ctgggcaagc	cttgacctcg	tgggctaggg	atgactaaaa	tatttatttt	4680
	tttaagtat	ttaggttttt	gtttgtttcc	tttgttctta	cctgtatgtc	tccagtatcc	4740
	actttgcaca	gctctccggg	ctctctctct	ctacaaactc	ccacttgtca	tgtgacaggt	4800
	aaactatctt	ggtgaattht	tttttcttag	ccctctcaca	tttatgaagc	aagcccact	4860
45	tattccccat	tcttcttagt	tttctcctcc	caggaactgg	gccaactcac	ctgagtcacc	4920
	ctacctgtgc	ctgaccctac	ttcttttggc	cttagctgtc	tgctcagaca	gaacccttac	4980
	atgaaacaga	aacaaaaaca	ctaaaaataa	aaatggccat	ttgctttttc	accagatttg	5040
	ctaattttatc	ctgaaatttc	agattcccag	agcaaaataa	ttttaaaca	aggttgagat	5100
	gtaaaaggta	ttaaattgat	gttgctggac	tgtcatagaa	attacacca	aagaggtatt	5160
	tatctttact	tttaaacagt	gagcctgaat	tttgttgcgt	ttttgatttg	tactgaaaaa	5220
	tggttaattgt	tgctaactct	cttatgcaat	ttcctttttt	gttattatta	cttatttttg	5280
50	acagtgttga	aaatgttcag	aaggttgcct	tagattgaga	gaagagaca	acacctccca	5340
	ggagacagtt	caagaaagct	tcaaaactgca	tgattcatgc	caattagcaa	ttgactgtca	5400
	ctgttccctg	tactggttag	accaaaataa	aaccagctct	actggctctg	tggaattggg	5460
	agcttgggaa	tggatcctgg	aggatgccc	attagggcct	agccttaac	aggtcctcag	5520
	agaattttcta	ccatttcaga	gagccctttt	ggaatgtggc	ccctgaacaa	gaattggaag	5580
	ctgcctgcc	catgggagct	ggttagaaat	gcagaatcct	aggctccacc	ccatccagtt	5640
55	catgagaatc	tatatthaac	aagatctgca	gggggtgtgt	ctgctcagta	atthgaggac	5700
	aaccattcca	gactgcttcc	aatthtctgg	aatacatgaa	atatagatca	gttataagta	5760

EP 2 272 975 A1

5
 gcaggccaag tcaggccctt attttcaaga aactgaggaa ttttctttgt gtagctttgc 5820
 tctttggttag aaaaggctag gtacacagct ctacacactg ccacacaggg tctgcaaggt 5880
 ctttggttca gctaagctag gaatgaaatc ctgcttcagt gtatggaaat aaatgtatca 5940
 tagaaatgta acttttgtaa gacaaaaggt ttctcttctc attttgtaaa ctcaaaatat 6000
 ttgtacatag ttatttattt attggagata atctagaaca caggcaaaat ccttgcttat 6060
 gacatcactt gtacaaaata aacaaaataac aatgtg 6096

<210> 10
 <211> 2500
 <212> DNA
 <213> Homo sapiens

10
 <400> 10
 acccacttct gtgtgtggat agtatcctgc aggagagatg ttgtctgcag tgtgagctgg 60
 gccaccggga gtgtgtgaat aggatcctgc aggagaaatg gaatccggag tgtgagctgc 120
 atccgctgta gagggtggat aaaatcctgc aggaaagatg gcatctggaa tgcagcggg 180
 15 agccaccgac ctctgaggat gcaccccgca ggtgtgatgc ggggccagtt ccaaggctgg 240
 gtttagtttt accctggctt ctgtgttcta ctctcattct ctctccttt cttctaatac 300
 ctgctctggg aggcattcagg ccatgtccag tgtgcaggcc atggagacc acacggcaag 360
 gaactggaac ccctgcccag cagcctcggg ggtccagtc ttagatggtg ccctgtggtc 420
 agcaatgcac ctgtgacctc cgggctatgt ctctgtggtag ttgctttgt gttttaacat 480
 20 agcaacagga aactagccta ttaccacca atcccattcc aggctgcttt caaacgcagc 540
 tcaggctaga acaccagcac ggggacacag ctgagacttg gggtttgcga cgggaacacg 600
 cccatgtgtt gcctctgaat ctggcaccgt caccctgtgg cctgggttca gcaacttggc 660
 ctcaccttcc ttgtctgtga aattcagact gggtccttgt gagatgattg gagagaatgt 720
 atgaactatg tgagaacgct acctttgtgc gtaatctcacg cagtgtcttc cctcctttcc 780
 aaagtcttct gctgtctcta gacacaccg acgtgggggg ggggggttcc ctgggtctcc 840
 tcctaggtct gtcccaggag ggcacgcact gaaggccgag agaatcccgg ggctgcat 900
 25 gcgccgccc aaggactcca cacaggacct ttcatthtcc caactgtgt gagccaggcg 960
 gccggcagag agcaggtggc tgacagccc cggggagccc gaccgctgg gtctaactct 1020
 cccgcagact ccctgtctgt gcgctttggg gcttgggccc cagtttcttc aaaaggaatg 1080
 aggggctttt ttggaacgtt aaataattc ctacgtgggt gcgggtaggg agaaggagaa 1140
 agagaggagc gcgctgcgc gcctggaatc gtcccggat cagagcaagc gctctaaaag 1200
 tgttacaac attaaggcgc caactaaaaa acccgtagtg agcgcaggca gaaaccacgg 1260
 30 gtaagagaag tggagaagct tcgctaggg ccaagggtcc cgagcccga gtctcgagc 1320
 cagaatcagg ggtgccaatg ctctcctccg cgccccgag cgctcgcctt ggccatgccc 1380
 gccgcccac cgggatgagg gcgctcaggc cggacgctgg ggccccgggt tctcgcccc 1440
 ccccgcctc ggggattcag aggggcccgg aggagcctcg cgcatgtgca cagctggcgc 1500
 ccccccccc ccgcccacag ctgggacgtg ggccgcccgc gggcggggcg agtcgggagc 1560
 cgcccggtgt ggtccggtgc gtcgagcgt ccgctcgcgc cgtcggccat ggccaagcgc 1620
 35 tccaggggccc ccgggcccgc ctgcccgttg gcgctcgtgc tgttctgcgc ctgggggacg 1680
 ctggccgtgg tggcccagaa gccgggcccga ggggtgccga gccgctgctt gtgcttccc 1740
 accaccgtgc gctgcatgca tctgctctg gagccgctgc ccgcccgtgg gccgcagacc 1800
 tccatctctg gactgcccgc ggggaccccg ggggcccggg gtcccggggt tctgaggatg 1860
 ccgggagcgc aggggtgac ggaggtgggg gcgcccggag gtggaggggg catcggggcg 1920
 gcggggggccc tggggacttg ggacgcagaa ggaacctc gaagggggac gtggggggac 1980
 ctgggcccgg ggaccgctg ggcctttgtt cgccctgccc gagaccccga ggggcccgaac 2040
 40 agagcgtgt gcgcccggcc ttctgtagcc cttttgttcc gaactcgaa tccccgcag 2100
 actgggaagt tgttgagacc tcccgggctc ccccgcctc cctcccgcg cccctctca 2160
 tgcctcccgc gctcccgcct tccccctggg tcgcccggcc cctcctcctc accttctccc 2220
 cgctcaggac ccctcggctc ccctcgcctc cccgagcgcg gcgcagccc cctcctcctc 2280
 ccagcccct ccgcccgtt cctcctcctg ttctcctccc tctcctcctc ctcttctccc 2340
 tccccttctt cctcctcctc ccttctctcc tctcctccc cttctcctc ctctcctct 2400
 45 cccctcctcc tccccctt ccttctctcc cccagcctc cgccctctcc ccctccccg 2460
 ccccttggag cgcagtgccc accccatccc cccgcccgg 2500

<210> 11
 <211> 2200
 <212> DNA
 <213> Homo sapiens

50
 <400> 11
 cctcggcccc tccagccggc cccccgggccc cctcctctcg gcgcccggac cttggccctc 60
 cctctctttt cccacttctc tctttgcctt aacttggccc ccatccccg ctatttctct 120
 ctgcaccccg ggtcgcgcaa tccctcttcc caagtccctc tccagcccg gccttctct 180
 cgggttcgcc ccccttctcc ccaatctccc tctcttccc tcccttcgcc ctccccct 240
 55 tcttctctct tcccctcacc caacctgggt tcccctcgtt cctcagtcct gatctctccc 300
 ttactctgtc cccgcccact ctgcgcccgc ctctcagtc gggttgagcc ccacgtgtgg 360

EP 2 272 975 A1

acggccggcg ccccaactgac agccgcccgc cgcgggccc ccccggccc cgcgggct 420
 ctaaaacccc cgcgcccgc cctccaccgc cgcattctct ccagcgccca gcctcccgc 480
 ctctctcttg ctggccgcac gccccggccc cgcgcacctc cgcgggctc cgcagccgt 540
 acccgcgctt cgttgccctg tgggactccg agcagaccgc gagggaacc tcctctctt 600
 5 ctggggcgca cttttgtttg cttgctgtt tctttctggt gacttttgca gctttccaat 660
 atccgtcttc ggagcgcacg ggaatccgcg gagctctgcg tgcaggccct tttttcttt 720
 gaggttcaca tttttgaaa ttttacgcca gggcttttgt aatttcctcc cccgcccgt 780
 gacggtcctg gagtcgctcg gggctttagg ccggttatgc aacgtgtacc gctcggggct 840
 gccggctgca cctccgccc gcctcggccg tcaactgcgt agaccggcg ccccgctct 900
 cgcttcgagg gcagtcagg ggccggcgct ctgctgaggt ctccagctag agcaggggag 960
 10 ccgagcccga gggagtcctc ggagccgacg aaggcctat tagaccctga ctctttctg 1020
 aggcgcccag attttgtctt tgatcactcc ctctccgagg gtctacggcc gcgctcttc 1080
 ggcgcccggc atggggagaa gacggaggct gtgtctccag ctctacttcc tgtggctggg 1140
 ctgtgtggtg ctctgggccc agggcacggc cggccagcct cagcctcctc cgcccaagcc 1200
 gccccggccc cagccgccc cgcaacaggt tcggtccgct acagcaggct ctgaaggcgg 1260
 gtttctagcg cccagatctc gcgaggaggg tgcccgatg gccagcccg tccgcccggc 1320
 15 aggcagcagc gacgtgctcc gagggttaagt gggcaagcgg ctccgcacct agggctccgg 1380
 cttgggggag gggggaatcc tcagtttggc ggctttctgg cccactccgt cccagaccct 1440
 ttagctggag cctagagctg cagccccctt tgccagaata tccaaagacc cccaggagcg 1500
 cgtccccctt ttccttccca accccgcagc tcagcgggcg gaaagccctc tctccggggc 1560
 ttggccggcg ggtggttagg gggtcaggg gtgccgatcg cagagcgtgt gcagagctcg 1620
 cgctcgggga acaggttctg aatgtccggc ggcaggcggg cctgggtccg cctgctgcag 1680
 20 gggccagaga agcctgcttg ctccccacgt cggggcccgc gctcgtgagc cttttgtttg 1740
 aggacgtgtg cagggttcac agctcacctt ctcatcgtca acccgagcgc tccaccttgc 1800
 gacgcgcttt ccttgacacg tcggggccaa agtaacagtt gaccaaggag gaatggatt 1860
 gggaaaggag gcaaggattc tttggaacgg aatggctcct ttgttctctg catctggaag 1920
 ctagaatagt agcaaattat atgtttccat gcctcttttc gccctttaa aaggcaggca 1980
 agggacgaca gatgaaaggc agtgtttaga catttctgac cctcctgcat tccagcatct 2040
 25 agctcttttg cttccacgct tgcctcccga tctccaataa tttgaagtgt aattttgatt 2100
 tgtttgttgt cctgaaatct actcgtcggg ggcattgctt acgaagaccg tttatatggt 2160
 gctgcatccc tctacctatc tgttacgtga ccgcgcttgt 2200

<210> 12
 <211> 2000
 <212> DNA
 30 <213> Homo sapiens

<400> 12
 ttggaagaaa aggatctccg aggaaggggc tgagagaagg gcagggtgaa ctggactaaa 60
 ggccagagta ggaaggagaa gaggggccaa aaaagaagg gatgaaatta agcacagaag 120
 atgggtaaa gaaaaagtat cagggaaagg gcaaaataag agaaagcctt gaggataaga 180
 35 gggtagaagg ctaaagaaca aggggaccac tgggtcgggg aagcgtgccc tgaacggcgg 240
 gacagtgaca aagaaaggcc gctggcgata ttcgcaccaa gggtcgcaaa cgcaatcggg 300
 aggtgagaaa tggaaagaag gcgaatgccc ggctacaagt agcctgggac tgaaggggga 360
 cctgggggag gggctgggcc cagggcagaa aagtcaggt tcccatgccc cctgggcca 420
 cgtggagcgg gcgctgaatc accgctcagc cgccccctc cctcctccc cgaccggtgc 480
 ccgagctccc cgctcctcg gccgcccct ccacggggcg gggccctggc ccgggaccag 540
 40 cgcccggtct ataaatgggc tgcggcgagg ccggcagaac gctgtgacag ccacacgccc 600
 caagcctcc aagatgagct acacgttga ctcgtgggc aaccctccg cctaccggcg 660
 ggtaaccgag acccgctcga gcttcagccg cgtcageggc tccccgtcca gtggcttccg 720
 ctgcgagctg tggctcccgc gctcggcccag caccgtgtcc tcctcctata agcgcagcat 780
 gctcggcccg cgctcgtctt acagctcggc catgctcagc tccgcccgaga gcagccttga 840
 cttcagccag tcctcgtccc tgctcaacgg cggctccgga cccggcggcg actacaagct 900
 45 gtcccgtctc aacgagaagg agcagctgca ggggtgaac gaccgctttg ccggctacat 960
 agagaagggt cactacctgg agcagcagaa taaggagatt gaggcggaga tccaggcgct 1020
 gggcagaaag caggcctcgc acgcccagct gggcagcgc tacgaccagg agatccgcga 1080
 gctgcgccc accctggaga tgggtgaacca cgagaaggct caggtgcagc tggactcggg 1140
 ccacctggag gaagacatcc accggtcaa ggagcgttt gaggaggagg cgcggttgcg 1200
 cgacgacact gaggcggcca tccgcccgtc gcgcaaaagc atcgaggagg cgtcgtggt 1260
 caaggtggag ctggacaaga aggtgcagtc gctgcaggat gaggtggcct tcctcgggag 1320
 50 caaccacgag gaggaggtgg ccgaccttct ggcccagatc caggcatcgc acatcacggt 1380
 ggagcgaaaa gactacctga agacagacat ctgcagggcg ctgaaggaaa tccgctccca 1440
 gctcgaagac cactcagacc agaatatgca ccaggccgaa gatgtgttca aatgccgta 1500
 cgccaagctc accgagggcg ccgagcagaa caaggaggcc atccgctccg ccaaggaaga 1560
 gatcggcggg tacccggccc agctgcagtc caagagcctc gagctagagt cgggtgcgcg 1620
 caccaaggag tcctggagc ggcagctcag cgacatcgag gagcgcaca accacgacct 1680
 55 cagcagctac caggtaggaa ccgcccgtgc gcggccagcc tgcgcccagc ccagcggccc 1740
 gcgccccga cacttgggct cgtgcccagg cgcctctcc gccgcgctcc ctggtggcgg 1800

EP 2 272 975 A1

ctcgctagag cacgcgcgcc gcagacctag ggtatttgcg gatcagcgtc ctcgcccac 1860
 tcaccccca cactccgccc ccaccacact gccccagctg ctaagggctc tgaccttttt 1920
 cagaaacgtg catcttttcc agttctaatt ttgcacgctt gcacgtttaa agcaggaggg 1980
 atgaattcgg tagtgataa 2000

5
 <210> 13
 <211> 2300
 <212> DNA
 <213> Homo sapiens

10
 <400> 13
 tcagattgct attgggaggg tgaataaatg aatgcttgca ttatgagagt ttgggggag 60
 aaatattgcca cagactctta tctgaagcca tcagatttag tggctgcgaa cccaccgaag 120
 tcagggatatt acatttttta cagcaacgag agaaaacttc ccctttcctc tgcagaagt 180
 aggactggat ctcaaaaata gaaatgtgtc ctctaaatg tgtgcccac cccgtgggtg 240
 acaaacacag gatttcccaa gatagctgcc acacacttg tttctaactc ctgtattgct 300
 15
 tccccgccag aatgtcgaag tcttcccgga atatgccag tcatactttc tgaacttttg 360
 agcaaacacc gtccggcttc ttgtgcttcc ctcaaagacc ccaggcaccg gcaggaggga 420
 cacaggcccg ggcagagcgc ccctgcgcgg gggattcctg ccactccgcg ccagcctgcg 480
 gcgaaaacgc tcttctcagc cgcagtccca cccgctgctg gcaatctgaa tgaggagccg 540
 cgctattttt acctccccgg ctgcaatcct ttatatttac atgcaggaag caaatatata 600
 agggattaag aaggagatgc gtggccttag tttatccaga gcaggaagag gttggaatag 660
 gagagggtat gtgaagtctg ggggtgggga aaaggcaggt ggacttcggc tggttgtttt 720
 20
 ctcccgatca tccctgtctc tggcctggaa acccccgtac tctctttctt ctggcttacc 780
 cgtgactgac ggtccccctt ccaccgcccc catcttttga ggtaccaccg gtcacctccg 840
 atgctgcttg ggctgctgca tcaactctgt gctttacccc cttccccgcc cccaacaaa 900
 gcatgctcag tgcgttccgg gccaggcaac agcagcagca cagcatccag caacagcatc 960
 agcaccgcaa gcccgctcgc ggcgcgctct cggggggcgg ggcgcacgcc cgtcccgcg 1020
 gtccccgccc cgtcgcctcc cgcgcgctcc cgcgcgctc gctccccgcc gccgcctcag 1080
 25
 catcctcag cccggcggca gcccccag tcgctgaagc ggccgcgcc gccggggag 1140
 ggagtagccg ctggggaggg tccaagtgg cggagcggcg aggaccctg gactcctctg 1200
 cgtccccccc cgggagtggc tgcgaggcta ggcgagccgg gaaagggggc gccgccagc 1260
 cccgagcccc gcgccccgtg ccccagccc ggagccccct gcccgcccg gcaccatgag 1320
 cgccgagccg gctgaccgg ctccgcccgc ggccgcccc cagctagccc ggcgctctcg 1380
 cgggccacac ggagcggcgc ccgggagcta tgagccatga agccgcccgg cagcagctcg 1440
 30
 cggcagccgc cccctggcgg ctgcagcctt gccggcgctt cctgcggccc ccaacgcggc 1500
 cccgcccgtc cggctgctgc cagcgcgccg gcccgcacgc cgccctgcc cctgcttctc 1560
 gtccctctcc tgtgcctcc gctcgcgcc tctgcccggc cccgcgcctg gggggctgct 1620
 gcgcccagcg gtgggtatgg ccccgtgccc tttgcgttg ctttcccgg gggccctgca 1680
 gaggaaagcg aaggcgcgc gggtcctgt gctccgggct tgtccccggc tcggcctttc 1740
 cttccctccc tgcctgtctt tccaccctt tctgtccaa accccattc atcccagttc 1800
 35
 acttttgaa gtccattctt gttgcattcg cgaaaaacc attccaattc ttgttggttc 1860
 cactgggagg tgttagtggt atcctgggtc cctcagcag ctctgtgcaa ctgaggag 1920
 ggcaaccagt ggtgggaaa tacagcagag gagcaagttg ctacttgcgt ggtggaact 1980
 taatgtgaat gcggggagga tgtagtata atagtggtaa tgggctgttt cctcaaatt 2040
 cgtatccggc gcattcagtg cggttggaat taaggtggg gaggcacact tcggggacca 2100
 aagaattaag gtgctgaaga catacttcat gcacgacct tggttctgat tctcaaagt 2160
 40
 gcttgtcatt ataataaata attaatataa taccatcttc tatatattga tgattggaag 2220
 tcaactgaaag cagaagctg gcttctgtag gaaaataaaa agaaattggg aagctgccag 2280
 catctgtatc cctacatggc 2300

45
 <210> 14
 <211> 3000
 <212> DNA
 <213> Homo sapiens

50
 <400> 14
 tactgccgac ttttaggtctc tctggatctc aggccccctt ctctaagatg catcctagag 60
 gaccaaaaat aacttttatt tgggcttcgc ctgcttttgt ggaagggtag tttactagag 120
 gatataatct cgtgttttaa tttgctctct ctctaaagg aaatgtggag aaaaaaaaa 180
 agcagaaatt ggaaataacc aatatttagt ttatttcatt cgattcttag ggaactggt 240
 gaggagccta agatgatttt cccttcctag agaaagaatc caaagtcag ggaatagcg 300
 acaggggagt tcaagactgc ccctgctagt ccttccttg ctactctccg ctgcgactcg 360
 aggatagctc tcattagcag gagaatcggg caagtgtgtg gataagtaga gactgtgtg 420
 aacaacttgt aacgttttat gaaatacgca ttgtcatggt tccctaaaag gctttgcgga 480
 agccgtttgt ctttactaat caagtcttta cttacacaaa agtagaagta gaagtgttt 540
 55
 tagaaaacat actaacaatc ttctatcccc ttgaagacca gagtagcaga aaacaggtga 600
 tttgcattat aaaattgcac tcacttttcc ctcctttcag atttcacatt acattagccc 660

EP 2 272 975 A1

	atttgtgta	cgggtataa	aaaatggaac	aggcgcctcc	actgcattgt	tctcctttaa	720
	aaatagatca	cttacaccct	aactttgttt	tccttaaatt	cgattcttaa	caggagagct	780
	ttctattatt	tcagatggag	tgaggttgca	cgactgggat	ggaagaaagg	aatcccttaa	840
5	atttggggga	atttctgttc	tctgttccaa	gaccatttta	cttgggggtg	gggggtgggc	900
	gcggcggtca	gggcagtgga	acgcagtcgc	ggctgcgcca	tccctgcact	tccaggcgcg	960
	cgggagggac	cggcggggac	gcgagctcg	gactctggcg	aactcggggg	aggcagacag	1020
	ggggagggcg	acaccagcc	ggcagggctc	tcagcctccc	cgagccggc	gggcttttct	1080
	cctgacagct	ccagaaagg	cagaccctt	ccccagccag	ccaggtaagg	taaagactgc	1140
	tgttgagctt	gctgttactg	agggcgca	gaccctgggg	agaccgaagc	ttgccactgc	1200
	gggattctgt	gggtaacct	gggtctacgg	aagtttctctg	aaagagggga	gaagggtttg	1260
10	catttttct	atggaggatt	cttctctctc	tagcatttcg	ttgatgtat	tcaactggta	1320
	gaagtgagat	ttcaacaggt	agcagagagc	gctcacgtgg	aggaggtttg	ggcgcccg	1380
	gcgccacccc	caccctcct	cgggaccgcg	cctatttcta	aagttacacg	tcgacgaact	1440
	aacctatgct	ttaaattcct	ctttccagcc	ccgtgagtc	gcggcgacat	tggccctg	1500
	ggtggctggg	aacggtcccc	tcctccgga	aaaccagaga	acggcttga	gagctgaaac	1560
	gagcgtccgc	gagcaggtcc	gtgcagaacc	ggcttcagg	accgctgagc	tccgtagggc	1620
15	gtccttgggg	gacgccaggt	cgccggctcc	tctgccctcg	ttgagatgga	caacgcctcg	1680
	ttctcggagc	cctggcccgc	caacgcacg	ggcccggacc	cggcgctgag	ctgctccaac	1740
	gcgctcgactc	tggcggcgct	gccggcgccg	ctggcggtgg	ctgtaccagt	tgtctacgcg	1800
	gtgatctgcg	ccgtgggtct	ggcgggcaac	tccgccgtgc	tgtacgtgtt	gctgcggggc	1860
	ccccgcatga	agaccgtcac	caacctgttc	atcctcaacc	tggccatcgc	cgacgagctc	1920
	ttcacgctgg	tgtctcccat	caacatcgcc	gacttctctg	tgccgagctg	gcccttcggg	1980
20	gagctcatgt	gcaagctcat	cgtggctatc	gaccagtaca	acacctctc	cagcctctac	2040
	ttcctcaccg	tcatgagcgc	cgaccgctac	ctggtgggtg	tggccactgc	ggagtcgcgc	2100
	cgggtggccg	gcccgaacct	cagcgcgcg	cgccgggtga	gcctggccgt	gtgggggatc	2160
	gtcacactga	tcgtgctgcc	cttcgcagtc	ttcgcccggc	tagacgacga	gcagggcccg	2220
	cgccagtgcg	tgctagtctt	tccgcagccc	gaggccttct	ggtggcgcg	gagccgcctc	2280
	tacacgctcg	tgctgggctt	cgccatcccc	gtgtccacca	tctgtgtcct	ctataccacc	2340
25	ctgctgtgcc	ggctgcatgc	catgcccgtg	gacagccacg	ccaaggccct	ggagcgcgcc	2400
	aagaagcggg	tgaccttctt	ggtggtggca	atcctggcgg	tgtgcctcct	ctgctggacg	2460
	ccctaccacc	tgagcaccgt	ggtggcgctc	accaccgacc	tcccgcagac	gccgctggct	2520
	atcgctatct	cctacttcat	caccagcctg	agctacgcca	acagctgcct	caacccttc	2580
	ctctacgcct	tcctggagcgc	cagcttccgc	aggaacctcc	gccagctgat	aacttgcccg	2640
	gcggcagcct	gactccccca	gcgtccggct	ccgcaactgc	ccgccactcc	tggccagcga	2700
30	gggagggacc	ggcggcagag	tgccgggacca	gacagcccgc	ctaggcctcc	tggggaaacc	2760
	gactgcgccc	ccataaccga	cctagcagat	cggaagcgct	gcgactgtgc	ccgcaggttg	2820
	accttgccaa	gccctccagg	tgatgcccgg	ccatgccggg	tgaggagaa	tgaggctgag	2880
	atcgccacac	tgagggtctc	ctaaagccga	ggtggaggaa	gaggagggta	gaggagggag	2940
	gcggtattgc	tgggaaccgc	cccctcctg	cctgtctccc	tgtgcctcca	cccgagccct	3000
35	<210>	15					
	<211>	3000					
	<212>	DNA					
	<213>	Homo sapiens					
40	<400>	15					
	gaatacatta	aagttagggc	aacccttgag	ccgagacttc	tgccatgtga	agaccctttg	60
	aaaatcctga	caaacacagg	tactgcgtaa	gtggtcagct	aattaaagag	gggaggtgga	120
	gctgtccttt	gtgtatccaa	taagtacca	ttatctcatt	tgagcatgaa	aagagccac	180
	tgttattact	ttcaagaagg	aaagtaagca	ggatagctca	tatttttaga	accattcctc	240
	accaaattgga	ataattccgg	tgaaaagtgg	gagtgaggaa	gaaagaaaa	aaaacttct	300
	aatcataatg	tttgggaata	agaaaggaag	aagaaactca	cgtcaaaagg	gactttctcc	360
	tgcagctgta	aaataaactc	ttaagaccct	tctgtctgaa	actctggaga	ggaaaactgg	420
45	agtggcgggt	gggctttgcc	tgcagctcaa	ctctccctcg	cgccgcgggc	gcgctgggt	480
	tcagcacctc	ggaaagcgcc	cctgcggcgc	ccccgggatt	acgcatgctc	cttggggccc	540
	gccgccttgg	ccgtgcaagt	gccaccgtaa	ctggtgagag	ccgctggcaa	cccaccggga	600
	gttgacaacc	gcccagagac	gcagacaccc	actgacctcc	aggaagctga	gcgtgggtga	660
	tggaaactcta	cgatctcttt	ctctccaagg	acggaaacct	catccaagca	gtcccagagg	720
	aaacggataa	aggtatttga	aagggagcga	gcggcccaa	atcgcaaat	tgagcggctg	780
50	ggggagtatt	gcgccagtg	cccagtgacc	gcgggacacg	gagaggggaa	gtctgcgttg	840
	tacataagga	cctagggact	ccgagcttgg	cctgagaacc	cttgagcgc	gagtgcttgc	900
	cttacgggct	gactcctca	actctgctcc	aaagcagccg	ctgagctcaa	ctcctgcctc	960
	cagggcgctc	gctgcccgc	aggacgcgct	tagtaccag	tctctgggct	ctctcttcag	1020
	tagctgcttt	gaaagctccc	acgcagctcc	cgcaggttag	cctggcaaca	aaactggggt	1080
	aaaccgtggt	atcttaggtc	ttgtccccca	gaacatgacc	tagaggtacc	tgccgatgca	1140
	gatggccgat	gcagccacga	tagccacat	gaataaggca	gcagcgggg	acaagctagc	1200
55	agaactcttc	agtctggtcc	cggaccttct	ggagcggg	aacacgagtg	gtaacgcgtc	1260
	gctgcagctt	ccgacttgt	ggtgggagct	gggctggag	ttgccggacg	gcgcgccgc	1320

EP 2 272 975 A1

	aggacatccc	cggggcagcg	gcggggcaga	gagcgcggac	acagaggccc	gggtgcggat	1380
	tctcatcagc	gtggtgtact	gggtggtgtg	cgccctgggg	ttggcgggca	acctgctggt	1440
	tctctacctg	atgaagagca	tgcagggtcg	gcgcaagtcc	tctatcaacc	tcttctgtcac	1500
	caacctggcg	ctgacggact	ttcagtttgt	gctcaccctg	cccttctggg	cggtggagaa	1560
5	cgctcttgac	tcaaatggc	ccttcggcaa	ggccatgtgt	aagatcgtgt	ccatgggtgac	1620
	gtccatgaac	atgtacgcca	gcgtgttctt	cctcactgcc	atgagtgtga	cgcgctacca	1680
	ttcgggtggcc	tcggctctga	agagccaccg	gacccgagga	cacggccggg	cgactgctg	1740
	cgcccgagc	ctgggggaca	gctgctgctt	ctcggccaag	gcgctgtgtg	tgtggatctg	1800
	ggctttggcc	gcgctggcct	cgctgcccag	tgccatthtc	tccaccacgg	tcaagggtgat	1860
	gggcgaggag	ctgtgcctgg	tgcgtttccc	ggacaagtgt	ctgggcccgg	acagggcagtt	1920
10	ctggctgggc	ctctaccact	cgcagaaggt	gctgctgggc	ttcgtgctgc	cgctgggcat	1980
	cattatcttg	tgctacctgc	tgctggtgcg	cttcatcgcc	gaccgccggg	cgccggggac	2040
	caaaggaggg	gccgcggtag	ccggaggacg	cccgaaccga	gccagcgccc	ggagactgtc	2100
	gaaggtcacc	aaatcagtga	ccatcgttgt	cctgtccttc	ttcctgtggt	ggctgcccac	2160
	ccaggcgctc	accacctgga	gcatectcat	caagttcaac	gcggtgccct	tcagccagga	2220
	gtatthcctg	tgccagggat	acgcgttccc	tgtgagcgtg	tgcttagcgc	actccaacag	2280
15	ctgcctcaac	cccgtcctct	actgcctcgt	gcgcccggag	ttccgcaagg	cgctcaagag	2340
	cctgctgtgg	cgcatcgcgt	ctccttcgat	caccagcatg	cgccccttca	ccgccactac	2400
	caagccggag	cacgaggatc	aggggctgca	ggccccggcg	ccgcccacg	cgcccgcgga	2460
	gccggacctg	ctctactacc	cacctggcgt	cgthgtctac	agcggggggc	gctacgacct	2520
	gctgcccagc	agctctgcct	actgacgcag	gcctcaggcc	cagggcgcgc	cgctcgggca	2580
	aggtggcctt	ccccggcgcg	taaagaggtg	aaaggatgaa	ggagggctgg	ggggggcccc	2640
20	atttaagaag	taggtgggag	gaggatgggc	agagcatgga	ggaggagcct	gtggataggc	2700
	cgaggacctt	ctctggagag	gagatgcttc	gaaatcaggt	ggagagagga	aattggcaaa	2760
	gggatagaga	cgagccccac	gggacagaca	gccaacctcc	gctccgcacc	ccacagcctc	2820
	tccttactct	tcccacgctg	agtagtggg	ggcgcccag	aagcgaagac	aagcagcaaa	2880
	aatgtagaga	aattggcacg	gggagcgggg	cttagccaaa	tgatgcacag	acaattgtgc	2940
	ccgthttatc	cagcgacttc	tgccggagag	gcagccgctc	gcacaaacac	tcctttgctg	3000
25		<210> 16					
		<211> 2200					
		<212> DNA					
		<213> Homo sapiens					
30		<400> 16					
	gtcccccgat	tcctcacc	atcatataac	gtgtgtatth	attatgtthc	ccgtthcctc	60
	tgtctccgcc	agcagaatgt	aaactccatg	aggtcaggaa	tctccgagtt	atgthgcgcc	120
	agtgtaatcc	aagagcccgg	aacagtgctt	ggcacacagc	gggcatatgg	aagaacaaat	180
	gtgtgaaggt	gtgaatgaat	gaataattga	aagaataaat	agtagthctc	agcctcacag	240
	aacacgggtc	acaacctcaa	atgacctgct	accctgccc	taaataacag	agatgcagga	300
	gtaagtgtcg	ggctgtgacc	tgtcaacatg	ctaagccgct	caaacaaaac	tgcccaacag	360
35	cccgtggcc	gcctatthtg	agcactgggc	cctgagccgc	acattccc	ttcgttgata	420
	aagaaactga	ccagatagth	taagthgctt	gctgcggaag	acagagctgg	tgtgacaccg	480
	gtcgtgctt	cccagthcct	thththgctt	ctthctgac	gcgacgcaga	cccagthct	540
	ggagagthctg	tcactcgtc	cccgtggtgg	gagatcagag	gcctggtgth	ctgggagcg	600
	gcgagcggtg	ctcggcgcag	gatagaaagg	gagthgcgcg	ccgagthccc	cagatccctg	660
	ggaaccgcgc	ccaccctccc	gcccctgccc	atcccggcc	gcgctgtcag	thccattag	720
40	cgtaacagg	ctccagacgg	agcggggccg	gcgctgggth	aatgcaatcg	gcgcttacc	780
	tggggcgcag	gctacattac	cagcccggcc	ccgcccaggc	acggccagaa	ccagthacc	840
	cgccctctgc	ggccgcccc	gcgcctccag	ctctccccg	gccccggccg	aacgcccac	900
	ggcggagccc	agcccagcc	cgcccttag	agcctgccc	ggcgcggccg	gtcgggggccc	960
	ggcaggcgc	aaggcaccag	ggatcccctc	gcccgggac	acgtgagthc	gcctgagcg	1020
	cgggacaggg	ctagthctgc	ctgggaggcc	cgggccgaga	cgccagca	gagggctagc	1080
45	gagththtag	tgcagtgacg	thaaagthcc	gagaaggctc	ctgtggctgt	thaaagthctg	1140
	cgacctgag	ctggggaggg	ggtcggcacg	ctgcccctag	cctcgtgthg	thcaatccc	1200
	gccatthggg	gcaggcgaga	gtgggtgaa	gaggaaaagt	gctgcagggt	ctcagccgc	1260
	ccccagaggg	ctgtcagaag	thtcccactc	thgagthccg	gcgthcccca	acctctgth	1320
	ccaaatthth	ccagcggacg	cgcgctctth	thtgggaa	ctgctccgc	thcagcgcgcg	1380
	ctcatcccag	thtctaaggc	gctcccgggt	ggtctggga	gthgcaagta	gggaggaacg	1440
50	gcccgggtaac	cacctctth	ccctthtacc	aagcagagcc	thggcgtgccc	cccaggaccg	1500
	gtaaagthcc	thtccgaccg	cgcatccatg	ctthtggcgc	ggatgaaacc	gcaggtgthc	1560
	cccagagaaca	acggggcgga	cacgggtcca	gagcagcccc	thcgggcgcg	caaaactgth	1620
	gagctgctgg	thgtgaagga	gcgcaaccgg	gthccagthc	gthgctgccc	ccgacgccc	1680
	gacgcgcagc	cccgggagac	ctggggcaag	aagatcgact	thcctgctgth	cgtagthcgc	1740
	thcgcagthg	acctggccaa	cgthgtggcgc	thccccctacc	thtctgthca	gaaaggcggc	1800
	ggtgagcgtg	ggthcgggct	gggaatthga	atctgggag	thcactgthc	gcagcggthg	1860
55	ctgggacagg	agctggaata	cacacggaag	ggagggcagg	agacaggggc	aaatctgggg	1920
	cgcaaaaga	actggacagg	gctaaccggga	aaaaaaaaag	atthgagthc	thtggagth	1980

EP 2 272 975 A1

```

cattttccca ggctctttgc agagtacctc gagctcattc cagcgggaagt gtcaggattg 2040
ggcaccctgg aagcaaaaca gcagaagagt gaaatcgagt catgacccta aagtcattgt 2100
aggggatg atggaagga cagaatctgg ggtgccaggt tgggtggggg agcctgacct 2160
5 tttgatggtc tgctggaagg gaggtgaga ttccaagagc 2200

<210> 17
<211> 98
<212> DNA
<213> Artificial Sequence

10 <220>
<221> modified_base
<222> 20,23,31,46,51,53,55
<223> Designed oligonucleotide consisting of objective DNA domain (GPR7-
2079-2176), n=m5c

15 <400> 17
gttggccact gcgagtcgn gcnggggtggc nggccgcacc tacagngccg ngngngcggg 60
gagcctggcc gtgtggggga tcgtcacact cgtcgtgc 98

<210> 18
<211> 98
20 <212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> 31,46,51,53,55
25 <223> Designed oligonucleotide consisting of objective DNA domain (GPR7-
2079-2176),n=m5c

<400> 18
gttggccact gcgagtcgc gccgggtggc nggccgcacc tacagngccg ngngngcggg 60
gagcctggcc gtgtggggga tcgtcacact cgtcgtgc 98

30 <210> 19
<211> 98
<212> DNA
<213> Artificial Sequence

<220>
35 <223> Designed oligonucleotide consisting of objective DNA domain (GPR7-
2079-2176)

<400> 19
gttggccact gcgagtcgc gccgggtggc cggccgcacc tacagcgcgg cgcgcgcggt 60
gagcctggcc gtgtggggga tcgtcacact cgtcgtgc 98

40 <210> 20
<211> 14
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Designed oligonucleotide for experiment

<400> 20
gccacccggc gcga 14

50 <210> 21
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
55 <223> Designed oligonucleotide primer for PCR

<400> 21

```

EP 2 272 975 A1

```

gttggccact gcggagtcg          19

<210> 22
<211> 20
5 <212> DNA
   <213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer for PCR

10 <400> 22
    gcacgacgag tgtgacgatc          20

<210> 23
<211> 98
15 <212> DNA
   <213> Artificial Sequence

<220>
<223> Designed oligonucleotide consisting of objective DNA domain (GPR7-
2079-2176)

20 <400> 23
    gttggccact gcggagtcgc gccgggtggc cggccgcacc tacagcgccg cgcgcgcggt    60
    gagcctggcc gtgtggggga tcgtcacact cgtcgtgc          98

<210> 24
<211> 18
25 <212> DNA
   <213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer for PCR

30 <400> 24
    ctcagcaccc aggcggcc          18

<210> 25
<211> 20
35 <212> DNA
   <213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer for PCR

40 <400> 25
    ctggccaaac tggagatcgc          20

<210> 26
<211> 386
45 <212> DNA
   <213> Artificial Sequence

<220>
<223> Amplified oligonucleotide consisting of objective DNA domain ( Genbank
Accession No.NT_029419 25687390-25687775 Homo sapiens )

50 <400> 26
    ctcagcaccc aggcggccgc gatcatgagg cgcgagcggc gcgcgggctg ttgcagagtc    60
    ttgagcgggt ggcacaccgc gatgtagcgg tcggctgtca tgactaccag catgtaggcc    120
    gacgcaaca tgccgaacac ctgcaggtgc ttcaccacgc ggcacagcca gtcggggccg    180
    cggaagcggg aggtgatgtc ccagcacatt tgcggcagca cctggaagaa tgccacggcc    240
    aggtcggcca ggctgaggtg tcggatgaag aggtgcatgc gggacgtctt gcgcggcgtc    300
    cggtgcaag ccagcagtac gctgctgttg cccagcacgg ccaccgcgaa agtcaccgcc    360
    agcacggcga tctccagttt ggccag          386

55 <210> 27
   <211> 386

```

EP 2 272 975 A1

<212> DNA
 <213> Artificial Sequence

5
 <220>
 <221> modified_base
 <222>
 14,18,20,31,33,38,40,42,44,66,78,80,88,92,120,123,134,160,173,179,181,187,203,237,245,262,280,285,292,294,297,301,320,338,346,357,365,368
 <223> Designed oligonucleotide consisting of objective DNA domain (Genbank Accession No.NT_029419 25687390-25687775 Homo sapiens), n=m5c

10
 <400> 27
 ctcagcacc c agngggcngn gatcatgagg nngagnggn gngngggctg ttgcagagtc 60
 ttgagngggg ggcacacnng gatgtagnng tnggctgtca tgactaccag catgtaggcn 120
 gangcaaaca tgcngaacac ctgcaggtgc ttcaccangn ggcacagcca gtngggggcng 180
 nggaagnggt aggtgatgtc ccagcacatt tngggcagca cctggaagaa tgccanggcc 240
 15 aggtnggccca ggctgaggtg tnggatgaag aggtgcatgn gggangtctt gngngnggtc 300
 nggtgcagag ccagcagtan gctgctgttg cccagcangg ccacngngaa agtcacngcc 360
 agcangngga tctccagttt ggccag 386

<210> 28
 <211> 386
 <212> DNA
 <213> Artificial Sequence

20
 <220>
 <223> Designed oligonucleotide consisting of objective DNA domain (Genbank Accession No.NT_029419 25687390-25687775 Homo sapiens)

25
 <400> 28
 ctcagcacc c agcgggccgc gatcatgagg cgcgagcggc gcgcgggctg ttgcagagtc 60
 ttgagcgggt ggcacaccgc gatgtagcgg tcggctgtca tgactaccag catgtaggcc 120
 gacgcaaaca tgccgaacac ctgcaggtgc ttcaccacgc ggcacagcca gtcggggccg 180
 cggaagcggg aggtgatgtc ccagcacatt tgcggcagca cctggaagaa tgccacggcc 240
 aggtcggcca ggctgaggtg tcggatgaag aggtgcatgc gggacgtctt gcgcggcgtc 300
 30 cggtgcagag ccagcagtac gctgctgttg cccagcagcg ccaccgcaa agtcaccgcc 360
 agcacggcga tctccagttt ggccag 386

<210> 29
 <211> 30
 <212> DNA
 <213> Artificial Sequence

35
 <220>
 <223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

40
 <400> 29
 gccaccgcga aagtcaccgc cagcacggcg 30

<210> 30
 <211> 30
 <212> DNA
 <213> Artificial Sequence

45
 <220>
 <223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

50
 <400> 30
 gccagcagta cgctgctgtt gccagcagc 30

<210> 31
 <211> 30
 <212> DNA
 <213> Artificial Sequence

55
 <220>

EP 2 272 975 A1

<223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

5 <400> 31
cgggacgtct tgcgcggcgt ccggtgcaga 30

<210> 32
<211> 30
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

15 <400> 32
aggctgaggt gtcggatgaa gaggtgcatg 30

<210> 33
<211> 30
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

25 <400> 33
acctggaaga atgccacggc caggtcggcc 30

<210> 34
<211> 30
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

35 <400> 34
taggtgatgt cccagcacat ttgcggcagc 30

<210> 35
<211> 30
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

45 <400> 35
cggcacagcc agtcggggcc gcggaagcgg 30

<210> 36
<211> 30
<212> DNA
<213> Artificial Sequence

50 <220>
<223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

55 <400> 36
atgccgaaca cctgcagggtg cttcaccacg 30

<210> 37
<211> 30

EP 2 272 975 A1

<212> DNA
<213> Artificial Sequence

5 <220>
<223> Designed counter oligonucleotide for making an objective DNA domain a
single strand DNA

<400> 37
atgactacca gcatgtaggc cgacgcaaac 30

10 <210> 38
<211> 30
<212> DNA
<213> Artificial Sequence

15 <220>
<223> Designed counter oligonucleotide for making an objective DNA domain a
single strand DNA

<400> 38
tggcacaccg cgatgtagcg gtcggctgtc 30

20 <210> 39
<211> 30
<212> DNA
<213> Artificial Sequence

25 <220>
<223> Designed counter oligonucleotide for making an objective DNA domain a
single strand DNA

<400> 39
cgcgcgggct gttgcagagt cttgagcggg 30

30 <210> 40
<211> 30
<212> DNA
<213> Artificial Sequence

35 <220>
<223> Designed counter oligonucleotide for making an objective DNA domain a
single strand DNA

<400> 40
caggcggccg cgatcatgag gcgcgagcgg 30

40 <210> 41
<211> 19
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Designed oligonucleotide primer for PCR

<400> 41
tgagctccgt agggcgtcc 19

50 <210> 42
<211> 17
<212> DNA
<213> Artificial Sequence

55 <220>
<223> Designed oligonucleotide primer for PCR

<400> 42
gcgcccgggtc cgggccc 17

EP 2 272 975 A1

<210> 43
 <211> 121
 <212> DNA
 <213> Artificial Sequence
 5

<220>
 <223> Amplified oligonucleotide consisting of objective DNA domain (Genbank
 Accession No.AC009800 76606-76726 Homo sapiens)

<220>
 <400> 43
 10
 gcgccgggtc cgggcccgat gcgttgccgg gccagggtc cgagaacgag gcgttggtcca 60
 tctcaacgag ggcagaggag ccggcgacct ggcgtcccc aaggacgcc tacggagctc 120
 a 121

<210> 44
 <211> 121
 <212> DNA
 <213> Artificial Sequence
 15

<220>
 <221> modified_base
 <222> 2,5,11,17,22,28,41,47,52,67,82,85,93,106,113
 <223> Designed oligonucleotide consisting of objective DNA domain (Genbank
 Accession No.AC009800 76606-76726 Homo sapiens) n=m5c
 20

<400> 44
 25
 gngcnggtc ngggccngat gngttgngg gccagggtc ngagaangag gngttgtcca 60
 tctcaangag ggcagaggag cngngacct gngtcccc aaggangccc tanggagctc 120
 a 121

<210> 45
 <211> 121
 <212> DNA
 <213> Artificial Sequence
 30

<220>
 <223> Designed oligonucleotide consisting of objective DNA domain (Genbank
 Accession No.AC009800 76606-76726 Homo sapiens)

<400> 45
 35
 gcgccgggtc cgggcccgat gcgttgccgg gccagggtc cgagaacgag gcgttggtcca 60
 tctcaacgag ggcagaggag ccggcgacct ggcgtcccc aaggacgcc tacggagctc 120
 a 121

<210> 46
 <211> 30
 <212> DNA
 <213> Artificial Sequence
 40

<220>
 <223> Designed counter oligonucleotide for making an objective DNA domain a
 single strand DNA

<400> 46
 45
 gcgtcccca aggacgcct acggagctca 30

<210> 47
 <211> 30
 <212> DNA
 <213> Artificial Sequence
 50

<220>
 <223> Designed counter oligonucleotide for making an objective DNA domain a
 single strand DNA

<400> 47
 55
 ctcaacgag gcagaggag ccggcgacct 30

EP 2 272 975 A1

5
<210> 48
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

10
<400> 48
cgccgggtcc gggcccgatg cgttggcggg 30

<210> 49
<211> 21
<212> DNA
15 <213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer for PCR

20
<400> 49
ggacctgtgt ttgacgggta t 21

<210> 50
<211> 21
<212> DNA
25 <213> Artificial Sequence

<220>
<223> Designed oligonucleotide primer for PCR

30
<400> 50
agtacagatc tggcgttctc g 21

<210> 51
<211> 117
<212> DNA
35 <213> Artificial Sequence

<220>
<223> Amplified oligonucleotide consisting of objective DNA domain (Genbank Accession No.NC001139 384569-384685 Saccharomyces cerevisiae chromosome VII)

40
<400> 51
ggacctgtgt ttgacgggta taactactaag ttgcaatt tgctgtattg cgaatccgc 60
ccggacgata tcaactcttga ggcgatgtgc cgttccgag aacgccagat ctgtact 117

<210> 52
<211> 117
<212> DNA
45 <213> Artificial Sequence

<220>
<221> modified_base
<222> 15,34,51,58,61,66,82,91,97,103
<223> Designed oligonucleotide consisting of objective DNA domain (Genbank Accession No.NC001139 384569-384685 Saccharomyces cerevisiae chromosome VII) n=m5c

50
<400> 52
ggacctgtgt ttgangggta taactactaag ttgngcaatt tgctgtattg ngaaatcngc 60
cnggangata tcaactcttga gngcatgtgc ngtttcngag aangccagat ctgtact 117

<210> 53
<211> 117
55 <212> DNA
<213> Artificial Sequence

EP 2 272 975 A1

5
<220>
<223> Designed oligonucleotide consisting of objective DNA domain (Genbank
Accession No.NC001139 384569-384685 Saccharomyces cerevisiae chromosome VII)

<400> 53
ggacctgtgt ttgacgggta taactaag ttgcgaatt tgctgtattg cgaaatccgc 60
ccggacgata tcaactctga ggcgatgtgc cgttccgag aacgccagat ctgtact 117

<210> 54
<211> 21
<212> DNA
<213> Artificial Sequence

10
<220>
<223> Designed counter oligonucleotide for making an objective DNA domain a
single strand DNA

15
<400> 54
ggacctgtgt ttgacgggta t 21

<210> 55
<211> 25
<212> DNA
<213> Artificial Sequence

20
<220>
<223> Designed counter oligonucleotide for making an objective DNA domain a
single strand DNA

25
<400> 55
aacactaagt tgcgaattt gctgt 25

<210> 56
<211> 25
<212> DNA
<213> Artificial Sequence

30
<220>
<223> Designed counter oligonucleotide for making an objective DNA domain a
single strand DNA

35
<400> 56
attgcgaaat ccgcccggac gatat 25

<210> 57
<211> 25
<212> DNA
<213> Artificial Sequence

40
<220>
<223> Designed counter oligonucleotide for making an objective DNA domain a
single strand DNA

45
<400> 57
cactcttgag cgcgatgtgcc gtttc 25

<210> 58
<211> 244
<212> DNA
<213> Artificial Sequence

50
<220>
<223> Designed oligonucleotide primer for PCR

55
<400> 58
taggaaatac attccgaggg cgcccgcaca aggcctatta ttagagggac ctgtgtttga 60
cgggtataac actaagttgc gcaatttgct gtattgcgaa atccgcccg acgatcac 120

tcttgagcgc atgtgccgtt tccgagaacg ccagatctgt actgcatcg cacacgagga 180
 gacacagcgt cacgtgtttt gccattttgt acgacaaatg aaccgcctgg ccacgcctct 240
 aatc 244

5

<210> 59
 <211> 30
 <212> DNA
 <213> Artificial Sequence

10

<220>
 <223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

<400> 59
 aatacattcc gagggcgccc gcacaaggcc 30

15

<210> 60
 <211> 21
 <212> DNA
 <213> Artificial Sequence

20

<220>
 <223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

<400> 60
 gcgatcgcac acgaggagac a 21

25

<210> 61
 <211> 30
 <212> DNA
 <213> Artificial Sequence

30

<220>
 <223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

<400> 61
 agcgtcacgt gttttgccat tttgtacgac 30

35

<210> 62
 <211> 29
 <212> DNA
 <213> Artificial Sequence

40

<220>
 <223> Designed counter oligonucleotide for making an objective DNA domain a single strand DNA

<400> 62
 aatgaaccg cctggccacg cctctaac 29

45

50 **Claims**

1. A method of measuring the content of methylated DNA in a objective DNA region in a genomic DNA contained in a biological specimen, comprising:

55

- (1) First step of subjecting a DNA sample derived from the genomic DNA contained in the biological specimen to a digestion treatment with a methylation-sensitive restriction enzyme;
- (2) Second step of obtaining methylated single-stranded DNA from the DNA sample that has been subjected to the digestion treatment and obtained in First step, and binding the single-stranded DNA to an immobilized

methylated DNA antibody, thereby selecting the single-stranded DNA; and
 (3) Third step comprising, as a pre step of each of the following regular steps:

5 a step (First pre step) of separating the single-stranded DNA selected in Second step from the immobilized
 immobilized methylated DNA antibody to provide DNA in a single-stranded state (plus strand);
 a step (Second pre step) of extensionally-forming a double-stranded DNA from a single-stranded DNA
 (plus strand) containing the objective DNA region by a single extension of an extension primer, using the
 genomic DNA (plus strand) provided in a single-stranded state in First pre step and the extension primer,
 10 wherein the extension primer (forward primer) comprises the nucleotide sequence (minus strand) comple-
 mentary to a partial nucleotide sequence (plus strand) of the nucleotide sequence of the DNA in a single-
 stranded state (plus strand), the partial nucleotide sequence (plus strand) being located on further 3'-end
 side than the 3'-end of the nucleotide sequence (plus strand) of the objective DNA region; and
 a step (Third pre step) of temporarily separating the double-stranded DNA extensionally formed in Second
 pre step into a single-stranded DNA (plus strand) containing the objective DNA region and a single-stranded
 15 DNA (minus strand) containing the nucleotide sequence complementary to the objective DNA region;
 and as regular steps:

(a) Step A (regular step) of extensionally forming double-stranded DNA from the single-stranded DNA
 20 containing the objective DNA region, by a single extension of the extension primer, using as a template
 the generated single-stranded DNA (plus strand) containing the objective DNA region, and the forward
 primer as the extension primer; and

(b) Step B (regular step) of extensionally forming double-stranded DNA from the single-stranded DNA
 containing the objective DNA region, by a single extension of an extension primer, using as a template
 25 the generated single-stranded DNA (minus strand) containing the nucleotide sequence complementary
 to the objective DNA region, and using as the extension primer an extension primer (reverse primer)
 comprising the nucleotide sequence (plus strand) complementary to a partial nucleotide sequence
 (minus strand) of the nucleotide sequence of the single-stranded DNA (minus strand) containing the
 nucleotide sequence complementary to the objective DNA region, the partial nucleotide sequence
 (minus strand) being located on further 3'-end side than the 3'-end of the nucleotide sequence (minus
 30 strand) complementary to the nucleotide sequence (plus strand) of the objective DNA region; and where-
 in

Third step further comprises:

35 amplifying the methylated DNA in the objective DNA region to a detectable level by repeating each
 regular step of Third step after temporarily separating the extensionally formed double-stranded DNA
 obtained in each of the regular steps into a single-stranded state; and quantifying the amount of the
 amplified DNA.

- 40 **2.** The method of claim 1, wherein the immobilized methylated DNA antibody is a methylcytosine antibody.
- 3.** The method of claim 1 or 2, wherein the biological specimen is blood, a bodily fluid, serum, plasma, a cell lysate,
 or a tissue lysate from a mammal.
- 45 **4.** The method of any one of claims 1 to 3, wherein the DNA sample derived from the genomic DNA contained in the
 biological specimen is a DNA sample digested in advance with a restriction enzyme recognition cleavage site for
 which is not present in the objective DNA region of the genomic DNA, or a DNA sample purified in advance.
- 5.** The method of any one of claims 1 to 4, wherein First step comprises:

50 First (A) step of mixing a single-stranded DNA (plus strand) containing the objective DNA region and a masking
 oligonucleotide comprising a nucleotide sequence complementary to a nucleotide sequence of a recognition
 site for a methylation-sensitive restriction enzyme, thereby selecting single-stranded DNA in which the recog-
 nition site for the methylation-sensitive restriction enzyme is protected; and
 55 First (B) step of digesting the single-stranded DNA selected in First (A) step with the methylation-sensitive
 restriction enzyme.

- 6.** The method of any one of claims 1 to 5, wherein the methylation-sensitive restriction enzyme is a restriction enzyme

the restriction site for which is included in the objective DNA region in the genomic DNA contained in the biological specimen, or the methylation-sensitive restriction enzyme is HhaI.

5 7. The method of any one of claims 1 to 6, wherein Second step is performed without digestion treatment with the methylation-sensitive restriction enzyme in First step.

8. The method of any one of claims 1 to 7, wherein Second step comprises:

10 Second (A) step of separating into methylated single-stranded DNA the methylated double-stranded DNA contained in the DNA sample that has been subjected to the digestion treatment and obtained in First step; and Second (B) step of binding the methylated single-stranded DNA obtained in Second (A) step to an immobilized methylated DNA antibody; and wherein

15 a counter oligonucleotide is added when separating the methylated double-stranded DNA into the methylated single-stranded DNA in Second (A) step.

20

25

30

35

40

45

50

55

Fig.1




Fig.2






Fig.3



MK MD D MC C MB B MA A

Fig.4



MK MD D MC C MB B MA A

Fig. 5



MK MD D MC C MB B MA A

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2009/056785

A. CLASSIFICATION OF SUBJECT MATTER C12Q1/68(2006.01) i, C12N15/09(2006.01) i, G01N33/53(2006.01) i		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) C12Q1/68, C12N15/00-15/90		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) MEDLINE/WPIDS (STN), JSTPlus/JMEDPlus (JDreamII)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	TONG, Yu K., et al., Detection of restriction enzyme-digested target DNA by PCR amplification using a stem-loop primer: application to the detection of hypomethylated fetal DNA in maternal plasma., Clinical chemistry, 2007, Vol.53, No.11, pages 1906-1914	1-8
Y	Edited by The Japanese Biochemical Society, Shin Seikagaku Jikken Koza 2 Kakusan I -Bunri Seisei-, Tokyo Kagaku Dojin, 1991, 1st edition, pages 169 to 172, 180	1-8
Y	WO 2007/119518 A1 (The University of Tokyo), 25 October, 2007 (25.10.07), Full text (Family: none)	1-8
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 29 May, 2009 (29.05.09)		Date of mailing of the international search report 09 June, 2009 (09.06.09)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (April 2007)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2009/056785

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	YARMUSH, Martin L., et al., Immunoabsorption: strategies for antigen elution and production of reusable adsorbents., Biotechnology progress, 1992, Vol.8, No.3, pages 168-178	1-8
Y	HEISKANEN, Mervi, et al., A novel method to quantitate methylation of specific genomic regions., PCR methods and applications, 1994, Vol.4, No.1, pages 26-30	1-8
Y	ALLEN, R. Cutler, et al., Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation., American journal of human genetics, 1992, Vol.51, No.6, pages 1229-1239	1-8
Y	NYGREN, Anders O. H., et al., Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences., Nucleic acids research, 2005, Vol.33, No.14, pages e128(1-9)	1-8
Y	STERKY, Fredrik, et al., Direct sequencing of bacterial artificial chromosomes (BACs) and prokaryotic genomes by biotin-capture PCR., Journal of biotechnology, 1998, Vol.60, No.1-2, pages 119-129	1-8
Y	SCHMIDT, Peter M., et al., Detection of activity of telomerase in tumor cells using fiber optical biosensors., Biosensors & bioelectronics, 2002, Vol.17, No.11-12, pages 1081-1087	1-8
Y	BUCKLE, Malcolm., et al., Real time measurements of elongation by a reverse transcriptase using surface plasmon resonance., Proceedings of the National Academy of Sciences of the United States of America, 1996, Vol.93, No.2, pages 889-894	1-8

Form PCT/ISA/210 (continuation of second sheet) (April 2007)

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description

- *Nucleic Acids Res.*, 11 August 1994, vol. 22 (15), 2990-7 [0002]
- *Proc. Natl. Acad. Sci. U.S.A.*, 18 March 1997, vol. 94 (6), 2284-9 [0002]
- **Gruenbaum et al.** *Nucleic Acid Research*, vol. 9, 2509-2515 [0050]

专利名称(译)	测定DNA甲基化的方法		
公开(公告)号	EP2272975A4	公开(公告)日	2011-06-29
申请号	EP2009725639	申请日	2009-03-25
[标]申请(专利权)人(译)	住友化学有限公司		
申请(专利权)人(译)	住友化学公司		
当前申请(专利权)人(译)	住友化学公司		
[标]发明人	TOMIGAHARA YOSHITAKA SATOH HIDEO TARUI HIROKAZU		
发明人	TOMIGAHARA, YOSHITAKA SATOH, HIDEO TARUI, HIROKAZU		
IPC分类号	C12Q1/68 C12N15/09 G01N33/53		
CPC分类号	G01N33/6854 C12Q1/683 C12Q1/6851 G01N33/5308 G01N2333/922 G01N2440/12		
优先权	2008077967 2008-03-25 JP		
其他公开文献	EP2272975B1 EP2272975A1		
外部链接	Espacenet		

摘要(译)

本发明涉及测量生物样本中包含的基因组DNA中的目标DNA区域中甲基化DNA含量的方法，等等。